{
"documentInfo": {
"documentType": "https://xbrl.org/2021/xbrl-json",
"features": {
"xbrl:canonicalValues": true
},
"namespaces": {
"COL": "http://xbrl.coloplast.com/2025-09-30",
"ifrs-full": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
"iso4217": "http://www.xbrl.org/2003/iso4217",
"scheme": "http://standards.iso.org/iso/17442",
"xbrl": "https://xbrl.org/2021",
"xbrli": "http://www.xbrl.org/2003/instance"
},
"taxonomy": [
"http://xbrl.coloplast.com/2025-09-30/Coloplast-2025-09-30.xsd"
]
},
"facts": {
"f0__s7__7__17": {
"value": "NPLH Holding ApS",
"dimensions": {
"concept": "ifrs-full:NameOfUltimateParentOfGroup",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__16": {
"value": "Coloplast Holding ApS",
"dimensions": {
"concept": "ifrs-full:NameOfParentEntity",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s2__3__5": {
"value": "27874000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:Revenue",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s2__4__5": {
"value": "27030000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:Revenue",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s2__3__6": {
"value": "8929000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:CostOfSales",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s2__4__6": {
"value": "8761000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:CostOfSales",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s2__3__7": {
"value": "18945000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:GrossProfit",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s2__4__7": {
"value": "18269000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:GrossProfit",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s2__3__8": {
"value": "9150000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:DistributionCosts",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s2__4__8": {
"value": "8825000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:DistributionCosts",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s2__3__9": {
"value": "1270000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:AdministrativeExpense",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s2__4__9": {
"value": "1244000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:AdministrativeExpense",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s2__3__10": {
"value": "946000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:ResearchAndDevelopmentExpense",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s2__4__10": {
"value": "913000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:ResearchAndDevelopmentExpense",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s2__3__11": {
"value": "159000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:OtherIncome",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s2__4__11": {
"value": "75000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:OtherIncome",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s2__3__12": {
"value": "68000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:OtherExpenseByFunction",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s2__4__12": {
"value": "76000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:OtherExpenseByFunction",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s2__3__13": {
"value": "7670000000.0",
"decimals": -6,
"dimensions": {
"concept": "COL:ProfitLossFromOperatingActivitiesBeforeSpecialItems",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s2__4__13": {
"value": "7286000000.0",
"decimals": -6,
"dimensions": {
"concept": "COL:ProfitLossFromOperatingActivitiesBeforeSpecialItems",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s2__3__14": {
"value": "-469000000.0",
"decimals": -6,
"dimensions": {
"concept": "COL:SpecialItemsIncomeExpense",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s2__4__14": {
"value": "34000000.0",
"decimals": -6,
"dimensions": {
"concept": "COL:SpecialItemsIncomeExpense",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s2__3__15": {
"value": "7201000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:ProfitLossFromOperatingActivities",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s2__4__15": {
"value": "7320000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:ProfitLossFromOperatingActivities",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s2__3__16": {
"value": "107000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:FinanceIncome",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s2__4__16": {
"value": "175000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:FinanceIncome",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s2__3__17": {
"value": "1151000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:FinanceCosts",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s2__4__17": {
"value": "1100000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:FinanceCosts",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s2__3__18": {
"value": "6157000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:ProfitLossBeforeTax",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s2__4__18": {
"value": "6395000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:ProfitLossBeforeTax",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s2__3__19": {
"value": "2521000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:IncomeTaxExpenseContinuingOperations",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s2__4__19": {
"value": "1343000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:IncomeTaxExpenseContinuingOperations",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s2__3__20": {
"value": "3636000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:ProfitLoss",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s2__4__20": {
"value": "5052000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:ProfitLoss",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s2__3__21": {
"value": "16.13",
"decimals": 2,
"dimensions": {
"concept": "ifrs-full:BasicEarningsLossPerShare",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK/xbrli:shares"
}
},
"f0__s2__4__21": {
"value": "22.46",
"decimals": 2,
"dimensions": {
"concept": "ifrs-full:BasicEarningsLossPerShare",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK/xbrli:shares"
}
},
"f0__s2__3__22": {
"value": "16.13",
"decimals": 2,
"dimensions": {
"concept": "ifrs-full:DilutedEarningsLossPerShare",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK/xbrli:shares"
}
},
"f0__s2__4__22": {
"value": "22.46",
"decimals": 2,
"dimensions": {
"concept": "ifrs-full:DilutedEarningsLossPerShare",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK/xbrli:shares"
}
},
"f0__s2__3__25": {
"value": "3636000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:ProfitLoss",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s2__4__25": {
"value": "5052000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:ProfitLoss",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s2__3__26": {
"value": "21000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s2__4__26": {
"value": "6000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s2__3__27": {
"value": "5000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s2__4__27": {
"value": "1000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s2__3__28": {
"value": "16000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s2__4__28": {
"value": "5000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s2__3__29": {
"value": "159000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s2__4__29": {
"value": "-45000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s2__3__30": {
"value": "26000000.0",
"decimals": -6,
"dimensions": {
"concept": "COL:ReclassificationAdjustmentsOnCashFlowHedgesBeforeTaxFinanceIncomeCost",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s2__4__30": {
"value": "75000000.0",
"decimals": -6,
"dimensions": {
"concept": "COL:ReclassificationAdjustmentsOnCashFlowHedgesBeforeTaxFinanceIncomeCost",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s2__3__31": {
"value": "105000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s2__4__31": {
"value": "-26000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s2__3__32": {
"value": "-330000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:OtherComprehensiveIncomeBeforeTaxExchangeDifferencesOnTranslation",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s2__4__32": {
"value": "-293000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:OtherComprehensiveIncomeBeforeTaxExchangeDifferencesOnTranslation",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s2__3__33": {
"value": "269000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s2__4__33": {
"value": "-109000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s2__3__34": {
"value": "-571000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s2__4__34": {
"value": "-278000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s2__3__35": {
"value": "-555000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:OtherComprehensiveIncome",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s2__4__35": {
"value": "-273000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:OtherComprehensiveIncome",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s2__3__36": {
"value": "3081000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:ComprehensiveIncome",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s2__4__36": {
"value": "4779000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:ComprehensiveIncome",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__3__5": {
"value": "7201000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:ProfitLossFromOperatingActivities",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__4__5": {
"value": "7320000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:ProfitLossFromOperatingActivities",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__3__6": {
"value": "590000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:AdjustmentsForAmortisationExpense",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__4__6": {
"value": "451000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:AdjustmentsForAmortisationExpense",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__3__7": {
"value": "863000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:AdjustmentsForDepreciationExpense",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__4__7": {
"value": "839000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:AdjustmentsForDepreciationExpense",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__3__8": {
"value": "142000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:OtherAdjustmentsForNoncashItems",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__4__8": {
"value": "-92000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:OtherAdjustmentsForNoncashItems",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__3__9": {
"value": "785000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:IncreaseDecreaseInWorkingCapital",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__4__9": {
"value": "1032000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:IncreaseDecreaseInWorkingCapital",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__3__10": {
"value": "30000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:InterestReceivedClassifiedAsOperatingActivities",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__4__10": {
"value": "82000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:InterestReceivedClassifiedAsOperatingActivities",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__3__11": {
"value": "825000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:InterestPaidClassifiedAsOperatingActivities",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__4__11": {
"value": "844000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:InterestPaidClassifiedAsOperatingActivities",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__3__12": {
"value": "571000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__4__12": {
"value": "3958000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__3__13": {
"value": "6645000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:CashFlowsFromUsedInOperatingActivities",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__4__13": {
"value": "2766000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:CashFlowsFromUsedInOperatingActivities",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__3__16": {
"value": "121000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__4__16": {
"value": "180000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__3__17": {
"value": "20000000.0",
"decimals": -6,
"dimensions": {
"concept": "COL:PurchaseOfLandAndBuildingsClassifiedAsInvestingActivities",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__4__17": {
"value": "7000000.0",
"decimals": -6,
"dimensions": {
"concept": "COL:PurchaseOfLandAndBuildingsClassifiedAsInvestingActivities",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__3__18": {
"value": "71000000.0",
"decimals": -6,
"dimensions": {
"concept": "COL:PurchaseOfPlantAndMachineryAndOtherFixturesFittingsToolsAndEquipmentClassifiedAsInvestingActivities",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__4__18": {
"value": "87000000.0",
"decimals": -6,
"dimensions": {
"concept": "COL:PurchaseOfPlantAndMachineryAndOtherFixturesFittingsToolsAndEquipmentClassifiedAsInvestingActivities",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__3__19": {
"value": "1215000000.0",
"decimals": -6,
"dimensions": {
"concept": "COL:PurchaseOfConstructionInProgressClassifiedAsInvestingActivities",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__4__19": {
"value": "1072000000.0",
"decimals": -6,
"dimensions": {
"concept": "COL:PurchaseOfConstructionInProgressClassifiedAsInvestingActivities",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__3__20": {
"value": "5000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__4__20": {
"value": "15000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__3__21": {
"value": "21000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__4__21": {
"value": "13000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__3__22": {
"value": "192000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__4__22": {
"value": "8000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__3__23": {
"value": "-1251000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:CashFlowsFromUsedInInvestingActivities",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__4__23": {
"value": "-1336000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:CashFlowsFromUsedInInvestingActivities",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__3__26": {
"value": "5394000000.0",
"decimals": -6,
"dimensions": {
"concept": "COL:CashFlowsFromUsedInOperatingAndInvestingActivities",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__4__26": {
"value": "1430000000.0",
"decimals": -6,
"dimensions": {
"concept": "COL:CashFlowsFromUsedInOperatingAndInvestingActivities",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__3__29": {
"value": "4958000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:DividendsPaidClassifiedAsFinancingActivities",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__4__29": {
"value": "4720000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:DividendsPaidClassifiedAsFinancingActivities",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__3__30": {
"value": "27000000.0",
"decimals": -6,
"dimensions": {
"concept": "COL:ProceedsFromSaleOrIssueOfTreasurySharesAndProceedsFromExerciseOfOptionsClassifiedAsFinancingActivities",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__4__30": {
"value": "500000000.0",
"decimals": -6,
"dimensions": {
"concept": "COL:ProceedsFromSaleOrIssueOfTreasurySharesAndProceedsFromExerciseOfOptionsClassifiedAsFinancingActivities",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__3__31": {
"value": "-4931000000.0",
"decimals": -6,
"dimensions": {
"concept": "COL:FinancingFromShareholdersClassifiedAsFinancingActivities",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__4__31": {
"value": "-4220000000.0",
"decimals": -6,
"dimensions": {
"concept": "COL:FinancingFromShareholdersClassifiedAsFinancingActivities",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__3__32": {
"value": "281000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__4__32": {
"value": "268000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__3__33": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:RepaymentsOfBondsNotesAndDebentures",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__4__33": {
"value": "4848000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:RepaymentsOfBondsNotesAndDebentures",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__3__34": {
"value": "2783000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__4__34": {
"value": "5000000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__3__35": {
"value": "-2758000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__4__35": {
"value": "2818000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__3__36": {
"value": "-5187000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:CashFlowsFromUsedInFinancingActivities",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__4__36": {
"value": "-1518000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:CashFlowsFromUsedInFinancingActivities",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__3__39": {
"value": "207000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__4__39": {
"value": "-88000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__3__40": {
"value": "788000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:CashAndCashEquivalents",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__4__40": {
"value": "911000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:CashAndCashEquivalents",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__3__41": {
"value": "-48000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__4__41": {
"value": "-31000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__3__42": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__4__42": {
"value": "-4000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__3__43": {
"value": "207000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__4__43": {
"value": "-88000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__3__44": {
"value": "947000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:CashAndCashEquivalents",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s3__4__44": {
"value": "788000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:CashAndCashEquivalents",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__3__5": {
"value": "29811000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:IntangibleAssetsAndGoodwill",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__4__5": {
"value": "30332000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:IntangibleAssetsAndGoodwill",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__3__6": {
"value": "6201000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:PropertyPlantAndEquipment",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__4__6": {
"value": "5649000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:PropertyPlantAndEquipment",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__3__7": {
"value": "884000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:RightofuseAssets",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__4__7": {
"value": "922000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:RightofuseAssets",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__3__8": {
"value": "90000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__4__8": {
"value": "74000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__3__9": {
"value": "587000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:DeferredTaxAssets",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__4__9": {
"value": "624000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:DeferredTaxAssets",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__3__10": {
"value": "316000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:CurrentTaxAssetsNoncurrent",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__4__10": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:CurrentTaxAssetsNoncurrent",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__3__11": {
"value": "25000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:OtherNoncurrentReceivables",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__4__11": {
"value": "28000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:OtherNoncurrentReceivables",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__3__12": {
"value": "37914000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:NoncurrentAssets",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__4__12": {
"value": "37629000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:NoncurrentAssets",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__3__15": {
"value": "3919000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:Inventories",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__4__15": {
"value": "3672000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:Inventories",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__3__16": {
"value": "4658000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:CurrentTradeReceivables",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__4__16": {
"value": "4675000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:CurrentTradeReceivables",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__3__17": {
"value": "64000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:CurrentTaxAssetsCurrent",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__4__17": {
"value": "509000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:CurrentTaxAssetsCurrent",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__3__18": {
"value": "454000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:OtherCurrentReceivables",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__4__18": {
"value": "366000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:OtherCurrentReceivables",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__3__19": {
"value": "411000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:CurrentPrepayments",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__4__19": {
"value": "434000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:CurrentPrepayments",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__3__20": {
"value": "947000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:CashAndCashEquivalents",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__4__20": {
"value": "788000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:CashAndCashEquivalents",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__3__21": {
"value": "10453000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:CurrentAssets",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__4__21": {
"value": "10444000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:CurrentAssets",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__3__24": {
"value": "48367000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:Assets",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__4__24": {
"value": "48073000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:Assets",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__3__27": {
"value": "228000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:IssuedCapital",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__4__27": {
"value": "228000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:IssuedCapital",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__3__28": {
"value": "-2137000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:ReserveOfExchangeDifferencesOnTranslation",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__4__28": {
"value": "-1837000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:ReserveOfExchangeDifferencesOnTranslation",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__3__29": {
"value": "356000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:ReserveOfCashFlowHedges",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__4__29": {
"value": "329000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:ReserveOfCashFlowHedges",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__3__30": {
"value": "4057000000.0",
"decimals": -6,
"dimensions": {
"concept": "COL:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersRecognisedInEquity",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__4__30": {
"value": "3831000000.0",
"decimals": -6,
"dimensions": {
"concept": "COL:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersRecognisedInEquity",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__3__31": {
"value": "13618000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:RetainedEarnings",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__4__31": {
"value": "15391000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:RetainedEarnings",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__3__32": {
"value": "16122000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:Equity",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__4__32": {
"value": "17942000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:Equity",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__3__35": {
"value": "111000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:NoncurrentProvisionsForEmployeeBenefits",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__4__35": {
"value": "126000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:NoncurrentProvisionsForEmployeeBenefits",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__3__36": {
"value": "3042000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:DeferredTaxLiabilities",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__4__36": {
"value": "2481000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:DeferredTaxLiabilities",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__3__37": {
"value": "25000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:OtherLongtermProvisions",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__4__37": {
"value": "21000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:OtherLongtermProvisions",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__3__38": {
"value": "11570000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:NoncurrentPortionOfNoncurrentBondsIssued",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__4__38": {
"value": "11557000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:NoncurrentPortionOfNoncurrentBondsIssued",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__3__39": {
"value": "7783000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:NoncurrentPortionOfOtherNoncurrentBorrowings",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__4__39": {
"value": "5000000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:NoncurrentPortionOfOtherNoncurrentBorrowings",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__3__40": {
"value": "2488000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:CurrentTaxLiabilitiesNoncurrent",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__4__40": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:CurrentTaxLiabilitiesNoncurrent",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__3__41": {
"value": "19000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:OtherNoncurrentPayables",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__4__41": {
"value": "1000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:OtherNoncurrentPayables",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__3__42": {
"value": "696000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:NoncurrentLeaseLiabilities",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__4__42": {
"value": "734000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:NoncurrentLeaseLiabilities",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__3__43": {
"value": "6000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:NoncurrentAccrualsAndNoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__4__43": {
"value": "7000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:NoncurrentAccrualsAndNoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__3__44": {
"value": "25740000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:NoncurrentLiabilities",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__4__44": {
"value": "19927000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:NoncurrentLiabilities",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__3__47": {
"value": "8000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:CurrentProvisionsForEmployeeBenefits",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__4__47": {
"value": "7000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:CurrentProvisionsForEmployeeBenefits",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__3__48": {
"value": "51000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:OtherShorttermProvisions",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__4__48": {
"value": "48000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:OtherShorttermProvisions",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__3__49": {
"value": "2328000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__4__49": {
"value": "5085000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__3__50": {
"value": "1324000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__4__50": {
"value": "1519000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__3__51": {
"value": "149000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:CurrentTaxLiabilitiesCurrent",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__4__51": {
"value": "866000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:CurrentTaxLiabilitiesCurrent",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__3__52": {
"value": "2382000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:OtherCurrentPayables",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__4__52": {
"value": "2425000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:OtherCurrentPayables",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__3__53": {
"value": "262000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:CurrentLeaseLiabilities",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__4__53": {
"value": "253000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:CurrentLeaseLiabilities",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__3__54": {
"value": "1000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:CurrentAccrualsAndCurrentDeferredIncomeIncludingCurrentContractLiabilities",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__4__54": {
"value": "1000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:CurrentAccrualsAndCurrentDeferredIncomeIncludingCurrentContractLiabilities",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__3__55": {
"value": "6505000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:CurrentLiabilities",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__4__55": {
"value": "10204000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:CurrentLiabilities",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__3__58": {
"value": "48367000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:EquityAndLiabilities",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s4__4__58": {
"value": "48073000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:EquityAndLiabilities",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s5__3__5": {
"value": "18000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:Equity",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:IssuedCapitalASharesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__4__5": {
"value": "210000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:Equity",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:IssuedCapitalBSharesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__5__5": {
"value": "-1837000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:Equity",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__6__5": {
"value": "329000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:Equity",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfCashFlowHedgesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__7__5": {
"value": "3831000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:Equity",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersRecognisedInEquityMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__8__5": {
"value": "15391000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:Equity",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__9__5": {
"value": "17942000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:Equity",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s5__3__6": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:ProfitLoss",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:IssuedCapitalASharesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__4__6": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:ProfitLoss",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:IssuedCapitalBSharesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__5__6": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:ProfitLoss",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__6__6": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:ProfitLoss",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfCashFlowHedgesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__7__6": {
"value": "5184000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:ProfitLoss",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersRecognisedInEquityMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__8__6": {
"value": "-1548000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:ProfitLoss",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__9__6": {
"value": "3636000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:ProfitLoss",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s5__3__7": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:OtherComprehensiveIncome",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:IssuedCapitalASharesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__4__7": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:OtherComprehensiveIncome",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:IssuedCapitalBSharesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__5__7": {
"value": "-300000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:OtherComprehensiveIncome",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__6__7": {
"value": "27000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:OtherComprehensiveIncome",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfCashFlowHedgesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__7__7": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:OtherComprehensiveIncome",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersRecognisedInEquityMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__8__7": {
"value": "-283000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:OtherComprehensiveIncome",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__9__7": {
"value": "-555000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:OtherComprehensiveIncome",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s5__3__8": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:ComprehensiveIncome",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:IssuedCapitalASharesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__4__8": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:ComprehensiveIncome",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:IssuedCapitalBSharesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__5__8": {
"value": "-300000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:ComprehensiveIncome",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__6__8": {
"value": "27000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:ComprehensiveIncome",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfCashFlowHedgesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__7__8": {
"value": "5184000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:ComprehensiveIncome",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersRecognisedInEquityMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__8__8": {
"value": "-1831000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:ComprehensiveIncome",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__9__8": {
"value": "3081000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:ComprehensiveIncome",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s5__3__9": {
"value": "0.0",
"dimensions": {
"concept": "COL:IncreaseDecreaseThroughExerciseOfOptionsAndSaleOrIssueOfTreasuryShares",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:IssuedCapitalASharesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__4__9": {
"value": "0.0",
"dimensions": {
"concept": "COL:IncreaseDecreaseThroughExerciseOfOptionsAndSaleOrIssueOfTreasuryShares",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:IssuedCapitalBSharesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__5__9": {
"value": "0.0",
"dimensions": {
"concept": "COL:IncreaseDecreaseThroughExerciseOfOptionsAndSaleOrIssueOfTreasuryShares",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__6__9": {
"value": "0.0",
"dimensions": {
"concept": "COL:IncreaseDecreaseThroughExerciseOfOptionsAndSaleOrIssueOfTreasuryShares",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfCashFlowHedgesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__7__9": {
"value": "0.0",
"dimensions": {
"concept": "COL:IncreaseDecreaseThroughExerciseOfOptionsAndSaleOrIssueOfTreasuryShares",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersRecognisedInEquityMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__8__9": {
"value": "27000000.0",
"decimals": -6,
"dimensions": {
"concept": "COL:IncreaseDecreaseThroughExerciseOfOptionsAndSaleOrIssueOfTreasuryShares",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__9__9": {
"value": "27000000.0",
"decimals": -6,
"dimensions": {
"concept": "COL:IncreaseDecreaseThroughExerciseOfOptionsAndSaleOrIssueOfTreasuryShares",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s5__3__10": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:IssuedCapitalASharesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__4__10": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:IssuedCapitalBSharesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__5__10": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__6__10": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfCashFlowHedgesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__7__10": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersRecognisedInEquityMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__8__10": {
"value": "79000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__9__10": {
"value": "79000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s5__3__11": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:IssuedCapitalASharesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__4__11": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:IssuedCapitalBSharesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__5__11": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__6__11": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfCashFlowHedgesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__7__11": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersRecognisedInEquityMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__8__11": {
"value": "48000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__9__11": {
"value": "48000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s5__3__12": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParentRelatingToCurrentYear",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:IssuedCapitalASharesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__4__12": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParentRelatingToCurrentYear",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:IssuedCapitalBSharesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__5__12": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParentRelatingToCurrentYear",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__6__12": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParentRelatingToCurrentYear",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfCashFlowHedgesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__7__12": {
"value": "1127000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParentRelatingToCurrentYear",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersRecognisedInEquityMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__8__12": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParentRelatingToCurrentYear",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__9__12": {
"value": "1127000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParentRelatingToCurrentYear",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s5__3__13": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:DividendsPaid",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:IssuedCapitalASharesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__4__13": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:DividendsPaid",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:IssuedCapitalBSharesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__5__13": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:DividendsPaid",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__6__13": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:DividendsPaid",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfCashFlowHedgesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__7__13": {
"value": "3831000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:DividendsPaid",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersRecognisedInEquityMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__8__13": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:DividendsPaid",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__9__13": {
"value": "3831000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:DividendsPaid",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s5__3__14": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:IssuedCapitalASharesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__4__14": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:IssuedCapitalBSharesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__5__14": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__6__14": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfCashFlowHedgesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__7__14": {
"value": "-4958000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersRecognisedInEquityMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__8__14": {
"value": "58000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__9__14": {
"value": "-4899000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s5__3__15": {
"value": "18000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:Equity",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2025-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:IssuedCapitalASharesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__4__15": {
"value": "210000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:Equity",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2025-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:IssuedCapitalBSharesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__5__15": {
"value": "-2137000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:Equity",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2025-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__6__15": {
"value": "356000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:Equity",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2025-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfCashFlowHedgesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__7__15": {
"value": "4057000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:Equity",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2025-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersRecognisedInEquityMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__8__15": {
"value": "13618000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:Equity",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2025-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__9__15": {
"value": "16122000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:Equity",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2025-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s5__3__22": {
"value": "18000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:Equity",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:IssuedCapitalASharesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__4__22": {
"value": "210000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:Equity",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:IssuedCapitalBSharesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__5__22": {
"value": "-1579000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:Equity",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__6__22": {
"value": "423000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:Equity",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfCashFlowHedgesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__7__22": {
"value": "3595000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:Equity",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersRecognisedInEquityMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__8__22": {
"value": "14632000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:Equity",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__9__22": {
"value": "17299000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:Equity",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s5__3__23": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:ProfitLoss",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:IssuedCapitalASharesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__4__23": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:ProfitLoss",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:IssuedCapitalBSharesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__5__23": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:ProfitLoss",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__6__23": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:ProfitLoss",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfCashFlowHedgesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__7__23": {
"value": "4956000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:ProfitLoss",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersRecognisedInEquityMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__8__23": {
"value": "96000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:ProfitLoss",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__9__23": {
"value": "5052000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:ProfitLoss",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s5__3__24": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:OtherComprehensiveIncome",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:IssuedCapitalASharesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__4__24": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:OtherComprehensiveIncome",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:IssuedCapitalBSharesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__5__24": {
"value": "-258000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:OtherComprehensiveIncome",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__6__24": {
"value": "-94000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:OtherComprehensiveIncome",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfCashFlowHedgesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__7__24": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:OtherComprehensiveIncome",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersRecognisedInEquityMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__8__24": {
"value": "79000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:OtherComprehensiveIncome",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__9__24": {
"value": "-273000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:OtherComprehensiveIncome",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s5__3__25": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:ComprehensiveIncome",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:IssuedCapitalASharesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__4__25": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:ComprehensiveIncome",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:IssuedCapitalBSharesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__5__25": {
"value": "-258000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:ComprehensiveIncome",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__6__25": {
"value": "-94000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:ComprehensiveIncome",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfCashFlowHedgesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__7__25": {
"value": "4956000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:ComprehensiveIncome",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersRecognisedInEquityMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__8__25": {
"value": "175000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:ComprehensiveIncome",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__9__25": {
"value": "4779000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:ComprehensiveIncome",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s5__3__26": {
"value": "0.0",
"dimensions": {
"concept": "COL:IncreaseDecreaseThroughExerciseOfOptionsAndSaleOrIssueOfTreasuryShares",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:IssuedCapitalASharesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__4__26": {
"value": "0.0",
"dimensions": {
"concept": "COL:IncreaseDecreaseThroughExerciseOfOptionsAndSaleOrIssueOfTreasuryShares",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:IssuedCapitalBSharesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__5__26": {
"value": "0.0",
"dimensions": {
"concept": "COL:IncreaseDecreaseThroughExerciseOfOptionsAndSaleOrIssueOfTreasuryShares",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__6__26": {
"value": "0.0",
"dimensions": {
"concept": "COL:IncreaseDecreaseThroughExerciseOfOptionsAndSaleOrIssueOfTreasuryShares",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfCashFlowHedgesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__7__26": {
"value": "0.0",
"dimensions": {
"concept": "COL:IncreaseDecreaseThroughExerciseOfOptionsAndSaleOrIssueOfTreasuryShares",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersRecognisedInEquityMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__8__26": {
"value": "500000000.0",
"decimals": -6,
"dimensions": {
"concept": "COL:IncreaseDecreaseThroughExerciseOfOptionsAndSaleOrIssueOfTreasuryShares",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__9__26": {
"value": "500000000.0",
"decimals": -6,
"dimensions": {
"concept": "COL:IncreaseDecreaseThroughExerciseOfOptionsAndSaleOrIssueOfTreasuryShares",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s5__3__27": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:IssuedCapitalASharesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__4__27": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:IssuedCapitalBSharesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__5__27": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__6__27": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfCashFlowHedgesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__7__27": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersRecognisedInEquityMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__8__27": {
"value": "67000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__9__27": {
"value": "67000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s5__3__28": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:IssuedCapitalASharesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__4__28": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:IssuedCapitalBSharesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__5__28": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__6__28": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfCashFlowHedgesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__7__28": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersRecognisedInEquityMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__8__28": {
"value": "-17000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__9__28": {
"value": "-17000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s5__3__29": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParentRelatingToCurrentYear",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:IssuedCapitalASharesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__4__29": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParentRelatingToCurrentYear",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:IssuedCapitalBSharesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__5__29": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParentRelatingToCurrentYear",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__6__29": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParentRelatingToCurrentYear",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfCashFlowHedgesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__7__29": {
"value": "1125000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParentRelatingToCurrentYear",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersRecognisedInEquityMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__8__29": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParentRelatingToCurrentYear",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__9__29": {
"value": "1125000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParentRelatingToCurrentYear",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s5__3__30": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:DividendsPaid",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:IssuedCapitalASharesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__4__30": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:DividendsPaid",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:IssuedCapitalBSharesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__5__30": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:DividendsPaid",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__6__30": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:DividendsPaid",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfCashFlowHedgesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__7__30": {
"value": "3595000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:DividendsPaid",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersRecognisedInEquityMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__8__30": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:DividendsPaid",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__9__30": {
"value": "3595000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:DividendsPaid",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s5__3__31": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:IssuedCapitalASharesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__4__31": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:IssuedCapitalBSharesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__5__31": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__6__31": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfCashFlowHedgesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__7__31": {
"value": "-4720000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersRecognisedInEquityMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__8__31": {
"value": "584000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__9__31": {
"value": "-4136000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s5__3__32": {
"value": "18000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:Equity",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:IssuedCapitalASharesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__4__32": {
"value": "210000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:Equity",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:IssuedCapitalBSharesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__5__32": {
"value": "-1837000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:Equity",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__6__32": {
"value": "329000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:Equity",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfCashFlowHedgesMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__7__32": {
"value": "3831000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:Equity",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "COL:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersRecognisedInEquityMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__8__32": {
"value": "15391000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:Equity",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember",
"unit": "iso4217:DKK"
}
},
"f0__s5__9__32": {
"value": "17942000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:Equity",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00",
"unit": "iso4217:DKK"
}
},
"f0__s7__7__19": {
"value": "Note 1Basis of preparationThe consolidated financial statements for 2024/25 have been prepared in accordance with the IFRS Accounting Standards as adopted by the EU and additional disclosure requirements pursuant to the Danish Financial Statements Act for Class D companies.General informationThe financial statements have been prepared on the basis of the historical cost principle, modified in that certain financial assets and liabilities are measured at fair value. Subsequent to initial recognition, the assets and liabilities are measured as described below in respect of each individual item or in the relevant note.Significant estimates and judgementsIn connection with application of the accounting policies described, it may be necessary for Management to make estimates and judgements in respect of the accounting items. Further, Management make judgements on the reported amounts of assets, liabilities, net sales, expenses and related disclosures. The estimates and assumptions applied are based on historical experience and other factors that Management considers reasonable under the circumstances, but which are inherently uncertain and unpredictable. Such assumptions may be incomplete or inaccurate, and unexpected events or circumstances may arise. In addition, the company is subject to risks and uncertainties that may cause actual outcomes to deviate from these estimates.It may be necessary to change previous estimates as a result of changes to the assumptions on which the estimates were based or due to new information or subsequent events. A further description of the principal accounting estimates and judgements is provided in the relevant notes. Management has made significant accounting estimates and judgements in respect of the following areas:Risk of impact and degree of Area Estimate / judgement NoteestimationGoodwill and other intangible assets Estimate and judgement 11Acquisitions of businesses Estimate and judgement 11Inventories Estimate 14Deferred tax assets and uncertain tax positions Estimate and judgement 8Other provisions Estimate 18Macroeconomic uncertaintyManagement has considered the ongoing impacts on income and expenses from the inflationary pressure and higher interest rates. Changes in prices and direct costs are based on past experience and management\u2019s expectation of future changes in the markets where the Group operates. Climate-related risksColoplast is exposed to risks associated with climate change. In preparing the consolidated financial statements for 2024/25, management has considered the impact of climate change. While sustainability is an embedded part of doing business, management does not consider sustainability targets or climate change to have a significant impact on the accounting estimates and judgements consistent with the assessment that climate change is not expected to have significant impact on the Group\u2019s future cash flows, the carrying amount of non-current assets, or going concern assessment.Note 2Changes in accounting policiesEffective from the 2024/25 financial year, the Coloplast Group has implemented all new, updated or amended IFRS Accounting Standards and interpretations (IFRSs) as issued by the IASB and IFRSs adopted by the EU that are effective for the 2024/25 financial year.Coloplast has implemented the amendments to IAS 1 Presentation of Financial Statements - Classification of Liabilities as Current or Non-current and IFRS 16 Leases. The amendment did not have a material impact on recognition or measurement.The implementation of new, updated or amended IFRS Accounting Standards and interpretations (IFRSs and IFRICs) did not, in all material respects, affect the financial statements. New financial reporting standards to be adoptedNew and amended standards are implemented when taking effect. In April 2024, the IASB issued IFRS 18, which replaces IAS 1. IFRS 18 introduces amongst other new requirements for presentation within the statement of profit and loss and disclosures of management-defined performance measures. The standard will be effective from the financial year 2027/28. The Group is currently working to identify all impacts the amendments will have on the primary financial statements and notes to the financial statements. The new IFRS 18 is expected to change the presentation of the Income statement and to differentiate between earnings from operating activities, investment activities and financing activities. IFRS 18 will also add additional disclosures but will not change any accounting policies on recognition and measurement, hence it will not change reported net results.Reporting standards or interpretations which are not adopted by the EU have not been applied in this annual report.Note 3General accounting policiesThis section provides a summary of significant accounting policies, and other general accounting policies. A detailed description of the accounting policies applied and the estimates made relative to each individual item is provided in relevant notes, such that all information about a specific accounting item can be found there.Foreign currencyThe financial statement items of individual Group entities are measured in the currency used in the primary economic environment in which the entity operates (functional currency). The consolidated financial statements are presented in Danish kroner (DKK), which is the functional and presentation currency of the parent company. Other currencies are considered foreign currencies.Translation of foreign currenciesTransactions denominated in foreign currencies are translated into an entity\u2019s functional currency at the exchange rate prevailing at the transaction date.Monetary items denominated in foreign currencies are translated at the exchange rate prevailing at the balance sheet date. Exchange adjustments arising as the difference between exchange rates at the balance sheet date and exchange rates at the transaction date of monetary items are recognised in the income statement as financial income or expenses. Exchange differences from a monetary item that is included as part of the net investment in a foreign operation, is recognized in other comprehensive income.On translation of entities with a functional currency other than DKK, balance sheet items are translated at the exchange rates at the balance sheet date and income statement items are translated at the exchange rates at the transaction date. The resulting exchange adjustments are taken directly to other comprehensive income.The Argentinian economy has been considered a hyperinflation economy effective from 1 July 2018. Accordingly, the Group\u2019s Argentinian subsidiary is recognised in accordance with IAS 29. The subsidiary\u2019s financial statements were inflation adjusted at a retail price index increase of 33% (237% in 2023/24 - source: Bloomberg) prior to recognition in the consolidated financial statements. The adjustment of the beginning of period equity is recognised in currency translation in equity. The income statement and the balance sheet of the inflation-adjusted financial statements are included in the consolidated financial statements at the exchange rate applying at the balance sheet date standing at 0.47.Consolidation and business combinationsThe consolidated financial statements comprise the financial statements of Coloplast A/S (the parent company) and enterprises (subsidiaries) controlled by the parent company. The parent company is considered to exercise control when it has power over the relevant activities of the enterprise, is exposed or has rights to a variable return from the investment and has the ability to affect those returns through its power.The consolidated financial statements are prepared by aggregating the financial statements of the parent company and the individual subsidiaries, all of which are prepared in accordance with the Group\u2019s accounting policies. Intra-group transactions, balances, dividends and unrealised gains and losses on transactions between Group companies are eliminated. Enterprises, which are not subsidiaries but in which the Group holds at least 20% of the voting rights or otherwise exercise a significant influence, are regarded as associates. The Group\u2019s proportionate share of unrealised gains and losses on transactions between the Coloplast Group and associates is eliminated. Enterprises recently acquired or divested are included in the consolidation in the period in which the Coloplast Group has control of the enterprise. Comparative figures are not restated to reflect acquisitions.Acquisitions are accounted for using the acquisition method, according to which the assets and liabilities and contingent liabilities of enterprises acquired are measured at fair value at the date of acquisition. Goodwill on the acquisition of subsidiaries or associates is calculated as the difference between the fair value of the consideration and the fair value of the Group companies\u2019 proportionate share of identifiable assets less liabilities and contingent liabilities at the date of acquisition.The consideration for an enterprise consists of the fair value of the agreed consideration for the acquired enterprise. If part of the consideration is contingent on future events, such part is recognised at its fair value at the date of acquisition. Costs directly attributable to business combinations are recognised directly in the income statement as special items when incurred. In cases where the fair value of acquired identifiable assets, liabilities or contingent liabilities subsequently turns out to differ from the values calculated at the date of acquisition, the calculation, including goodwill and contingent consideration are adjusted until up to 12 months after the date of acquisition. Subsequently, goodwill is not adjusted.Goodwill arising in connection with the acquisition of subsidiaries is recognised in the balance sheet under intangible assets in the consolidated financial statements and tested annually for impairment.Marketable securitiesMarketable securities are part of a portfolio which is managed and measured on a fair value basis as per transaction date. Adjustments to fair value is recognised through profit or loss as financial items. Bonds forming part of repo transactions, i.e. the sale of bonds that are bought back at a later date for a fixed price remain classified as financial assets in the balance sheet, while amounts received from repo transactions are recognised as repo debt. Returns on such bonds are recognised under financials.Cash flow statementThe consolidated cash flow statement, which is presented according to the indirect method, shows the Group\u2019s cash flow from operating, investing and financing activities as well as the Group\u2019s cash and cash equivalents at the beginning and end of the year. Cash and cash equivalents comprise cash. Marketable securities include bonds with maturities of more than three months and are recognised under investing activities.Reporting under the ESEF RegulationThe Commission Delegated Regulation (EU) 2019/815 on the European Single Electronic Format (ESEF Regulation) has introduced a single electronic reporting format for the annual financial reports of issuers with securities listed on the EU regulated markets. The ESEF Regulation sets out the following main requirements: (1) Issuers shall draw up and disclose their annual financial reports using the XHTML format; and (2) issuers that draw-up their primary consolidated financial statements in accordance with IFRS as endorsed by the EU shall tag those consolidated financial statements using inline eXtensible Business Reporting Language (iXBRL) and with effect from the 2022/23 annual report block-tag the notes to the consolidated financial statements. The combination of the XHTML format with the iXBRL tags makes the annual financial reports both human-readable and machine-readable, thus enhancing accessibility, analysis and comparability of the information included in the annual financial reports.iXBRL tags shall comply with the ESEF taxonomy, which is included in the ESEF Regulation and developed based on the IFRS taxonomy published by the IFRS Foundation. As part of the tagging process financial statement line items are marked up to elements in the ESEF taxonomy. If a financial statement line item is not defined in the ESEF taxonomy, an extension to the taxonomy is created. Extensions have to be anchored to elements in the ESEF taxonomy, except for extensions which are subtotals.The annual report submitted to the Danish Financial Supervisory Authority (The Officially Appointed Mechanisms) consists of the XHTML document together with some technical files all included in a ZIP file named Coloplast-2025-09-30-en.ZIP.Accounting policiesRevenueRevenue comprises income from the sale of goods after deduction of any price reductions, quantity discounts or cash discounts. Sales transactions are recognised in the income statement at the point in time when control of the goods is transferred to the customer, and when the consideration is assessed to be collectible. Revenues from sales transactions are measured at the transaction price to which Coloplast expects to be entitled.Within all segments, revenues are typically recognised when the customer takes possession of the goods. Exceptions to this comprise Interventional Urology and Biologics revenues, as revenues from certain surgical products are generated from consignment sales as well as the contract manufacturing business. Certain surgical products within Interventional Urology are always available at our partner hospitals to ensure that all sizes and fits are always available. Revenues from consignment sales are recognised as the goods are used (i.e. in surgery). Revenues from contract manufacturing business is recognised when the products are available for delivery when this coincides with the transfer of control of the products.Coloplast generates most of its sales through distributors that operate under various conditions and who for that reason require varying sales agreements. Coloplast\u2019s distributor agreements contain volume and product-specific rebates, which require data management and monitoring of sales to individual distributors at the product level. Payment terms for trade receivables from customers depend on creditworthiness, customary business practices and contract negotiations. Payment terms for some customers include a period of credit which commences when the products are shipped while other customers are requested to pay in advance or provide appropriate collateral for the payment. Prepayments from customers are recognised as revenue in the following period upon satisfying the performance obligations.Variable considerations include volume and product-specific rebates which, for some markets, are accumulated and paid annually or quarterly. Accruals for variable considerations are constrained by uncertainty of future events, such as the expected volume of sales, and require estimate.Revenue is measured at the fair value of the agreed consideration. All discounts granted are recognised in revenue. An estimate of expected returns is also recognised in revenue.Coloplast applies the practical expedient in IFRS 15, para 63 associated with the determination of whether a significant financing component exists for transactions where payment is expected in less than 12 months from the delivery of goods (transfer of control).As permitted under IFRS 15, no disclosures are made to the remaining performance obligations at 30 September 2025 that have an original expected duration of one year or less. There are no material performance obligations with an original expected duration extending beyond the period of more than one year after 30 September 2025.The operating segments are defined on the basis of the monthly reporting to the Executive Leadership Team, which is considered the chief operating decision maker, and the management structure. Reporting to Management is based on five operating segments: Chronic Care, Voice & Respiratory Care, Interventional Urology, Advanced Wound Dressings and Biologics. Management does not receive reporting on assets and liabilities by operating segments. Accordingly, the operating segments are not measured in this respect, nor do we allocate resources on this background.Accounting policiesSpecial items comprise material amounts of a non-recurring nature, such as costs relating to acquisitions, divestment, closure or structural changes etc. These items are presented separately to facilitate the comparability of the income statement and to provide a better picture of the operating results.Accounting policiesFinancial income and expenses include interest, financing costs of leases, realised and unrealised foreign exchange adjustments, gains on net monetary items in hyperinflationary economies, fair value adjustment of forward contracts transferred from other comprehensive income, fair value adjustments of cash settled share options, fees, market value adjustments of securities and dividend received on shares recognised under securities.See Note 22 to the consolidated financial statements for more information about accounting policy for items transferred from hedging reserve.Accounting policiesCurrent income tax assets and liabilities are measured at the amounts expected to be recovered from or paid to the tax authorities, based on tax legislation that is either enacted or substantively enacted as of the reporting date.Current and deferred income tax related to profit for the year is recognised in income statement, current and deferred income tax related to other comprehensive income is recognised in statement of comprehensive income and current and deferred income tax related to items recognised directly in equity is recognised in equity.Uncertain tax positions are assessed individually and are generally recognised as part of non-current tax assets or liabilities. The uncertain tax positions that materialise and become certain or virtually certain are classified as current tax assets or liabilities.Interest income and expenses related to current taxes are included in financial items. Deferred tax is measured using the balance sheet liability method, based on temporary differences between the carrying amounts of assets and liabilities and their respective tax bases. Deferred tax is not recognised for differences arising from the initial recognition of assets or liabilities in transactions that do not affect accounting profit or taxable income, unless the transaction is part of a business combination. In such cases, deferred tax is determined based on management\u2019s intended use of the assets and settlement of the liabilities.Deferred tax assets are recognised to the extent it is probable that future positive taxable income will be generated, against which the temporary differences and tax losses can be utilised. Deferred tax assets are measured at expected net realisable values. The value of future tax deductions related to share option programmes is recognised as deferred tax, until they are exercised by the employees. Any estimated excess tax deduction compared to the costs realised in the income statement is charged to equity.Deferred tax is measured according to current tax regulations and the tax rates assumed to apply in year in which the asset or liability is expected to crystallise as current tax. Changes in deferred tax due to changed tax rates are recognised in the income statement or in the equity, depending on where the underlying item is recognised.No deferred tax is recognised on undistributed earnings in subsidiaries, as Coloplast has control over the timing of the distribution and can prevent the realisation of the related tax liability.Accounting policiesEarnings per share (EPS) reflects the ratio between profit for the year and the year\u2019s weighted average of issued, ordinary shares, excluding ordinary shares purchased by the Group and held as treasury shares. Earnings per share, diluted, is calculated as the net profit for the year divided by the average number of outstanding shares adjusted for the dilutive effect of outstanding share options in the moneyAccounting policiesIntangible assets with a finite life are measured at cost less accumulated amortisation and impairment losses. Subsequent milestone payments related to acquired patents, trademarks and know-how payable on achievement of a contingent event will be capitalised when the contingent event is achieved. Amortisation is made on a straight-line basis over the expected useful lives of the assets, which are: Software 3 \u2013 5 yearsAcquired patents, customer list, trademarks and know-how etc. 5 \u2013 20 yearsGoodwill and other intangible assets with indefinite lives are tested for impairment annually or whenever there is an indication of impairment, while the carrying amount of intangible assets with finite lives measured at cost or amortised cost are assessed if there is an indication of impairment. If a write-down is required, the carrying amount is written down to the recoverable amount. For the purpose of assessing impairment, assets are grouped in the smallest group of assets that generates identifiable cash inflows (cash-generating units). The cash-generating units are defined as the smallest identifiable group of assets that generates cash inflows and which are largely independent of cash flows from other assets or groups of assets.For other intangible assets, the amortisation period is determined on the basis of Management\u2019s best estimate of the expected economic lives of the assets. The expected economic lives are assessed at least annually, and the amortisation period is determined based on the latest assessment. For purposes of calculating amortisation, the residual value of the assets is zero, unless a third party has committed to purchasing the asset after its use or there is an active market for the asset. With the exception of goodwill and some specific trademarks, all intangible assets have a finite life.All in-house research and development costs are recognised in the income statement as incurred. Management believes that mandatory regulatory approvals of products, completing the development of new products involves a high degree of uncertainty, for which reason the technical feasibility criteria are not considered to have been met.Gains or losses on the disposal of intangible assets are stated as the difference between the selling price less costs to sell and the carrying amount at the date of disposal and are included in the income statement under other operating income or other operating expenses, respectively.Accounting policiesProperty, plant and equipment is measured at cost less accumulated depreciation and impairment losses. Cost comprises the cost of acquisition and expenses directly attributable to an acquisition until the asset is ready for use. In case of assets manufactured by the company, cost comprises materials, components, sub-supplier services, direct labour and costs directly attributable to the manufactured asset. In addition, borrowing costs are recognised as part of cost. Depreciation is provided on a straight-line basis over the expected useful lives of the assets. The expected useful lives are:Land Not depreciatedBuildings 15 - 25 yearsBuilding installations 5 - 10 yearsPlant and machinery 5 - 15 yearsOther fixtures and fittings, tools and equipment 3 - 7 yearsAccounting policiesAt the commencement date, when a leased asset is made available for use, a right-of-use asset and a corresponding lease liability is recognised on the balance sheet.Right-of-use assets are initially measured at cost, which comprises the initial amount of the lease liability, any lease payments made prior to the commencement date and any initial direct costs. Subsequently, the right-of-use asset is measured at cost less depreciation and impairment losses and adjusted for the remeasurement of the lease liability. The right-of-use assets are depreciated on a straight-line basis over the shorter of the lease term or the useful life of the right-of-use asset.Options to extend the initial leasing period are only included in the initial measurement if it is reasonably certain that the option will be utilised.Lease liabilities are initially measured at the present value of future lease payments. The lease payments are discounted using the implicit rate of the lease contract or, if not readily determinable, the incremental borrowing rate of Coloplast for loans with similar term and security. As a practical expedient, the discount rates are determined on basis of a portfolio of leases with similar characteristics, e.g. a portfolio of leased cars in a specific country. The lease liabilities are subsequently reduced by the portion of lease payments which is regarded as repayment of those lease liabilities. Lease liabilities are remeasured in the event of a lease modification or a reassessment of the lease term which in turn may also impact the carrying value of the right-of-use assets. The lease term is reassessed when a significant event or change, which is within the control of Coloplast, affects the prior assessment.Short-term leases and leases of low-value assets are exempted from the above accounting model. Consequently, lease payments associated with such lease contracts are recognised as an operating expense on either a straight-line basis over the lease term or another systematic basis which is more representative of the pattern of the benefit of the leased assets.The extent of residual value guarantees for right-of-use assets is limited and expected payments are included in the initial amount of the lease liability.Accounting policiesInventories are measured at the lower of cost and net realisable value. Cost is determined using the FIFO principle. The cost of finished goods and work in progress comprises raw materials, direct labour, other direct costs and indirect production overheads. Production overheads comprise indirect material and labour costs, maintenance and depreciation of the machinery and production buildings used in the manufacturing process as well as costs of production administration and management. Net realisable value is the expected selling price less cost of completion and costs to sell.Accounting policiesReceivables consist mainly of trade receivables. On initial recognition, receivables are measured at fair value and subsequently at amortised cost. Receivables are written down on the basis of an individual assessment and the simplified approach in accordance with IFRS 9 where loss allowances are based on lifetime expected credit losses.Accounting policiesShare options are granted to the executive management and senior management. For equity-settled schemes, the fair value of options is determined at the grant date. The option value is subsequently recognised over the vesting period as staff costs. For cash-settled schemes, the fair value of options granted during the period is recognised as staff costs, whereas the fair value adjustment of granted options from previous periods is recognised under financial items. The purchase and selling prices of treasury shares on exercise of share options are deducted from or added to equity, as the case may be.Accounting policiesIn defined contribution plans, the Group makes regular payments of fixed contributions to independent pension funds and insurance companies. The Group is under no obligation to pay additional contributions. Costs for defined contribution plans are recognised in the income statement as Coloplast assumes an obligation to make the payment.In defined benefit plans, the Group is under an obligation to pay a defined benefit on retirement. The actuarially calculated present value less the fair value of any plan assets is recognised in the balance sheet under provision for pension and similar obligations or in plan assets in the balance sheet. The total service costs of the year plus calculated interest based on actuarial estimates and financial assumptions at the beginning of the year are recognised in the income statement. The difference between the forecast development in plan assets and liabilities and the realised values at the end of the year is called actuarial gains or losses and is recognised in other comprehensive income. In connection with a change in benefits regarding the employees\u2019 employment with the Group to date, there will be a change in the actuarial calculation of the net present value, which is taken directly to the profit or loss.Accounting policiesProvisions are recognised when the Group has a legal or constructive obligation arising from a past event, and it is probable that an outflow of the Group\u2019s financial resources will be required to settle the obligation. Provisions are measured as Management's best estimate of the amount with which the liability is expected to be settled. The Group recognises a provision for the replacement of products covered by warranties at the balance sheet date.Accounting policiesBorrowings from credit institutions are recognised at fair value less expenses incurred and subsequently at amortised cost.Certain borrowings are subject to specific leverage covenants which are complied with.Accounting policiesFinancial instruments are measured at either amortised cost or fair value. Those financial instruments, which are measured at fair value, can be categorised according to the fair value measurement hierarchy below:Level 1: Observable prices in active markets for identical instruments.Level 2: Valuation models primarily based on observable prices or traded prices of comparable instruments.Level 3: Valuation models primarily based on non-observable prices.The fair value of forward exchange contracts and other derivative financial instruments are considered a level 2 fair value measurement as the fair value is determined directly based on the published exchange rates and quoted forward exchange rates at balance sheet dates. The fair value of derivative financial instruments is calculated on the basis of current market data.Accounting policiesAt the initiation of derivative contracts, it is assessed whether they qualify for hedge accounting and the derivatives are classified as either cash flow hedges or fair value hedges. Cash flow hedges relates to highly probable forecasted transactions at a future point in time. Fair value hedges relate to changes in the fair value of assets or liabilities recognised on the balance sheet.Upon initial recognition, the fair values of derivative financial instruments are recognised as an asset or a liability on the balance sheet date. These are presented together with other receivables or other payables, respectively. The fair values of derivative financial instruments are subsequently remeasured at fair value at each reporting date.The subsequent value adjustments of cash flow hedges are recognised through other comprehensive income as a cash flow hedge reserve when the hedging relationship continues to meet the effectiveness requirement. The reserve is recognised in the income statement upon realisation of the hedged transactions. Interest hedge of bonds with fixed rate is recognised in the other comprehensive income as reserve for hedging, until the hedged interests will be recognised in the income statement. If a derivative financial instrument used to hedge expected future transactions expires, is sold or no longer qualifies for hedge accounting, any accumulated reserve remains in equity until the hedged transaction is concluded. If a transaction is no longer expected to be concluded, any reserve accumulated under equity is transferred to the income statement.The subsequent value adjustments of fair value hedges are recognised through profit or loss along with any adjustments of the value of the hedged asset that concern the hedged risk.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__22": {
"value": "Basis of preparationThe consolidated financial statements for 2024/25 have been prepared in accordance with the IFRS Accounting Standards as adopted by the EU and additional disclosure requirements pursuant to the Danish Financial Statements Act for Class D companies.",
"dimensions": {
"concept": "ifrs-full:StatementOfIFRSCompliance",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__20": {
"value": "Significant estimates and judgementsIn connection with application of the accounting policies described, it may be necessary for Management to make estimates and judgements in respect of the accounting items. Further, Management make judgements on the reported amounts of assets, liabilities, net sales, expenses and related disclosures. The estimates and assumptions applied are based on historical experience and other factors that Management considers reasonable under the circumstances, but which are inherently uncertain and unpredictable. Such assumptions may be incomplete or inaccurate, and unexpected events or circumstances may arise. In addition, the company is subject to risks and uncertainties that may cause actual outcomes to deviate from these estimates.It may be necessary to change previous estimates as a result of changes to the assumptions on which the estimates were based or due to new information or subsequent events. A further description of the principal accounting estimates and judgements is provided in the relevant notes. Management has made significant accounting estimates and judgements in respect of the following areas:Risk of impact and degree of Area Estimate / judgement NoteestimationGoodwill and other intangible assets Estimate and judgement 11Acquisitions of businesses Estimate and judgement 11Inventories Estimate 14Deferred tax assets and uncertain tax positions Estimate and judgement 8Other provisions Estimate 18Macroeconomic uncertaintyManagement has considered the ongoing impacts on income and expenses from the inflationary pressure and higher interest rates. Changes in prices and direct costs are based on past experience and management\u2019s expectation of future changes in the markets where the Group operates. Climate-related risksColoplast is exposed to risks associated with climate change. In preparing the consolidated financial statements for 2024/25, management has considered the impact of climate change. While sustainability is an embedded part of doing business, management does not consider sustainability targets or climate change to have a significant impact on the accounting estimates and judgements consistent with the assessment that climate change is not expected to have significant impact on the Group\u2019s future cash flows, the carrying amount of non-current assets, or going concern assessment.Key accounting estimates and judgementsThe recognition of deferred tax assets and uncertain tax positions requires judgement by management. Deferred tax assets, including those arising from tax loss carry-forwards, are recognised when management assesses that it is probable the assets can be utilised within a foreseeable future through offsetting against future taxable income. This assessment is conducted annually and is based on updated forecasts and business plans, including any planned strategic initiatives. Given the Group\u2019s global operations, transfer pricing disputes may arise with tax authorities concerning intercompany pricing and related matters. Management evaluates such exposures using a probability-weighted approach to determine the appropriate recognition of obligations related to these disputes.Key accounting estimates and judgementsGoodwill and other intangible assets: The measurement of intangible assets, including goodwill and acquired patents, trademarks and know-how etc., could be materially affected by significant changes in estimates and assumptions underlying the calculation of recoverable amount. The carrying amount of these intangible assets was DKK 29,349 million as at 30 September 2025 (30 September 2024: DKK 29,736 million).Key accounting estimates and judgementsCapitalised production overheads have been calculated using a standard cost method, which is reviewed regularly to ensure the relevant assumptions concerning capacity utilisation, lead times and other relevant factors in the calculation of actual costs of sales. Changes to the calculation method for production overheads, including levels of capacity utilisation, lead times, etc. could affect the gross margin and the overall valuation of inventories.Key accounting estimates and judgementsProvisions for legal obligations consist of provisions for pending litigation. Management makes assessments of provisions and contingent liabilities, including the probable outcome of pending and possible future litigation, which is inherently subject to uncertain future events. Based on information available, Management believes that adequate provisions have been made for pending litigation, but there can be no assurance that the scope of these matters will not be extended, nor that material lawsuits, claims, legal proceedings or investigations will not arise in the future",
"dimensions": {
"concept": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__24": {
"value": "Note 2Changes in accounting policiesEffective from the 2024/25 financial year, the Coloplast Group has implemented all new, updated or amended IFRS Accounting Standards and interpretations (IFRSs) as issued by the IASB and IFRSs adopted by the EU that are effective for the 2024/25 financial year.Coloplast has implemented the amendments to IAS 1 Presentation of Financial Statements - Classification of Liabilities as Current or Non-current and IFRS 16 Leases. The amendment did not have a material impact on recognition or measurement.The implementation of new, updated or amended IFRS Accounting Standards and interpretations (IFRSs and IFRICs) did not, in all material respects, affect the financial statements. New financial reporting standards to be adoptedNew and amended standards are implemented when taking effect. In April 2024, the IASB issued IFRS 18, which replaces IAS 1. IFRS 18 introduces amongst other new requirements for presentation within the statement of profit and loss and disclosures of management-defined performance measures. The standard will be effective from the financial year 2027/28. The Group is currently working to identify all impacts the amendments will have on the primary financial statements and notes to the financial statements. The new IFRS 18 is expected to change the presentation of the Income statement and to differentiate between earnings from operating activities, investment activities and financing activities. IFRS 18 will also add additional disclosures but will not change any accounting policies on recognition and measurement, hence it will not change reported net results.Reporting standards or interpretations which are not adopted by the EU have not been applied in this annual report.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__23": {
"value": "Note 2Changes in accounting policiesEffective from the 2024/25 financial year, the Coloplast Group has implemented all new, updated or amended IFRS Accounting Standards and interpretations (IFRSs) as issued by the IASB and IFRSs adopted by the EU that are effective for the 2024/25 financial year.Coloplast has implemented the amendments to IAS 1 Presentation of Financial Statements - Classification of Liabilities as Current or Non-current and IFRS 16 Leases. The amendment did not have a material impact on recognition or measurement.The implementation of new, updated or amended IFRS Accounting Standards and interpretations (IFRSs and IFRICs) did not, in all material respects, affect the financial statements. New financial reporting standards to be adoptedNew and amended standards are implemented when taking effect. In April 2024, the IASB issued IFRS 18, which replaces IAS 1. IFRS 18 introduces amongst other new requirements for presentation within the statement of profit and loss and disclosures of management-defined performance measures. The standard will be effective from the financial year 2027/28. The Group is currently working to identify all impacts the amendments will have on the primary financial statements and notes to the financial statements. The new IFRS 18 is expected to change the presentation of the Income statement and to differentiate between earnings from operating activities, investment activities and financing activities. IFRS 18 will also add additional disclosures but will not change any accounting policies on recognition and measurement, hence it will not change reported net results.Reporting standards or interpretations which are not adopted by the EU have not been applied in this annual report.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__26": {
"value": "Foreign currencyThe financial statement items of individual Group entities are measured in the currency used in the primary economic environment in which the entity operates (functional currency). The consolidated financial statements are presented in Danish kroner (DKK), which is the functional and presentation currency of the parent company. Other currencies are considered foreign currencies.Translation of foreign currenciesTransactions denominated in foreign currencies are translated into an entity\u2019s functional currency at the exchange rate prevailing at the transaction date.Monetary items denominated in foreign currencies are translated at the exchange rate prevailing at the balance sheet date. Exchange adjustments arising as the difference between exchange rates at the balance sheet date and exchange rates at the transaction date of monetary items are recognised in the income statement as financial income or expenses. Exchange differences from a monetary item that is included as part of the net investment in a foreign operation, is recognized in other comprehensive income.On translation of entities with a functional currency other than DKK, balance sheet items are translated at the exchange rates at the balance sheet date and income statement items are translated at the exchange rates at the transaction date. The resulting exchange adjustments are taken directly to other comprehensive income.The Argentinian economy has been considered a hyperinflation economy effective from 1 July 2018. Accordingly, the Group\u2019s Argentinian subsidiary is recognised in accordance with IAS 29. The subsidiary\u2019s financial statements were inflation adjusted at a retail price index increase of 33% (237% in 2023/24 - source: Bloomberg) prior to recognition in the consolidated financial statements. The adjustment of the beginning of period equity is recognised in currency translation in equity. The income statement and the balance sheet of the inflation-adjusted financial statements are included in the consolidated financial statements at the exchange rate applying at the balance sheet date standing at 0.47.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__25": {
"value": "Foreign currencyThe financial statement items of individual Group entities are measured in the currency used in the primary economic environment in which the entity operates (functional currency). The consolidated financial statements are presented in Danish kroner (DKK), which is the functional and presentation currency of the parent company. Other currencies are considered foreign currencies.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForFunctionalCurrencyExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__27": {
"value": "The Argentinian economy has been considered a hyperinflation economy effective from 1 July 2018. Accordingly, the Group\u2019s Argentinian subsidiary is recognised in accordance with IAS 29. The subsidiary\u2019s financial statements were inflation adjusted at a retail price index increase of 33% (237% in 2023/24 - source: Bloomberg) prior to recognition in the consolidated financial statements. The adjustment of the beginning of period equity is recognised in currency translation in equity. The income statement and the balance sheet of the inflation-adjusted financial statements are included in the consolidated financial statements at the exchange rate applying at the balance sheet date standing at 0.47.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfHyperinflationaryReportingExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__31": {
"value": "Consolidation and business combinationsThe consolidated financial statements comprise the financial statements of Coloplast A/S (the parent company) and enterprises (subsidiaries) controlled by the parent company. The parent company is considered to exercise control when it has power over the relevant activities of the enterprise, is exposed or has rights to a variable return from the investment and has the ability to affect those returns through its power.The consolidated financial statements are prepared by aggregating the financial statements of the parent company and the individual subsidiaries, all of which are prepared in accordance with the Group\u2019s accounting policies. Intra-group transactions, balances, dividends and unrealised gains and losses on transactions between Group companies are eliminated. Enterprises, which are not subsidiaries but in which the Group holds at least 20% of the voting rights or otherwise exercise a significant influence, are regarded as associates. The Group\u2019s proportionate share of unrealised gains and losses on transactions between the Coloplast Group and associates is eliminated. Enterprises recently acquired or divested are included in the consolidation in the period in which the Coloplast Group has control of the enterprise. Comparative figures are not restated to reflect acquisitions.Acquisitions are accounted for using the acquisition method, according to which the assets and liabilities and contingent liabilities of enterprises acquired are measured at fair value at the date of acquisition. Goodwill on the acquisition of subsidiaries or associates is calculated as the difference between the fair value of the consideration and the fair value of the Group companies\u2019 proportionate share of identifiable assets less liabilities and contingent liabilities at the date of acquisition.The consideration for an enterprise consists of the fair value of the agreed consideration for the acquired enterprise. If part of the consideration is contingent on future events, such part is recognised at its fair value at the date of acquisition. Costs directly attributable to business combinations are recognised directly in the income statement as special items when incurred. In cases where the fair value of acquired identifiable assets, liabilities or contingent liabilities subsequently turns out to differ from the values calculated at the date of acquisition, the calculation, including goodwill and contingent consideration are adjusted until up to 12 months after the date of acquisition. Subsequently, goodwill is not adjusted.Goodwill arising in connection with the acquisition of subsidiaries is recognised in the balance sheet under intangible assets in the consolidated financial statements and tested annually for impairment.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__30": {
"value": "Consolidation and business combinationsThe consolidated financial statements comprise the financial statements of Coloplast A/S (the parent company) and enterprises (subsidiaries) controlled by the parent company. The parent company is considered to exercise control when it has power over the relevant activities of the enterprise, is exposed or has rights to a variable return from the investment and has the ability to affect those returns through its power.The consolidated financial statements are prepared by aggregating the financial statements of the parent company and the individual subsidiaries, all of which are prepared in accordance with the Group\u2019s accounting policies. Intra-group transactions, balances, dividends and unrealised gains and losses on transactions between Group companies are eliminated. Enterprises, which are not subsidiaries but in which the Group holds at least 20% of the voting rights or otherwise exercise a significant influence, are regarded as associates. The Group\u2019s proportionate share of unrealised gains and losses on transactions between the Coloplast Group and associates is eliminated. Enterprises recently acquired or divested are included in the consolidation in the period in which the Coloplast Group has control of the enterprise. Comparative figures are not restated to reflect acquisitions.Acquisitions are accounted for using the acquisition method, according to which the assets and liabilities and contingent liabilities of enterprises acquired are measured at fair value at the date of acquisition. Goodwill on the acquisition of subsidiaries or associates is calculated as the difference between the fair value of the consideration and the fair value of the Group companies\u2019 proportionate share of identifiable assets less liabilities and contingent liabilities at the date of acquisition.The consideration for an enterprise consists of the fair value of the agreed consideration for the acquired enterprise. If part of the consideration is contingent on future events, such part is recognised at its fair value at the date of acquisition. Costs directly attributable to business combinations are recognised directly in the income statement as special items when incurred. In cases where the fair value of acquired identifiable assets, liabilities or contingent liabilities subsequently turns out to differ from the values calculated at the date of acquisition, the calculation, including goodwill and contingent consideration are adjusted until up to 12 months after the date of acquisition. Subsequently, goodwill is not adjusted.Goodwill arising in connection with the acquisition of subsidiaries is recognised in the balance sheet under intangible assets in the consolidated financial statements and tested annually for impairment.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__29": {
"value": "Consolidation and business combinationsThe consolidated financial statements comprise the financial statements of Coloplast A/S (the parent company) and enterprises (subsidiaries) controlled by the parent company. The parent company is considered to exercise control when it has power over the relevant activities of the enterprise, is exposed or has rights to a variable return from the investment and has the ability to affect those returns through its power.The consolidated financial statements are prepared by aggregating the financial statements of the parent company and the individual subsidiaries, all of which are prepared in accordance with the Group\u2019s accounting policies. Intra-group transactions, balances, dividends and unrealised gains and losses on transactions between Group companies are eliminated. Enterprises, which are not subsidiaries but in which the Group holds at least 20% of the voting rights or otherwise exercise a significant influence, are regarded as associates. The Group\u2019s proportionate share of unrealised gains and losses on transactions between the Coloplast Group and associates is eliminated. Enterprises recently acquired or divested are included in the consolidation in the period in which the Coloplast Group has control of the enterprise. Comparative figures are not restated to reflect acquisitions.Acquisitions are accounted for using the acquisition method, according to which the assets and liabilities and contingent liabilities of enterprises acquired are measured at fair value at the date of acquisition. Goodwill on the acquisition of subsidiaries or associates is calculated as the difference between the fair value of the consideration and the fair value of the Group companies\u2019 proportionate share of identifiable assets less liabilities and contingent liabilities at the date of acquisition.The consideration for an enterprise consists of the fair value of the agreed consideration for the acquired enterprise. If part of the consideration is contingent on future events, such part is recognised at its fair value at the date of acquisition. Costs directly attributable to business combinations are recognised directly in the income statement as special items when incurred. In cases where the fair value of acquired identifiable assets, liabilities or contingent liabilities subsequently turns out to differ from the values calculated at the date of acquisition, the calculation, including goodwill and contingent consideration are adjusted until up to 12 months after the date of acquisition. Subsequently, goodwill is not adjusted.Goodwill arising in connection with the acquisition of subsidiaries is recognised in the balance sheet under intangible assets in the consolidated financial statements and tested annually for impairment.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfBusinessCombinationsExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__28": {
"value": "Consolidation and business combinationsThe consolidated financial statements comprise the financial statements of Coloplast A/S (the parent company) and enterprises (subsidiaries) controlled by the parent company. The parent company is considered to exercise control when it has power over the relevant activities of the enterprise, is exposed or has rights to a variable return from the investment and has the ability to affect those returns through its power.The consolidated financial statements are prepared by aggregating the financial statements of the parent company and the individual subsidiaries, all of which are prepared in accordance with the Group\u2019s accounting policies. Intra-group transactions, balances, dividends and unrealised gains and losses on transactions between Group companies are eliminated. Enterprises, which are not subsidiaries but in which the Group holds at least 20% of the voting rights or otherwise exercise a significant influence, are regarded as associates. The Group\u2019s proportionate share of unrealised gains and losses on transactions between the Coloplast Group and associates is eliminated. Enterprises recently acquired or divested are included in the consolidation in the period in which the Coloplast Group has control of the enterprise. Comparative figures are not restated to reflect acquisitions.Acquisitions are accounted for using the acquisition method, according to which the assets and liabilities and contingent liabilities of enterprises acquired are measured at fair value at the date of acquisition. Goodwill on the acquisition of subsidiaries or associates is calculated as the difference between the fair value of the consideration and the fair value of the Group companies\u2019 proportionate share of identifiable assets less liabilities and contingent liabilities at the date of acquisition.The consideration for an enterprise consists of the fair value of the agreed consideration for the acquired enterprise. If part of the consideration is contingent on future events, such part is recognised at its fair value at the date of acquisition. Costs directly attributable to business combinations are recognised directly in the income statement as special items when incurred. In cases where the fair value of acquired identifiable assets, liabilities or contingent liabilities subsequently turns out to differ from the values calculated at the date of acquisition, the calculation, including goodwill and contingent consideration are adjusted until up to 12 months after the date of acquisition. Subsequently, goodwill is not adjusted.Goodwill arising in connection with the acquisition of subsidiaries is recognised in the balance sheet under intangible assets in the consolidated financial statements and tested annually for impairment.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfBasisOfConsolidationExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__33-1": {
"value": "Marketable securitiesMarketable securities are part of a portfolio which is managed and measured on a fair value basis as per transaction date. Adjustments to fair value is recognised through profit or loss as financial items. Bonds forming part of repo transactions, i.e. the sale of bonds that are bought back at a later date for a fixed price remain classified as financial assets in the balance sheet, while amounts received from repo transactions are recognised as repo debt. Returns on such bonds are recognised under financials.Note 20Financial instruments by categoryAccounting policiesFinancial instruments are measured at either amortised cost or fair value. Those financial instruments, which are measured at fair value, can be categorised according to the fair value measurement hierarchy below:Level 1: Observable prices in active markets for identical instruments.Level 2: Valuation models primarily based on observable prices or traded prices of comparable instruments.Level 3: Valuation models primarily based on non-observable prices.The fair value of forward exchange contracts and other derivative financial instruments are considered a level 2 fair value measurement as the fair value is determined directly based on the published exchange rates and quoted forward exchange rates at balance sheet dates. The fair value of derivative financial instruments is calculated on the basis of current market data.Contingent Financial consideration Fair value instruments at fair value through at fair value through profit Amortised profit or lossthrough OCI or loss DKK millioncost(level 1)(level 2)(level 3) Total2025Trade receivables 4,658 \u2013 \u2013 \u2013 4,658 Other receivables 299 \u2013 180 \u2013 479 Cash and cash equivalents 947 \u2013 \u2013 \u2013 947 Financial assets 5,904 \u2013 180 \u2013 6,084 Other credit institutions 10,111 \u2013 \u2013 \u2013 10,111 Bonds\u00b9) 11,570 \u2013 \u2013 \u2013 11,570 Trade payables 1,324 \u2013 \u2013 \u2013 1,324 Other payables 2,390 \u2013 11 \u2013 2,401 Lease liabilities 958 \u2013 \u2013 \u2013 958 Financial liabilities 26,353 \u2013 11 \u2013 26,364 2024Trade receivables 4,675 \u2013 \u2013 \u2013 4,675 Other receivables 355 \u2013 39 \u2013 394 Cash and cash equivalents 788 \u2013 \u2013 \u2013 788 Financial assets 5,818 \u2013 39 \u2013 5,857 Other credit institutions 10,085 \u2013 \u2013 \u2013 10,085 Bonds\u00b9) 11,557 \u2013 \u2013 \u2013 11,557 Trade payables 1,519 \u2013 \u2013 \u2013 1,519 Other payables 2,353 \u2013 73 \u2013 2,426 Lease liabilities 987 \u2013 \u2013 \u2013 987 Financial liabilities 26,501 \u2013 73 \u2013 26,574 \u00b9\u207e The fair value of the bonds amounts to DKK 11,493 million (DKK 11,392 million 30 September 2024) calculated based on market prices (level 1).",
"dimensions": {
"concept": "ifrs-full:DisclosureOfFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__32-1": {
"value": "Marketable securitiesMarketable securities are part of a portfolio which is managed and measured on a fair value basis as per transaction date. Adjustments to fair value is recognised through profit or loss as financial items. Bonds forming part of repo transactions, i.e. the sale of bonds that are bought back at a later date for a fixed price remain classified as financial assets in the balance sheet, while amounts received from repo transactions are recognised as repo debt. Returns on such bonds are recognised under financials.Accounting policiesFinancial instruments are measured at either amortised cost or fair value. Those financial instruments, which are measured at fair value, can be categorised according to the fair value measurement hierarchy below:Level 1: Observable prices in active markets for identical instruments.Level 2: Valuation models primarily based on observable prices or traded prices of comparable instruments.Level 3: Valuation models primarily based on non-observable prices.The fair value of forward exchange contracts and other derivative financial instruments are considered a level 2 fair value measurement as the fair value is determined directly based on the published exchange rates and quoted forward exchange rates at balance sheet dates. The fair value of derivative financial instruments is calculated on the basis of current market data.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__35-1": {
"value": "Cash flow statementThe consolidated cash flow statement, which is presented according to the indirect method, shows the Group\u2019s cash flow from operating, investing and financing activities as well as the Group\u2019s cash and cash equivalents at the beginning and end of the year. Cash and cash equivalents comprise cash. Marketable securities include bonds with maturities of more than three months and are recognised under investing activities.Note 23Specifications of cash flow from operating and financing activitiesDKK million 2024/25 2023/24Net gain/loss on divestment of non-current assets 49 23 Change in other provisions 14 -182 Other non-cash operating items 79 67 Adjustment for other non-cash operating items 142 -92 Inventories -441 -290 Trade receivables -36 -506 Other receivables, including amounts held in escrow -109 -155 Trade and other payables etc. -199 -81 Changes in working capital -785 -1,032 2024/252023/24Credit Credit DKK million Lease liability Bondsfacilities Total Lease liability Bondsfacilities TotalBalance 1 October 987 11,557 10,085 22,629 894 16,405 2,268 19,567 Additions during the year 315 \u2013 2,783 3,098 418 \u2013 5,000 5,418 Settlement of issued bonds \u2013 \u2013 \u2013 \u2013 \u2013 -4,848 \u2013 -4,848 Cash flow -281 \u2013 -2,758 -3,039 -268 \u2013 2,818 2,550 Exchange and other adjustments -63 13 1 -49 -57 \u2013 -1 -58 Balance 30 September 958 11,570 10,111 22,639 987 11,557 10,085 22,629",
"dimensions": {
"concept": "ifrs-full:DisclosureOfCashFlowStatementExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__34": {
"value": "Cash flow statementThe consolidated cash flow statement, which is presented according to the indirect method, shows the Group\u2019s cash flow from operating, investing and financing activities as well as the Group\u2019s cash and cash equivalents at the beginning and end of the year. Cash and cash equivalents comprise cash. Marketable securities include bonds with maturities of more than three months and are recognised under investing activities.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForCashFlowsExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__38": {
"value": "Note 4Revenue and segment information Accounting policiesRevenueRevenue comprises income from the sale of goods after deduction of any price reductions, quantity discounts or cash discounts. Sales transactions are recognised in the income statement at the point in time when control of the goods is transferred to the customer, and when the consideration is assessed to be collectible. Revenues from sales transactions are measured at the transaction price to which Coloplast expects to be entitled.Within all segments, revenues are typically recognised when the customer takes possession of the goods. Exceptions to this comprise Interventional Urology and Biologics revenues, as revenues from certain surgical products are generated from consignment sales as well as the contract manufacturing business. Certain surgical products within Interventional Urology are always available at our partner hospitals to ensure that all sizes and fits are always available. Revenues from consignment sales are recognised as the goods are used (i.e. in surgery). Revenues from contract manufacturing business is recognised when the products are available for delivery when this coincides with the transfer of control of the products.Coloplast generates most of its sales through distributors that operate under various conditions and who for that reason require varying sales agreements. Coloplast\u2019s distributor agreements contain volume and product-specific rebates, which require data management and monitoring of sales to individual distributors at the product level. Payment terms for trade receivables from customers depend on creditworthiness, customary business practices and contract negotiations. Payment terms for some customers include a period of credit which commences when the products are shipped while other customers are requested to pay in advance or provide appropriate collateral for the payment. Prepayments from customers are recognised as revenue in the following period upon satisfying the performance obligations.Variable considerations include volume and product-specific rebates which, for some markets, are accumulated and paid annually or quarterly. Accruals for variable considerations are constrained by uncertainty of future events, such as the expected volume of sales, and require estimate.Revenue is measured at the fair value of the agreed consideration. All discounts granted are recognised in revenue. An estimate of expected returns is also recognised in revenue.Coloplast applies the practical expedient in IFRS 15, para 63 associated with the determination of whether a significant financing component exists for transactions where payment is expected in less than 12 months from the delivery of goods (transfer of control).As permitted under IFRS 15, no disclosures are made to the remaining performance obligations at 30 September 2025 that have an original expected duration of one year or less. There are no material performance obligations with an original expected duration extending beyond the period of more than one year after 30 September 2025.The operating segments are defined on the basis of the monthly reporting to the Executive Leadership Team, which is considered the chief operating decision maker, and the management structure. Reporting to Management is based on five operating segments: Chronic Care, Voice & Respiratory Care, Interventional Urology, Advanced Wound Dressings and Biologics. Management does not receive reporting on assets and liabilities by operating segments. Accordingly, the operating segments are not measured in this respect, nor do we allocate resources on this background.Segmentation of the income statementThe segment Chronic Care covers the sale of ostomy care products and continence care products. The segment Interventional Urology covers the sale of urological products, including disposable products. The segment Advanced Wound Dressings covers the sale of wound and skin care products and the segment Voice & Respiratory Care covers the sale of laryngectomy and tracheostomy products. Biologics represents a new segment covering the sale of tissue-based products. The segmentation reflects the structure of reporting to the Executive Leadership Team. The shared/non-allocated functions comprises support functions (production units and staff functions) and eliminations, as these functions do not generate revenue. While the costs of R&D for Interventional Urology, Voice & Respiratory Care and Biologics are included in the segment operating profit/loss for the respective segments, R&D activities for Chronic Care and Advanced Wound Dressings are shared functions which are included in shared/non-allocated. The shared/non-allocated functions also include PPA amortisation expenditures related to Voice & Respiratory Care and Biologics. Financial items and income tax are not allocated to the reportable segments.Geographic informationColoplast A/S\u2019 registered office is situated in Denmark. No single customer accounted for more than 10% of the Group\u2019s revenue in 2024/25 and 2023/24.DKK million 2024/25 2023/24Specification of revenue representing over 10% of the Group\u2019s revenue by customer location including Denmark.US 6,549 6,371 UK 3,895 3,685 France 2,815 2,735 Germany 2,705 2,510 Denmark 416 401 Other 11,494 11,328 Total 27,874 27,030 Specification of non-current assets\u00b9\u207e by location of the subsidiaryDenmark 30,483 22,368 Iceland 19 8,600 Hungary 1,918 1,823 Other 4,575 4,112 Total 36,995 36,903 \u00b9\u207e Non-current assets by location consist of intangible assets, property plant and equipment and right-of-use assets.Voice & Res-Interven-Advanced Chronic piratory tional Wound DKK millionCareCareUrologyDressings Biologics Total2024/25Segment revenue:Ostomy Care 9,897 \u2013 \u2013 \u2013 \u2013 9,897 Continence Care 8,984 \u2013 \u2013 \u2013 \u2013 8,984 Voice & Respiratory Care \u2013 2,280 \u2013 \u2013 \u2013 2,280 Interventional Urology \u2013 \u2013 2,784 \u2013 \u2013 2,784 Wound & Tissue Repair \u2013 \u2013 \u2013 2,675 1,254 3,929 External revenue as per the comprehensive income 18,881 2,280 2,784 2,675 1,254 27,874 Costs allocated to segment -7,818 -1,443 -1,800 -1,570 -1,095 -13,726 Segment operating profit/loss 11,063 837 984 1,105 159 14,148 Shared/non-allocated -6,478 Special items not included in segment operating profit/loss (see note 6) -469 Operating profit before tax (EBIT) as per the Statement of comprehensive income 7,201 Net financials -1,044 Tax on profit/loss for the year -2,521 Profit/loss for the year as per the Statement of comprehensive income 3,636 Voice & Res-Interven-Advanced Chronic piratory tional Wound DKK millionCareCareUrologyDressings Biologics Total2023/24Segment revenue:Ostomy Care 9,545 \u2013 \u2013 \u2013 \u2013 9,545 Continence Care 8,540 \u2013 \u2013 \u2013 \u2013 8,540 Voice & Respiratory Care \u2013 2,110 \u2013 \u2013 \u2013 2,110 Interventional Urology \u2013 \u2013 2,775 \u2013 \u2013 2,775 Wound & Tissue Repair \u2013 \u2013 \u2013 3,034 1,026 4,060 External revenue as per the comprehensive income 18,085 2,110 2,775 3,034 1,026 27,030 Costs allocated to segment -7,644 -1,374 -1,799 -1,881 -925 -13,623 Segment operating profit/loss 10,441 736 976 1,153 101 13,407 Shared/non-allocated -6,121 Special items not included in segment operating profit/loss (see note 6) 34 Operating profit before tax (EBIT) as per the Statement of comprehensive 7,320 Net financials -925 Tax on profit/loss for the year -1,343 Profit/loss for the year as per the Statement of comprehensive income 5,052 Management reviews each operating segment separately, applying their market contributions to earnings and allocating resources on that basis. The market contribution is defined as external revenue less the sum of direct and indirect production costs, distribution, sales and marketing costs and administrative expenses. Costs are allocated directly to segments. Certain immaterial indirect costs are allocated systematically to the shared/non-allocated and the reporting segment",
"dimensions": {
"concept": "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__37": {
"value": "Note 4Revenue and segment information Accounting policiesRevenueRevenue comprises income from the sale of goods after deduction of any price reductions, quantity discounts or cash discounts. Sales transactions are recognised in the income statement at the point in time when control of the goods is transferred to the customer, and when the consideration is assessed to be collectible. Revenues from sales transactions are measured at the transaction price to which Coloplast expects to be entitled.Within all segments, revenues are typically recognised when the customer takes possession of the goods. Exceptions to this comprise Interventional Urology and Biologics revenues, as revenues from certain surgical products are generated from consignment sales as well as the contract manufacturing business. Certain surgical products within Interventional Urology are always available at our partner hospitals to ensure that all sizes and fits are always available. Revenues from consignment sales are recognised as the goods are used (i.e. in surgery). Revenues from contract manufacturing business is recognised when the products are available for delivery when this coincides with the transfer of control of the products.Coloplast generates most of its sales through distributors that operate under various conditions and who for that reason require varying sales agreements. Coloplast\u2019s distributor agreements contain volume and product-specific rebates, which require data management and monitoring of sales to individual distributors at the product level. Payment terms for trade receivables from customers depend on creditworthiness, customary business practices and contract negotiations. Payment terms for some customers include a period of credit which commences when the products are shipped while other customers are requested to pay in advance or provide appropriate collateral for the payment. Prepayments from customers are recognised as revenue in the following period upon satisfying the performance obligations.Variable considerations include volume and product-specific rebates which, for some markets, are accumulated and paid annually or quarterly. Accruals for variable considerations are constrained by uncertainty of future events, such as the expected volume of sales, and require estimate.Revenue is measured at the fair value of the agreed consideration. All discounts granted are recognised in revenue. An estimate of expected returns is also recognised in revenue.Coloplast applies the practical expedient in IFRS 15, para 63 associated with the determination of whether a significant financing component exists for transactions where payment is expected in less than 12 months from the delivery of goods (transfer of control).As permitted under IFRS 15, no disclosures are made to the remaining performance obligations at 30 September 2025 that have an original expected duration of one year or less. There are no material performance obligations with an original expected duration extending beyond the period of more than one year after 30 September 2025.The operating segments are defined on the basis of the monthly reporting to the Executive Leadership Team, which is considered the chief operating decision maker, and the management structure. Reporting to Management is based on five operating segments: Chronic Care, Voice & Respiratory Care, Interventional Urology, Advanced Wound Dressings and Biologics. Management does not receive reporting on assets and liabilities by operating segments. Accordingly, the operating segments are not measured in this respect, nor do we allocate resources on this background.Segmentation of the income statementThe segment Chronic Care covers the sale of ostomy care products and continence care products. The segment Interventional Urology covers the sale of urological products, including disposable products. The segment Advanced Wound Dressings covers the sale of wound and skin care products and the segment Voice & Respiratory Care covers the sale of laryngectomy and tracheostomy products. Biologics represents a new segment covering the sale of tissue-based products. The segmentation reflects the structure of reporting to the Executive Leadership Team. The shared/non-allocated functions comprises support functions (production units and staff functions) and eliminations, as these functions do not generate revenue. While the costs of R&D for Interventional Urology, Voice & Respiratory Care and Biologics are included in the segment operating profit/loss for the respective segments, R&D activities for Chronic Care and Advanced Wound Dressings are shared functions which are included in shared/non-allocated. The shared/non-allocated functions also include PPA amortisation expenditures related to Voice & Respiratory Care and Biologics. Financial items and income tax are not allocated to the reportable segments.Geographic informationColoplast A/S\u2019 registered office is situated in Denmark. No single customer accounted for more than 10% of the Group\u2019s revenue in 2024/25 and 2023/24.DKK million 2024/25 2023/24Specification of revenue representing over 10% of the Group\u2019s revenue by customer location including Denmark.US 6,549 6,371 UK 3,895 3,685 France 2,815 2,735 Germany 2,705 2,510 Denmark 416 401 Other 11,494 11,328 Total 27,874 27,030 Specification of non-current assets\u00b9\u207e by location of the subsidiaryDenmark 30,483 22,368 Iceland 19 8,600 Hungary 1,918 1,823 Other 4,575 4,112 Total 36,995 36,903 \u00b9\u207e Non-current assets by location consist of intangible assets, property plant and equipment and right-of-use assets.Voice & Res-Interven-Advanced Chronic piratory tional Wound DKK millionCareCareUrologyDressings Biologics Total2024/25Segment revenue:Ostomy Care 9,897 \u2013 \u2013 \u2013 \u2013 9,897 Continence Care 8,984 \u2013 \u2013 \u2013 \u2013 8,984 Voice & Respiratory Care \u2013 2,280 \u2013 \u2013 \u2013 2,280 Interventional Urology \u2013 \u2013 2,784 \u2013 \u2013 2,784 Wound & Tissue Repair \u2013 \u2013 \u2013 2,675 1,254 3,929 External revenue as per the comprehensive income 18,881 2,280 2,784 2,675 1,254 27,874 Costs allocated to segment -7,818 -1,443 -1,800 -1,570 -1,095 -13,726 Segment operating profit/loss 11,063 837 984 1,105 159 14,148 Shared/non-allocated -6,478 Special items not included in segment operating profit/loss (see note 6) -469 Operating profit before tax (EBIT) as per the Statement of comprehensive income 7,201 Net financials -1,044 Tax on profit/loss for the year -2,521 Profit/loss for the year as per the Statement of comprehensive income 3,636 Voice & Res-Interven-Advanced Chronic piratory tional Wound DKK millionCareCareUrologyDressings Biologics Total2023/24Segment revenue:Ostomy Care 9,545 \u2013 \u2013 \u2013 \u2013 9,545 Continence Care 8,540 \u2013 \u2013 \u2013 \u2013 8,540 Voice & Respiratory Care \u2013 2,110 \u2013 \u2013 \u2013 2,110 Interventional Urology \u2013 \u2013 2,775 \u2013 \u2013 2,775 Wound & Tissue Repair \u2013 \u2013 \u2013 3,034 1,026 4,060 External revenue as per the comprehensive income 18,085 2,110 2,775 3,034 1,026 27,030 Costs allocated to segment -7,644 -1,374 -1,799 -1,881 -925 -13,623 Segment operating profit/loss 10,441 736 976 1,153 101 13,407 Shared/non-allocated -6,121 Special items not included in segment operating profit/loss (see note 6) 34 Operating profit before tax (EBIT) as per the Statement of comprehensive 7,320 Net financials -925 Tax on profit/loss for the year -1,343 Profit/loss for the year as per the Statement of comprehensive income 5,052 Management reviews each operating segment separately, applying their market contributions to earnings and allocating resources on that basis. The market contribution is defined as external revenue less the sum of direct and indirect production costs, distribution, sales and marketing costs and administrative expenses. Costs are allocated directly to segments. Certain immaterial indirect costs are allocated systematically to the shared/non-allocated and the reporting segment",
"dimensions": {
"concept": "ifrs-full:DisclosureOfRevenueExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__36": {
"value": "Note 4Revenue and segment information Accounting policiesRevenueRevenue comprises income from the sale of goods after deduction of any price reductions, quantity discounts or cash discounts. Sales transactions are recognised in the income statement at the point in time when control of the goods is transferred to the customer, and when the consideration is assessed to be collectible. Revenues from sales transactions are measured at the transaction price to which Coloplast expects to be entitled.Within all segments, revenues are typically recognised when the customer takes possession of the goods. Exceptions to this comprise Interventional Urology and Biologics revenues, as revenues from certain surgical products are generated from consignment sales as well as the contract manufacturing business. Certain surgical products within Interventional Urology are always available at our partner hospitals to ensure that all sizes and fits are always available. Revenues from consignment sales are recognised as the goods are used (i.e. in surgery). Revenues from contract manufacturing business is recognised when the products are available for delivery when this coincides with the transfer of control of the products.Coloplast generates most of its sales through distributors that operate under various conditions and who for that reason require varying sales agreements. Coloplast\u2019s distributor agreements contain volume and product-specific rebates, which require data management and monitoring of sales to individual distributors at the product level. Payment terms for trade receivables from customers depend on creditworthiness, customary business practices and contract negotiations. Payment terms for some customers include a period of credit which commences when the products are shipped while other customers are requested to pay in advance or provide appropriate collateral for the payment. Prepayments from customers are recognised as revenue in the following period upon satisfying the performance obligations.Variable considerations include volume and product-specific rebates which, for some markets, are accumulated and paid annually or quarterly. Accruals for variable considerations are constrained by uncertainty of future events, such as the expected volume of sales, and require estimate.Revenue is measured at the fair value of the agreed consideration. All discounts granted are recognised in revenue. An estimate of expected returns is also recognised in revenue.Coloplast applies the practical expedient in IFRS 15, para 63 associated with the determination of whether a significant financing component exists for transactions where payment is expected in less than 12 months from the delivery of goods (transfer of control).As permitted under IFRS 15, no disclosures are made to the remaining performance obligations at 30 September 2025 that have an original expected duration of one year or less. There are no material performance obligations with an original expected duration extending beyond the period of more than one year after 30 September 2025.The operating segments are defined on the basis of the monthly reporting to the Executive Leadership Team, which is considered the chief operating decision maker, and the management structure. Reporting to Management is based on five operating segments: Chronic Care, Voice & Respiratory Care, Interventional Urology, Advanced Wound Dressings and Biologics. Management does not receive reporting on assets and liabilities by operating segments. Accordingly, the operating segments are not measured in this respect, nor do we allocate resources on this background.Segmentation of the income statementThe segment Chronic Care covers the sale of ostomy care products and continence care products. The segment Interventional Urology covers the sale of urological products, including disposable products. The segment Advanced Wound Dressings covers the sale of wound and skin care products and the segment Voice & Respiratory Care covers the sale of laryngectomy and tracheostomy products. Biologics represents a new segment covering the sale of tissue-based products. The segmentation reflects the structure of reporting to the Executive Leadership Team. The shared/non-allocated functions comprises support functions (production units and staff functions) and eliminations, as these functions do not generate revenue. While the costs of R&D for Interventional Urology, Voice & Respiratory Care and Biologics are included in the segment operating profit/loss for the respective segments, R&D activities for Chronic Care and Advanced Wound Dressings are shared functions which are included in shared/non-allocated. The shared/non-allocated functions also include PPA amortisation expenditures related to Voice & Respiratory Care and Biologics. Financial items and income tax are not allocated to the reportable segments.Geographic informationColoplast A/S\u2019 registered office is situated in Denmark. No single customer accounted for more than 10% of the Group\u2019s revenue in 2024/25 and 2023/24.DKK million 2024/25 2023/24Specification of revenue representing over 10% of the Group\u2019s revenue by customer location including Denmark.US 6,549 6,371 UK 3,895 3,685 France 2,815 2,735 Germany 2,705 2,510 Denmark 416 401 Other 11,494 11,328 Total 27,874 27,030 Specification of non-current assets\u00b9\u207e by location of the subsidiaryDenmark 30,483 22,368 Iceland 19 8,600 Hungary 1,918 1,823 Other 4,575 4,112 Total 36,995 36,903 \u00b9\u207e Non-current assets by location consist of intangible assets, property plant and equipment and right-of-use assets.Voice & Res-Interven-Advanced Chronic piratory tional Wound DKK millionCareCareUrologyDressings Biologics Total2024/25Segment revenue:Ostomy Care 9,897 \u2013 \u2013 \u2013 \u2013 9,897 Continence Care 8,984 \u2013 \u2013 \u2013 \u2013 8,984 Voice & Respiratory Care \u2013 2,280 \u2013 \u2013 \u2013 2,280 Interventional Urology \u2013 \u2013 2,784 \u2013 \u2013 2,784 Wound & Tissue Repair \u2013 \u2013 \u2013 2,675 1,254 3,929 External revenue as per the comprehensive income 18,881 2,280 2,784 2,675 1,254 27,874 Costs allocated to segment -7,818 -1,443 -1,800 -1,570 -1,095 -13,726 Segment operating profit/loss 11,063 837 984 1,105 159 14,148 Shared/non-allocated -6,478 Special items not included in segment operating profit/loss (see note 6) -469 Operating profit before tax (EBIT) as per the Statement of comprehensive income 7,201 Net financials -1,044 Tax on profit/loss for the year -2,521 Profit/loss for the year as per the Statement of comprehensive income 3,636 Voice & Res-Interven-Advanced Chronic piratory tional Wound DKK millionCareCareUrologyDressings Biologics Total2023/24Segment revenue:Ostomy Care 9,545 \u2013 \u2013 \u2013 \u2013 9,545 Continence Care 8,540 \u2013 \u2013 \u2013 \u2013 8,540 Voice & Respiratory Care \u2013 2,110 \u2013 \u2013 \u2013 2,110 Interventional Urology \u2013 \u2013 2,775 \u2013 \u2013 2,775 Wound & Tissue Repair \u2013 \u2013 \u2013 3,034 1,026 4,060 External revenue as per the comprehensive income 18,085 2,110 2,775 3,034 1,026 27,030 Costs allocated to segment -7,644 -1,374 -1,799 -1,881 -925 -13,623 Segment operating profit/loss 10,441 736 976 1,153 101 13,407 Shared/non-allocated -6,121 Special items not included in segment operating profit/loss (see note 6) 34 Operating profit before tax (EBIT) as per the Statement of comprehensive 7,320 Net financials -925 Tax on profit/loss for the year -1,343 Profit/loss for the year as per the Statement of comprehensive income 5,052 Management reviews each operating segment separately, applying their market contributions to earnings and allocating resources on that basis. The market contribution is defined as external revenue less the sum of direct and indirect production costs, distribution, sales and marketing costs and administrative expenses. Costs are allocated directly to segments. Certain immaterial indirect costs are allocated systematically to the shared/non-allocated and the reporting segment",
"dimensions": {
"concept": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__39": {
"value": "Accounting policiesRevenueRevenue comprises income from the sale of goods after deduction of any price reductions, quantity discounts or cash discounts. Sales transactions are recognised in the income statement at the point in time when control of the goods is transferred to the customer, and when the consideration is assessed to be collectible. Revenues from sales transactions are measured at the transaction price to which Coloplast expects to be entitled.Within all segments, revenues are typically recognised when the customer takes possession of the goods. Exceptions to this comprise Interventional Urology and Biologics revenues, as revenues from certain surgical products are generated from consignment sales as well as the contract manufacturing business. Certain surgical products within Interventional Urology are always available at our partner hospitals to ensure that all sizes and fits are always available. Revenues from consignment sales are recognised as the goods are used (i.e. in surgery). Revenues from contract manufacturing business is recognised when the products are available for delivery when this coincides with the transfer of control of the products.Coloplast generates most of its sales through distributors that operate under various conditions and who for that reason require varying sales agreements. Coloplast\u2019s distributor agreements contain volume and product-specific rebates, which require data management and monitoring of sales to individual distributors at the product level. Payment terms for trade receivables from customers depend on creditworthiness, customary business practices and contract negotiations. Payment terms for some customers include a period of credit which commences when the products are shipped while other customers are requested to pay in advance or provide appropriate collateral for the payment. Prepayments from customers are recognised as revenue in the following period upon satisfying the performance obligations.Variable considerations include volume and product-specific rebates which, for some markets, are accumulated and paid annually or quarterly. Accruals for variable considerations are constrained by uncertainty of future events, such as the expected volume of sales, and require estimate.Revenue is measured at the fair value of the agreed consideration. All discounts granted are recognised in revenue. An estimate of expected returns is also recognised in revenue.Coloplast applies the practical expedient in IFRS 15, para 63 associated with the determination of whether a significant financing component exists for transactions where payment is expected in less than 12 months from the delivery of goods (transfer of control).As permitted under IFRS 15, no disclosures are made to the remaining performance obligations at 30 September 2025 that have an original expected duration of one year or less. There are no material performance obligations with an original expected duration extending beyond the period of more than one year after 30 September 2025.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__41": {
"value": "Denmark",
"dimensions": {
"concept": "ifrs-full:CountryOfIncorporation",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__40": {
"value": "The operating segments are defined on the basis of the monthly reporting to the Executive Leadership Team, which is considered the chief operating decision maker, and the management structure. Reporting to Management is based on five operating segments: Chronic Care, Voice & Respiratory Care, Interventional Urology, Advanced Wound Dressings and Biologics. Management does not receive reporting on assets and liabilities by operating segments. Accordingly, the operating segments are not measured in this respect, nor do we allocate resources on this background.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__43-1": {
"value": "Note 5Staff costsDKK million 2024/25 2023/24Specification of staff costs recognised in the financial yearSalaries, wages and directors' remuneration\u00b9\u207e 7,949 7,476 Pension costs - defined contribution plans (note 17) 458 472 Pension costs - defined benefit plans (note 17) 14 13 Other social security costs 847 800 Total 9,268 8,761 Staff costs allocated to functionsProduction costs 1,946 1,935 Distribution costs 5,639 5,403 2Administrative expenses\u207e 834 833 Research and development costs 608 570 2Special items\u207e 241 20 Total 9,268 8,761Average number of employees, FTEs 16,773 16,202Number of employees at 30 September, FTEs 16,907 16,639Number of employees at 30 September, headcount 17,156 16,875\u00b9\u207e Including share based payment. See Note 16 to the consolidated financial statements.2\u207e The comparison figures has been adjusted to show special items.See Note 27 to the consolidated financial statements for information on the Executive Management's and the Board of Directors' remuneration.Note 16Share optionsAccounting policiesShare options are granted to the executive management and senior management. For equity-settled schemes, the fair value of options is determined at the grant date. The option value is subsequently recognised over the vesting period as staff costs. For cash-settled schemes, the fair value of options granted during the period is recognised as staff costs, whereas the fair value adjustment of granted options from previous periods is recognised under financial items. The purchase and selling prices of treasury shares on exercise of share options are deducted from or added to equity, as the case may be.Share options are granted to members of the executive management and other senior management for the purpose of motivating and retaining a qualified management group and in order to align the interests of management with those of the shareholders. Options are awarded as unconditional allocations at the date of grant, but vest over a three-year period. The value of options at the date of grant equalled an average of three months' salary for each recipient, with the exception of the executive management.The carrying amount of the cash settled share option programmes was DKK 0 million at 30 September 2025 (DKK 2 million at 30 September 2024), while the fair value of all option programmes at grant date amounted to DKK 417 million at 30 September 2025 (DKK 291 million at 30 September 2024).DKK million2024/25 2023/24Share options have affected the profit or loss for the year as followsStaff costs, accounting value of cash and equity-settled programmes 79 70 Financial costs, fair value adjustment of cash-settled programmes -2 \u2013 Cost of share options recognised in profit or loss 77 70 The fair value of the options was calculated using the Black-Scholes formula at the date of the grant, in which the interest rate applied was the yield on Danish government securities. Volatility in the share is calculated as monthly movements (period-end to period-end) over five years. Options are assumed to be exercised on average one year into the exercise period.2024 2023The following assumptions were applied in determining the fair value of share options granted during the financial yearBlack-Scholes value, DKK125.12 121.41Share price, DKK787.60 773.22Exercise price, DKK826.98 811.88Expected dividend per share, DKK 1.50 % 1.50 %Expected duration, years4.00 4.00Volatility 23.35 % 22.12 %Risk-free interest 1.72 % 2.21 %Fair value at grant date, million DKK90.30 76.452024/25 2023/24Average Average Average Average No. of exercise share No. of exercise share optionspriceprice\u00b9\u207eoptionspriceprice\u00b9\u207eOutstanding share options at 1 October 2,041,988 888 2,129,562 871 Options awarded 721,701 827 629,716 812 Options expired -97,445 859 -2 608 Options forfeited -164,297 860 -36,990 862 Options exercised -31,341 849 917 -680,298 740 891 Outstanding share options at 30 September 2,470,606 867 2,041,988 8881) At the date of exerciseNot exercised No. ofShareat 30 options optionsOptionsSeptember ExerciseYear of issueissuedlapsedexercised2025\u00b9\u207eprice\u00b2\u207e\u00b3\u207e Exercise periodSpecification of outstanding share options2020 535,152 -335,224 \u2013 199,928 949 31/12/23 - 31/12/252020, repriced 241,296 -11,291 -32,836 197,169 897 31/12/23 - 31/12/252020 US 109,900 -97,446 \u2013 12,454 981 31/12/23 - 31/12/252020 US, repriced 65,197 -13,163 -3,816 48,218 920 31/12/23 - 31/12/252021 441,494 -287,303 \u2013 154,191 1,183 31/12/24 - 31/12/262021, repriced 103,554 -7,700 \u2013 95,854 897 31/12/24 - 31/12/262021 US 95,846 -83,387 \u2013 12,459 1,213 31/12/24 - 31/12/262021 US, repriced 29,592 -7,416 \u2013 22,176 920 31/12/24 - 31/12/262022 424,561 -26,609 \u2013 397,952 832 31/12/25 - 31/12/272022 US 108,646 -26,428 \u2013 82,218 855 31/12/25 - 31/12/272023 514,397 -25,688 \u2013 488,709 798 31/12/26 - 31/12/282023 US 115,319 -31,214 \u2013 84,105 812 31/12/26 - 31/12/282024 706,431 -43,592 \u2013 662,839 822 31/12/27 - 31/12/292024 US 15,270 -2,936 \u2013 12,334 827 31/12/27 - 31/12/29Total 3,506,655 -999,397 -36,652 2,470,606\u00b9\u207e Exercisable options as per 30 September 2025 was 742,449.\u00b2\u207e Average exercise price for options exercisable at the balance sheet date was DKK 979.33.\u00b3\u207e The exercise prices are adjusted for payment of dividend. In 2024/25, the adjustment of the exercise price was DKK -8.67.In 2024/25 111,201 options (2023/24: 141,526) were granted to key management. As per 30 September 2025 key managements holds 139,106 options (2023/24: 304,279) at an average exercise price of 907.84 (2023/24: 949.36).Coloplast's holding of treasury shares fully covers the option programmes, so the options exercised under the programme will not influence the Group's cash position by forcing it to buy up shares in the market. See Note 9 to the financial statements for an overview of treasury shares held by Coloplast at the balance sheet date.Note 17Provisions for pensions and similar obligationsAccounting policiesIn defined contribution plans, the Group makes regular payments of fixed contributions to independent pension funds and insurance companies. The Group is under no obligation to pay additional contributions. Costs for defined contribution plans are recognised in the income statement as Coloplast assumes an obligation to make the payment.In defined benefit plans, the Group is under an obligation to pay a defined benefit on retirement. The actuarially calculated present value less the fair value of any plan assets is recognised in the balance sheet under provision for pension and similar obligations or in plan assets in the balance sheet. The total service costs of the year plus calculated interest based on actuarial estimates and financial assumptions at the beginning of the year are recognised in the income statement. The difference between the forecast development in plan assets and liabilities and the realised values at the end of the year is called actuarial gains or losses and is recognised in other comprehensive income. In connection with a change in benefits regarding the employees\u2019 employment with the Group to date, there will be a change in the actuarial calculation of the net present value, which is taken directly to the profit or loss.Defined contribution plansThe Group offers pension plans to certain groups of employees in Denmark and abroad. Most of the pension plans are defined contribution plans. The Group funds the plans through regular payments of premiums to independent insurance companies responsible for the pension obligations towards the beneficiaries. Once the pension contributions for defined contribution plans have been made, the Group has no further obligation towards current or former employees. Contributions to defined contribution plans are recognised in the income statement when paid. In 2024/25, DKK 458 million (2023/24: DKK 472 million) was recognised.Defined benefit plansFor certain groups of employees in foreign subsidiaries, the Group has signed agreements to pay defined benefits, including pension payments.Share of gross defined benefit obligations by country 2025 2024France 26 % 22 %Germany 12 % 11 %UK 61 % 66 %Italy 1 % 1 %Total 100 % 100 %These pension liabilities are not or are only partly covered by insurance (in the UK). Defined benefit liabilities are recognised in the balance sheet and in the statement of comprehensive income as indicated below. Coloplast funds the plans in the UK.The pension plans are based on the individual employee's salary and years of service with the company, and benefits are paid as a lifelong pension. The active plans are not exclusive to any particular employee group.Special funding requirements apply in the UK, while this is not the case for the other countries. In the UK, employee interests are handled by a Trustee Board. Accounts are prepared every three years and funding of any deficit is determined. Coloplast have an unconditional right to any surplus in the scheme at the end of the life of the scheme when all the liabilities have been run off. Any deficit in the Scheme is recovered by additional contributions from the employer over a fixed period of time. The plans have no requirements for risk diversification on equities or for matching strategies The plans have a duration of an average of 11 years, and all plans generally mature after more than 10 years.The Group expects to pay DKK 8 million to the defined benefit plans in 2024/25 (2023/24: DKK 7 million).DKK million2024/25 2023/24Defined contribution plans 458 472 Defined benefit plans 14 13 Cost of pension plans recognised in profit or loss 472 485 Pension costs concerning current financial year 10 8 Net interest expenses 4 5 Cost of defined benefit plans recognised in profit or loss 14 13 Actuarial gains/losses on pension obligations 46 -10 Actuarial gains/losses on plan assets -25 16 Actuarial gains/losses on defined benefit plans recognisedin other comprehensive income 21 7 Plan assets at 1 October 254 225 Exchange adjustments -12 8 Actual rate of interest 13 12 Actuarial gains/losses on plan assets -25 16 Paid by the Coloplast Group 7 7 Benefit paid out -15 -14 Plan assets at 30 September 222 254 DKK million2025 2024Specification of plan assetsShares, listed 35 31 Bonds, listed 89 112 Investments funds, listed 97 109 Cash and similar assets 1 2 Plan assets at 30 September 222 254 DKK million2024/25 2023/24Specification of present value of defined benefit obligationPresent value of defined benefit liability at 1 October 387 356 Exchange adjustments -12 10 Current service costs 10 8 Calculated interest on liability 17 17 Actuarial gains/losses, financial assumptions -26 10 Actuarial gains/losses, demographic assumptions -5 5 Actuarial gains/losses, experience -15 -5 Benefit paid out -15 -14 Present value of defined benefit liability at 30 September 341 387 Fair value of plan assets at 30 September -222 -254 Net liability of defined benefit plans at 30 September 119 133 Net liability of defined benefit plans at 1 October 133 131 Expenditure for the year 14 13 Actuarial gains/losses on pension obligation -46 10 Exchange adjustment \u2013 1 Actuarial gains/losses on plan assets 25 -16 Payments received -7 -7 Net liability of defined benefit plans at 30 September 119 133 Actuarial assumptions applied at the balance sheet date (expressed as an average)Discount rate 3.6 % 3.6 %Future rate of salary increases 2.3 % 2.0 %Inflation 1.3 % 2.2 %The below sensibility analysis shows the change in one of the actuarial assumptions, while other assumptions are kept constant. In practice, a change in one of the assumptions will in many instances be matched by a change in the other assumptions.2024/25 2023/24+1%-point -1%-point +1%-point -1%-pointPercentage increase/decrease in the gross liability resulting from a change in a single actuarial assumptionDiscount rate -12 % 13 % -13 % 15 %Future rate of salary increases 3 % -3 % 3 % -2 %Inflation 7 % -6 % 8 % -8 %Note 27Remuneration of the Board of Directors and Executive ManagementThe current policy for the remuneration of the Board of Directors and Executive Management was adopted in 2023 and sets out the general guidelines for the remuneration of the Group\u2019s management. The guidelines for the remuneration of the Board of Directors and Executive Management are available on the Group website. Executive Management is defined as members registered with the Danish Business Authority. The board of directors decided 5 November 2024, that the CEO and CFO were to remain as the sole registered executives. In addition to the disclosures provided in this note, more details on the remuneration of Executive Management and Directors are provided in the separate Remuneration report for the Coloplast Group, which is not a part of the audited consolidated financial statements. The report is also available on the Group website.Fees to Board members in respect of the current financial yearBoard member fees has remained unchanged for the past nine years. At the Annual General Meeting held on 5 December 2024, it was decided to increase the remuneration for the Board of Directors, the Audit Committee, and the Remuneration and Nomination Committee. The total remuneration for the fiscal year 2024/25 amounts to DKK 7.6 million (2023/24: DKK 6.9 million), which is included in total staff costs (see Note 5 to the financial statements) and are specified as follows:DKK million 2024/25 2023/24Ordinary board member fee 5.7 5.3 Audit Committee 1.1 0.9 Nomination and Remuneration Committee 0.8 0.7 Fee to members of the Board of Directors 7.6 6.9 Remuneration of members of the Executive Management in respect of the current financial year Remuneration to members of the Executive Management make up DKK 83.2 million (2023/24: DKK 63.5 million) of the total staff costs (see Note 5 to the financial statements) and are specified as follows:DKK million 2024/25 2023/24Base salaries 20.2 35.6Pension 3.2 5.1Other benefits 0.5 1.4Cash bonus 0.8 4.9Severance payment to Executive Management 50.5 \u2013Remuneration of Executive Management, excluding value of share options and contingent salary items 75.2 47.0Share options 8.0 16.5Remuneration of Executive Management 83.2 63.5The value of share options, which is calculated as the fair value of share options at the grant date using the Black-Scholes Formula in line with IFRS 2, comprise the annual accounting cost of share options awarded in the current and in prior years in accordance with the accounting policies applied. Consequently, it does not represent the fair value of share options awarded or exercised in the current financial year.If a member of Executive Management is given notice of termination by the company and such termination is not due to breach on the part of the member of Executive Management, such member is entitled to compensation corresponding to a maximum of two years\u2019 salary and pension contribution.Share options are granted to members of Executive Management and senior management. See Note 16 to the financial statements for further information regarding share-based payments as well as the separate Remuneration Report for the Coloplast Group, which is not part of the audited financial statements. The report is available on the Group website.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfInformationAboutEmployeesExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__42-1": {
"value": "Note 5Staff costsDKK million 2024/25 2023/24Specification of staff costs recognised in the financial yearSalaries, wages and directors' remuneration\u00b9\u207e 7,949 7,476 Pension costs - defined contribution plans (note 17) 458 472 Pension costs - defined benefit plans (note 17) 14 13 Other social security costs 847 800 Total 9,268 8,761 Staff costs allocated to functionsProduction costs 1,946 1,935 Distribution costs 5,639 5,403 2Administrative expenses\u207e 834 833 Research and development costs 608 570 2Special items\u207e 241 20 Total 9,268 8,761Average number of employees, FTEs 16,773 16,202Number of employees at 30 September, FTEs 16,907 16,639Number of employees at 30 September, headcount 17,156 16,875\u00b9\u207e Including share based payment. See Note 16 to the consolidated financial statements.2\u207e The comparison figures has been adjusted to show special items.See Note 27 to the consolidated financial statements for information on the Executive Management's and the Board of Directors' remuneration.Note 16Share optionsAccounting policiesShare options are granted to the executive management and senior management. For equity-settled schemes, the fair value of options is determined at the grant date. The option value is subsequently recognised over the vesting period as staff costs. For cash-settled schemes, the fair value of options granted during the period is recognised as staff costs, whereas the fair value adjustment of granted options from previous periods is recognised under financial items. The purchase and selling prices of treasury shares on exercise of share options are deducted from or added to equity, as the case may be.Share options are granted to members of the executive management and other senior management for the purpose of motivating and retaining a qualified management group and in order to align the interests of management with those of the shareholders. Options are awarded as unconditional allocations at the date of grant, but vest over a three-year period. The value of options at the date of grant equalled an average of three months' salary for each recipient, with the exception of the executive management.The carrying amount of the cash settled share option programmes was DKK 0 million at 30 September 2025 (DKK 2 million at 30 September 2024), while the fair value of all option programmes at grant date amounted to DKK 417 million at 30 September 2025 (DKK 291 million at 30 September 2024).DKK million2024/25 2023/24Share options have affected the profit or loss for the year as followsStaff costs, accounting value of cash and equity-settled programmes 79 70 Financial costs, fair value adjustment of cash-settled programmes -2 \u2013 Cost of share options recognised in profit or loss 77 70 The fair value of the options was calculated using the Black-Scholes formula at the date of the grant, in which the interest rate applied was the yield on Danish government securities. Volatility in the share is calculated as monthly movements (period-end to period-end) over five years. Options are assumed to be exercised on average one year into the exercise period.2024 2023The following assumptions were applied in determining the fair value of share options granted during the financial yearBlack-Scholes value, DKK125.12 121.41Share price, DKK787.60 773.22Exercise price, DKK826.98 811.88Expected dividend per share, DKK 1.50 % 1.50 %Expected duration, years4.00 4.00Volatility 23.35 % 22.12 %Risk-free interest 1.72 % 2.21 %Fair value at grant date, million DKK90.30 76.452024/25 2023/24Average Average Average Average No. of exercise share No. of exercise share optionspriceprice\u00b9\u207eoptionspriceprice\u00b9\u207eOutstanding share options at 1 October 2,041,988 888 2,129,562 871 Options awarded 721,701 827 629,716 812 Options expired -97,445 859 -2 608 Options forfeited -164,297 860 -36,990 862 Options exercised -31,341 849 917 -680,298 740 891 Outstanding share options at 30 September 2,470,606 867 2,041,988 8881) At the date of exerciseNot exercised No. ofShareat 30 options optionsOptionsSeptember ExerciseYear of issueissuedlapsedexercised2025\u00b9\u207eprice\u00b2\u207e\u00b3\u207e Exercise periodSpecification of outstanding share options2020 535,152 -335,224 \u2013 199,928 949 31/12/23 - 31/12/252020, repriced 241,296 -11,291 -32,836 197,169 897 31/12/23 - 31/12/252020 US 109,900 -97,446 \u2013 12,454 981 31/12/23 - 31/12/252020 US, repriced 65,197 -13,163 -3,816 48,218 920 31/12/23 - 31/12/252021 441,494 -287,303 \u2013 154,191 1,183 31/12/24 - 31/12/262021, repriced 103,554 -7,700 \u2013 95,854 897 31/12/24 - 31/12/262021 US 95,846 -83,387 \u2013 12,459 1,213 31/12/24 - 31/12/262021 US, repriced 29,592 -7,416 \u2013 22,176 920 31/12/24 - 31/12/262022 424,561 -26,609 \u2013 397,952 832 31/12/25 - 31/12/272022 US 108,646 -26,428 \u2013 82,218 855 31/12/25 - 31/12/272023 514,397 -25,688 \u2013 488,709 798 31/12/26 - 31/12/282023 US 115,319 -31,214 \u2013 84,105 812 31/12/26 - 31/12/282024 706,431 -43,592 \u2013 662,839 822 31/12/27 - 31/12/292024 US 15,270 -2,936 \u2013 12,334 827 31/12/27 - 31/12/29Total 3,506,655 -999,397 -36,652 2,470,606\u00b9\u207e Exercisable options as per 30 September 2025 was 742,449.\u00b2\u207e Average exercise price for options exercisable at the balance sheet date was DKK 979.33.\u00b3\u207e The exercise prices are adjusted for payment of dividend. In 2024/25, the adjustment of the exercise price was DKK -8.67.In 2024/25 111,201 options (2023/24: 141,526) were granted to key management. As per 30 September 2025 key managements holds 139,106 options (2023/24: 304,279) at an average exercise price of 907.84 (2023/24: 949.36).Coloplast's holding of treasury shares fully covers the option programmes, so the options exercised under the programme will not influence the Group's cash position by forcing it to buy up shares in the market. See Note 9 to the financial statements for an overview of treasury shares held by Coloplast at the balance sheet date.Note 17Provisions for pensions and similar obligationsAccounting policiesIn defined contribution plans, the Group makes regular payments of fixed contributions to independent pension funds and insurance companies. The Group is under no obligation to pay additional contributions. Costs for defined contribution plans are recognised in the income statement as Coloplast assumes an obligation to make the payment.In defined benefit plans, the Group is under an obligation to pay a defined benefit on retirement. The actuarially calculated present value less the fair value of any plan assets is recognised in the balance sheet under provision for pension and similar obligations or in plan assets in the balance sheet. The total service costs of the year plus calculated interest based on actuarial estimates and financial assumptions at the beginning of the year are recognised in the income statement. The difference between the forecast development in plan assets and liabilities and the realised values at the end of the year is called actuarial gains or losses and is recognised in other comprehensive income. In connection with a change in benefits regarding the employees\u2019 employment with the Group to date, there will be a change in the actuarial calculation of the net present value, which is taken directly to the profit or loss.Defined contribution plansThe Group offers pension plans to certain groups of employees in Denmark and abroad. Most of the pension plans are defined contribution plans. The Group funds the plans through regular payments of premiums to independent insurance companies responsible for the pension obligations towards the beneficiaries. Once the pension contributions for defined contribution plans have been made, the Group has no further obligation towards current or former employees. Contributions to defined contribution plans are recognised in the income statement when paid. In 2024/25, DKK 458 million (2023/24: DKK 472 million) was recognised.Defined benefit plansFor certain groups of employees in foreign subsidiaries, the Group has signed agreements to pay defined benefits, including pension payments.Share of gross defined benefit obligations by country 2025 2024France 26 % 22 %Germany 12 % 11 %UK 61 % 66 %Italy 1 % 1 %Total 100 % 100 %These pension liabilities are not or are only partly covered by insurance (in the UK). Defined benefit liabilities are recognised in the balance sheet and in the statement of comprehensive income as indicated below. Coloplast funds the plans in the UK.The pension plans are based on the individual employee's salary and years of service with the company, and benefits are paid as a lifelong pension. The active plans are not exclusive to any particular employee group.Special funding requirements apply in the UK, while this is not the case for the other countries. In the UK, employee interests are handled by a Trustee Board. Accounts are prepared every three years and funding of any deficit is determined. Coloplast have an unconditional right to any surplus in the scheme at the end of the life of the scheme when all the liabilities have been run off. Any deficit in the Scheme is recovered by additional contributions from the employer over a fixed period of time. The plans have no requirements for risk diversification on equities or for matching strategies The plans have a duration of an average of 11 years, and all plans generally mature after more than 10 years.The Group expects to pay DKK 8 million to the defined benefit plans in 2024/25 (2023/24: DKK 7 million).DKK million2024/25 2023/24Defined contribution plans 458 472 Defined benefit plans 14 13 Cost of pension plans recognised in profit or loss 472 485 Pension costs concerning current financial year 10 8 Net interest expenses 4 5 Cost of defined benefit plans recognised in profit or loss 14 13 Actuarial gains/losses on pension obligations 46 -10 Actuarial gains/losses on plan assets -25 16 Actuarial gains/losses on defined benefit plans recognisedin other comprehensive income 21 7 Plan assets at 1 October 254 225 Exchange adjustments -12 8 Actual rate of interest 13 12 Actuarial gains/losses on plan assets -25 16 Paid by the Coloplast Group 7 7 Benefit paid out -15 -14 Plan assets at 30 September 222 254 DKK million2025 2024Specification of plan assetsShares, listed 35 31 Bonds, listed 89 112 Investments funds, listed 97 109 Cash and similar assets 1 2 Plan assets at 30 September 222 254 DKK million2024/25 2023/24Specification of present value of defined benefit obligationPresent value of defined benefit liability at 1 October 387 356 Exchange adjustments -12 10 Current service costs 10 8 Calculated interest on liability 17 17 Actuarial gains/losses, financial assumptions -26 10 Actuarial gains/losses, demographic assumptions -5 5 Actuarial gains/losses, experience -15 -5 Benefit paid out -15 -14 Present value of defined benefit liability at 30 September 341 387 Fair value of plan assets at 30 September -222 -254 Net liability of defined benefit plans at 30 September 119 133 Net liability of defined benefit plans at 1 October 133 131 Expenditure for the year 14 13 Actuarial gains/losses on pension obligation -46 10 Exchange adjustment \u2013 1 Actuarial gains/losses on plan assets 25 -16 Payments received -7 -7 Net liability of defined benefit plans at 30 September 119 133 Actuarial assumptions applied at the balance sheet date (expressed as an average)Discount rate 3.6 % 3.6 %Future rate of salary increases 2.3 % 2.0 %Inflation 1.3 % 2.2 %The below sensibility analysis shows the change in one of the actuarial assumptions, while other assumptions are kept constant. In practice, a change in one of the assumptions will in many instances be matched by a change in the other assumptions.2024/25 2023/24+1%-point -1%-point +1%-point -1%-pointPercentage increase/decrease in the gross liability resulting from a change in a single actuarial assumptionDiscount rate -12 % 13 % -13 % 15 %Future rate of salary increases 3 % -3 % 3 % -2 %Inflation 7 % -6 % 8 % -8 %Note 27Remuneration of the Board of Directors and Executive ManagementThe current policy for the remuneration of the Board of Directors and Executive Management was adopted in 2023 and sets out the general guidelines for the remuneration of the Group\u2019s management. The guidelines for the remuneration of the Board of Directors and Executive Management are available on the Group website. Executive Management is defined as members registered with the Danish Business Authority. The board of directors decided 5 November 2024, that the CEO and CFO were to remain as the sole registered executives. In addition to the disclosures provided in this note, more details on the remuneration of Executive Management and Directors are provided in the separate Remuneration report for the Coloplast Group, which is not a part of the audited consolidated financial statements. The report is also available on the Group website.Fees to Board members in respect of the current financial yearBoard member fees has remained unchanged for the past nine years. At the Annual General Meeting held on 5 December 2024, it was decided to increase the remuneration for the Board of Directors, the Audit Committee, and the Remuneration and Nomination Committee. The total remuneration for the fiscal year 2024/25 amounts to DKK 7.6 million (2023/24: DKK 6.9 million), which is included in total staff costs (see Note 5 to the financial statements) and are specified as follows:DKK million 2024/25 2023/24Ordinary board member fee 5.7 5.3 Audit Committee 1.1 0.9 Nomination and Remuneration Committee 0.8 0.7 Fee to members of the Board of Directors 7.6 6.9 Remuneration of members of the Executive Management in respect of the current financial year Remuneration to members of the Executive Management make up DKK 83.2 million (2023/24: DKK 63.5 million) of the total staff costs (see Note 5 to the financial statements) and are specified as follows:DKK million 2024/25 2023/24Base salaries 20.2 35.6Pension 3.2 5.1Other benefits 0.5 1.4Cash bonus 0.8 4.9Severance payment to Executive Management 50.5 \u2013Remuneration of Executive Management, excluding value of share options and contingent salary items 75.2 47.0Share options 8.0 16.5Remuneration of Executive Management 83.2 63.5The value of share options, which is calculated as the fair value of share options at the grant date using the Black-Scholes Formula in line with IFRS 2, comprise the annual accounting cost of share options awarded in the current and in prior years in accordance with the accounting policies applied. Consequently, it does not represent the fair value of share options awarded or exercised in the current financial year.If a member of Executive Management is given notice of termination by the company and such termination is not due to breach on the part of the member of Executive Management, such member is entitled to compensation corresponding to a maximum of two years\u2019 salary and pension contribution.Share options are granted to members of Executive Management and senior management. See Note 16 to the financial statements for further information regarding share-based payments as well as the separate Remuneration Report for the Coloplast Group, which is not part of the audited financial statements. The report is available on the Group website.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__48-1": {
"value": "Staff costs allocated to functionsProduction costs 1,946 1,935 Distribution costs 5,639 5,403 2Administrative expenses\u207e 834 833 Research and development costs 608 570 2Special items\u207e 241 20 Total 9,268 8,7612024/25 2023/24Amortisations on intangible assets break down as followsProduction costs 47 38 Distribution costs 407 386 Administrative expenses 29 20 Research and development costs 8 7 Special items 99 \u2013 Total 590 451DKK million 2024/25 2023/24Depreciations on property, plant and equipment break down as followsProduction costs 462 431 Distribution costs 51 45 Administrative expenses 26 38 Research and development costs 36 38 Total 575 552DKK million2024/25 2023/24Depreciations on right-of-use assets break down as followsProduction costs 36 37 Distribution costs 224 209 Administrative expenses 26 39 Research and development costs 2 2 Total 288 287 Other lease expenses recorded in the Statement of comprehensive incomeLease payments related to short-term leases 18 22 Lease payments related to low-value assets 24 28 Variable lease payments 31 13 Total 73 63 Total cash outflow for leasesPayments related to right-of-use assets 324 289 Payments related to other lease contracts 64 61 Total 388 350 DKK million 2025 2024Maturity analysis of lease liabilities (undiscounted)In less than one year 287 266 Current lease liability (undiscounted) 287 266 Within 1 to 5 years 547 579 After more than 5 years 243 252 Non-current lease liability (undiscounted) 790 831 Total lease liability (undiscounted) 1,077 1,097",
"dimensions": {
"concept": "ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__47-1": {
"value": "Staff costs allocated to functionsProduction costs 1,946 1,935 Distribution costs 5,639 5,403 2Administrative expenses\u207e 834 833 Research and development costs 608 570 2Special items\u207e 241 20 Total 9,268 8,7612024/25 2023/24Amortisations on intangible assets break down as followsProduction costs 47 38 Distribution costs 407 386 Administrative expenses 29 20 Research and development costs 8 7 Special items 99 \u2013 Total 590 451DKK million 2024/25 2023/24Depreciations on property, plant and equipment break down as followsProduction costs 462 431 Distribution costs 51 45 Administrative expenses 26 38 Research and development costs 36 38 Total 575 552DKK million2024/25 2023/24Depreciations on right-of-use assets break down as followsProduction costs 36 37 Distribution costs 224 209 Administrative expenses 26 39 Research and development costs 2 2 Total 288 287 Other lease expenses recorded in the Statement of comprehensive incomeLease payments related to short-term leases 18 22 Lease payments related to low-value assets 24 28 Variable lease payments 31 13 Total 73 63 Total cash outflow for leasesPayments related to right-of-use assets 324 289 Payments related to other lease contracts 64 61 Total 388 350 DKK million 2025 2024Maturity analysis of lease liabilities (undiscounted)In less than one year 287 266 Current lease liability (undiscounted) 287 266 Within 1 to 5 years 547 579 After more than 5 years 243 252 Non-current lease liability (undiscounted) 790 831 Total lease liability (undiscounted) 1,077 1,097",
"dimensions": {
"concept": "ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__46-1": {
"value": "Staff costs allocated to functionsProduction costs 1,946 1,935 Distribution costs 5,639 5,403 2Administrative expenses\u207e 834 833 Research and development costs 608 570 2Special items\u207e 241 20 Total 9,268 8,7612024/25 2023/24Amortisations on intangible assets break down as followsProduction costs 47 38 Distribution costs 407 386 Administrative expenses 29 20 Research and development costs 8 7 Special items 99 \u2013 Total 590 451DKK million 2024/25 2023/24Depreciations on property, plant and equipment break down as followsProduction costs 462 431 Distribution costs 51 45 Administrative expenses 26 38 Research and development costs 36 38 Total 575 552DKK million2024/25 2023/24Depreciations on right-of-use assets break down as followsProduction costs 36 37 Distribution costs 224 209 Administrative expenses 26 39 Research and development costs 2 2 Total 288 287 Other lease expenses recorded in the Statement of comprehensive incomeLease payments related to short-term leases 18 22 Lease payments related to low-value assets 24 28 Variable lease payments 31 13 Total 73 63 Total cash outflow for leasesPayments related to right-of-use assets 324 289 Payments related to other lease contracts 64 61 Total 388 350 DKK million 2025 2024Maturity analysis of lease liabilities (undiscounted)In less than one year 287 266 Current lease liability (undiscounted) 287 266 Within 1 to 5 years 547 579 After more than 5 years 243 252 Non-current lease liability (undiscounted) 790 831 Total lease liability (undiscounted) 1,077 1,097",
"dimensions": {
"concept": "ifrs-full:DisclosureOfExpensesByNatureExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__45-1": {
"value": "Staff costs allocated to functionsProduction costs 1,946 1,935 Distribution costs 5,639 5,403 2Administrative expenses\u207e 834 833 Research and development costs 608 570 2Special items\u207e 241 20 Total 9,268 8,7612024/25 2023/24Amortisations on intangible assets break down as followsProduction costs 47 38 Distribution costs 407 386 Administrative expenses 29 20 Research and development costs 8 7 Special items 99 \u2013 Total 590 451DKK million 2024/25 2023/24Depreciations on property, plant and equipment break down as followsProduction costs 462 431 Distribution costs 51 45 Administrative expenses 26 38 Research and development costs 36 38 Total 575 552DKK million2024/25 2023/24Depreciations on right-of-use assets break down as followsProduction costs 36 37 Distribution costs 224 209 Administrative expenses 26 39 Research and development costs 2 2 Total 288 287 Other lease expenses recorded in the Statement of comprehensive incomeLease payments related to short-term leases 18 22 Lease payments related to low-value assets 24 28 Variable lease payments 31 13 Total 73 63 Total cash outflow for leasesPayments related to right-of-use assets 324 289 Payments related to other lease contracts 64 61 Total 388 350 DKK million 2025 2024Maturity analysis of lease liabilities (undiscounted)In less than one year 287 266 Current lease liability (undiscounted) 287 266 Within 1 to 5 years 547 579 After more than 5 years 243 252 Non-current lease liability (undiscounted) 790 831 Total lease liability (undiscounted) 1,077 1,097",
"dimensions": {
"concept": "ifrs-full:DisclosureOfCostOfSalesExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__44-1": {
"value": "Staff costs allocated to functionsProduction costs 1,946 1,935 Distribution costs 5,639 5,403 2Administrative expenses\u207e 834 833 Research and development costs 608 570 2Special items\u207e 241 20 Total 9,268 8,7612024/25 2023/24Amortisations on intangible assets break down as followsProduction costs 47 38 Distribution costs 407 386 Administrative expenses 29 20 Research and development costs 8 7 Special items 99 \u2013 Total 590 451DKK million 2024/25 2023/24Depreciations on property, plant and equipment break down as followsProduction costs 462 431 Distribution costs 51 45 Administrative expenses 26 38 Research and development costs 36 38 Total 575 552DKK million2024/25 2023/24Depreciations on right-of-use assets break down as followsProduction costs 36 37 Distribution costs 224 209 Administrative expenses 26 39 Research and development costs 2 2 Total 288 287 Other lease expenses recorded in the Statement of comprehensive incomeLease payments related to short-term leases 18 22 Lease payments related to low-value assets 24 28 Variable lease payments 31 13 Total 73 63 Total cash outflow for leasesPayments related to right-of-use assets 324 289 Payments related to other lease contracts 64 61 Total 388 350 DKK million 2025 2024Maturity analysis of lease liabilities (undiscounted)In less than one year 287 266 Current lease liability (undiscounted) 287 266 Within 1 to 5 years 547 579 After more than 5 years 243 252 Non-current lease liability (undiscounted) 790 831 Total lease liability (undiscounted) 1,077 1,097",
"dimensions": {
"concept": "ifrs-full:DisclosureOfExpensesExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__49": {
"value": "Note 6Special items Accounting policiesSpecial items comprise material amounts of a non-recurring nature, such as costs relating to acquisitions, divestment, closure or structural changes etc. These items are presented separately to facilitate the comparability of the income statement and to provide a better picture of the operating results.In the financial year 2024/25 special items contain expenses related to integration costs for the Atos Medical and Kerecis acquisitions. Special items also includes cost for structural changes, the divestment of the skin care business and Executive leadership team severance costs. Costs related to structural changes include a reassessment of the useful lifetime of assets related to Heylo\u2122, due to sales in the only launch market, UK, significantly below forecast.Last year\u2019s special items contain expenses related to integration costs for the Atos Medical acquisition. and reversal of the remaining provision for earnout consideration related to Kerecis acquisition.DKK million 2024/25 2023/24Integration activities relating to acquisitions -78 -89 Costs related to structural changes -298 \u2013 Skin Care divestment 11 \u2013 Reversal of remaining provision for earnout consideration related to Kerecis \u2013 123 Executive leadership team severance costs -104 \u2013 Total -469 34 If not classified as \"Special items\", the cost would be charged to:Production cost -85 -3 Distribution costs -288 -45 Administrative expenses -101 -41 Research and development costs -6 \u2013 Other operating income 11 123 Total -469 -469 34",
"dimensions": {
"concept": "COL:DisclosureOfSpecialItems",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__50": {
"value": "Accounting policiesSpecial items comprise material amounts of a non-recurring nature, such as costs relating to acquisitions, divestment, closure or structural changes etc. These items are presented separately to facilitate the comparability of the income statement and to provide a better picture of the operating results.",
"dimensions": {
"concept": "COL:DescriptionOfAccountingPolicyForSpecialItems",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__53": {
"value": "Note 7Financial income and expensesAccounting policiesFinancial income and expenses include interest, financing costs of leases, realised and unrealised foreign exchange adjustments, gains on net monetary items in hyperinflationary economies, fair value adjustment of forward contracts transferred from other comprehensive income, fair value adjustments of cash settled share options, fees, market value adjustments of securities and dividend received on shares recognised under securities.See Note 22 to the consolidated financial statements for more information about accounting policy for items transferred from hedging reserve.DKK million 2024/25 2023/24Financial incomeInterest income 27 80Fair value adjustments of cash-based share options 2 \u2013Interest hedges 75 75Hyperinflationary adjustment of net monetary position \u2013 18Other financial income 3 2Total 107 175DKK million 2024/25 2023/24Financial expensesInterest expenses\u00b9\u207e 429 326 Capitalised borrowing cost -8 \u2013 Interest expenses, lease liabilities 39 33 Interest expenses, bonds\u00b9\u207e 293 436 Fair value adjustments of forward contracts transferred from other comprehensive income 49 \u2013 Foreign currency exchange adjustment, net 231 218 Hyperinflationary adjustment of net monetary position 46 \u2013 Other financial expenses and fees 72 87 Total 1,151 1,100\u00b9\u207e Total interest expenses are measured at amortised costs for financial assets and liability.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfFinanceCostExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__52": {
"value": "Note 7Financial income and expensesAccounting policiesFinancial income and expenses include interest, financing costs of leases, realised and unrealised foreign exchange adjustments, gains on net monetary items in hyperinflationary economies, fair value adjustment of forward contracts transferred from other comprehensive income, fair value adjustments of cash settled share options, fees, market value adjustments of securities and dividend received on shares recognised under securities.See Note 22 to the consolidated financial statements for more information about accounting policy for items transferred from hedging reserve.DKK million 2024/25 2023/24Financial incomeInterest income 27 80Fair value adjustments of cash-based share options 2 \u2013Interest hedges 75 75Hyperinflationary adjustment of net monetary position \u2013 18Other financial income 3 2Total 107 175DKK million 2024/25 2023/24Financial expensesInterest expenses\u00b9\u207e 429 326 Capitalised borrowing cost -8 \u2013 Interest expenses, lease liabilities 39 33 Interest expenses, bonds\u00b9\u207e 293 436 Fair value adjustments of forward contracts transferred from other comprehensive income 49 \u2013 Foreign currency exchange adjustment, net 231 218 Hyperinflationary adjustment of net monetary position 46 \u2013 Other financial expenses and fees 72 87 Total 1,151 1,100\u00b9\u207e Total interest expenses are measured at amortised costs for financial assets and liability.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfFinanceIncomeExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__51": {
"value": "Note 7Financial income and expensesAccounting policiesFinancial income and expenses include interest, financing costs of leases, realised and unrealised foreign exchange adjustments, gains on net monetary items in hyperinflationary economies, fair value adjustment of forward contracts transferred from other comprehensive income, fair value adjustments of cash settled share options, fees, market value adjustments of securities and dividend received on shares recognised under securities.See Note 22 to the consolidated financial statements for more information about accounting policy for items transferred from hedging reserve.DKK million 2024/25 2023/24Financial incomeInterest income 27 80Fair value adjustments of cash-based share options 2 \u2013Interest hedges 75 75Hyperinflationary adjustment of net monetary position \u2013 18Other financial income 3 2Total 107 175DKK million 2024/25 2023/24Financial expensesInterest expenses\u00b9\u207e 429 326 Capitalised borrowing cost -8 \u2013 Interest expenses, lease liabilities 39 33 Interest expenses, bonds\u00b9\u207e 293 436 Fair value adjustments of forward contracts transferred from other comprehensive income 49 \u2013 Foreign currency exchange adjustment, net 231 218 Hyperinflationary adjustment of net monetary position 46 \u2013 Other financial expenses and fees 72 87 Total 1,151 1,100\u00b9\u207e Total interest expenses are measured at amortised costs for financial assets and liability.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__55": {
"value": "Accounting policiesFinancial income and expenses include interest, financing costs of leases, realised and unrealised foreign exchange adjustments, gains on net monetary items in hyperinflationary economies, fair value adjustment of forward contracts transferred from other comprehensive income, fair value adjustments of cash settled share options, fees, market value adjustments of securities and dividend received on shares recognised under securities.See Note 22 to the consolidated financial statements for more information about accounting policy for items transferred from hedging reserve.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForFinanceCostsExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__54": {
"value": "Accounting policiesFinancial income and expenses include interest, financing costs of leases, realised and unrealised foreign exchange adjustments, gains on net monetary items in hyperinflationary economies, fair value adjustment of forward contracts transferred from other comprehensive income, fair value adjustments of cash settled share options, fees, market value adjustments of securities and dividend received on shares recognised under securities.See Note 22 to the consolidated financial statements for more information about accounting policy for items transferred from hedging reserve.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__56": {
"value": "Note 8Income taxesAccounting policiesCurrent income tax assets and liabilities are measured at the amounts expected to be recovered from or paid to the tax authorities, based on tax legislation that is either enacted or substantively enacted as of the reporting date.Current and deferred income tax related to profit for the year is recognised in income statement, current and deferred income tax related to other comprehensive income is recognised in statement of comprehensive income and current and deferred income tax related to items recognised directly in equity is recognised in equity.Uncertain tax positions are assessed individually and are generally recognised as part of non-current tax assets or liabilities. The uncertain tax positions that materialise and become certain or virtually certain are classified as current tax assets or liabilities.Interest income and expenses related to current taxes are included in financial items. Deferred tax is measured using the balance sheet liability method, based on temporary differences between the carrying amounts of assets and liabilities and their respective tax bases. Deferred tax is not recognised for differences arising from the initial recognition of assets or liabilities in transactions that do not affect accounting profit or taxable income, unless the transaction is part of a business combination. In such cases, deferred tax is determined based on management\u2019s intended use of the assets and settlement of the liabilities.Deferred tax assets are recognised to the extent it is probable that future positive taxable income will be generated, against which the temporary differences and tax losses can be utilised. Deferred tax assets are measured at expected net realisable values. The value of future tax deductions related to share option programmes is recognised as deferred tax, until they are exercised by the employees. Any estimated excess tax deduction compared to the costs realised in the income statement is charged to equity.Deferred tax is measured according to current tax regulations and the tax rates assumed to apply in year in which the asset or liability is expected to crystallise as current tax. Changes in deferred tax due to changed tax rates are recognised in the income statement or in the equity, depending on where the underlying item is recognised.No deferred tax is recognised on undistributed earnings in subsidiaries, as Coloplast has control over the timing of the distribution and can prevent the realisation of the related tax liability.Key accounting estimates and judgementsThe recognition of deferred tax assets and uncertain tax positions requires judgement by management. Deferred tax assets, including those arising from tax loss carry-forwards, are recognised when management assesses that it is probable the assets can be utilised within a foreseeable future through offsetting against future taxable income. This assessment is conducted annually and is based on updated forecasts and business plans, including any planned strategic initiatives. Given the Group\u2019s global operations, transfer pricing disputes may arise with tax authorities concerning intercompany pricing and related matters. Management evaluates such exposures using a probability-weighted approach to determine the appropriate recognition of obligations related to these disputes.OECD Pillar Two model rules The Coloplast Group is within the scope of the OECD Pillar Two model rules also known as the Global Anti-Base Erosion (GloBE) rules. The GloBE Rules came into effect as per 1 January 2024. Under the Pillar Two legislation Coloplast is liable to pay a top-up tax for jurisdictions where its GloBE effective tax rate is below the 15 percent minimum rate. In addition to the GloBE rules transitional Safe-Harbour rules have been enacted.Based on the Safe-Harbour assessment Coloplast has identified that 1 jurisdiction did not meet any of the safe harbour tests. For this jurisdiction Coloplast has calculated total top-up tax of DKK 0.2m, which is recognised as a current tax expense for the year. This is included in the income tax in the income statement.Coloplast applies the IAS 12 exception to recognising and disclosing information about deferred tax assets and liabilities related to Pillar Two Income taxes.Tax on profit for the yearDKK million 2024/25 2023/24Specification of tax on profit for the yearCurrent tax on profit for the year2,117 675 Change in deferred tax on profit for the year415 676 Tax on profit from ordinary activities for the year2,532 1,351 Adjustment of tax relating to prior years-11 -8 Tax on profit for the year 2,521 1,343 Tax on equity and other comprehensive income entries, income (-) / expense (+)427 -151 Reconciliation of the effective tax rateDanish corporate income tax rate 22.0 % 22.0 %Effect from transfer of intellectual property under the operational model 18.6 % 0.0 %Deviation in foreign subsidiaries' tax percentage 0.3 % 0.3 %Non-taxable income and non-deductible expenses 0.2 % -1.5 %Research and development incentives -0.9 % -0.8 %Global minimum tax (Pillar Two) 0.0 % \u2013 %Other taxes and other adjustments, net 0.7 % 1.0 %Effective tax rate 40.9 % 21.0 %The transfer of intellectual property under the operational model affects the effective tax rate due to the tax recognised on goodwill, which does not carry deferred tax at initial recognition on the acquisition date.Cash flow of corporate tax amount to DKK 571 million (DKK 3.958 million for 2023/24 impacted by transfer of IP during 2022/23). The Group\u2019s tax losses amount to DKK 2,240 million (DKK 1,139 million at 30 September 2024). Of these tax losses, the Group has recognised a tax asset of DKK 486 million at 30 September 2025 (DKK 240 million at 30 September 2024). Tax value of not recognised tax losses amount to DKK 8 million (DKK 9 million at 30 September 2024). Tax losses expiring after more than five years amount to DKK 12 million at 30 September 2025 (DKK 155 million at 30 September 2024). Tax losses of DKK 2,196 million at 30 September 2025 (DKK 926 million at 30 September 2024) can be carried forward infinitely.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__60": {
"value": "Accounting policiesCurrent income tax assets and liabilities are measured at the amounts expected to be recovered from or paid to the tax authorities, based on tax legislation that is either enacted or substantively enacted as of the reporting date.Current and deferred income tax related to profit for the year is recognised in income statement, current and deferred income tax related to other comprehensive income is recognised in statement of comprehensive income and current and deferred income tax related to items recognised directly in equity is recognised in equity.Uncertain tax positions are assessed individually and are generally recognised as part of non-current tax assets or liabilities. The uncertain tax positions that materialise and become certain or virtually certain are classified as current tax assets or liabilities.Interest income and expenses related to current taxes are included in financial items. Deferred tax is measured using the balance sheet liability method, based on temporary differences between the carrying amounts of assets and liabilities and their respective tax bases. Deferred tax is not recognised for differences arising from the initial recognition of assets or liabilities in transactions that do not affect accounting profit or taxable income, unless the transaction is part of a business combination. In such cases, deferred tax is determined based on management\u2019s intended use of the assets and settlement of the liabilities.Deferred tax assets are recognised to the extent it is probable that future positive taxable income will be generated, against which the temporary differences and tax losses can be utilised. Deferred tax assets are measured at expected net realisable values. The value of future tax deductions related to share option programmes is recognised as deferred tax, until they are exercised by the employees. Any estimated excess tax deduction compared to the costs realised in the income statement is charged to equity.Deferred tax is measured according to current tax regulations and the tax rates assumed to apply in year in which the asset or liability is expected to crystallise as current tax. Changes in deferred tax due to changed tax rates are recognised in the income statement or in the equity, depending on where the underlying item is recognised.No deferred tax is recognised on undistributed earnings in subsidiaries, as Coloplast has control over the timing of the distribution and can prevent the realisation of the related tax liability.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__59": {
"value": "Accounting policiesCurrent income tax assets and liabilities are measured at the amounts expected to be recovered from or paid to the tax authorities, based on tax legislation that is either enacted or substantively enacted as of the reporting date.Current and deferred income tax related to profit for the year is recognised in income statement, current and deferred income tax related to other comprehensive income is recognised in statement of comprehensive income and current and deferred income tax related to items recognised directly in equity is recognised in equity.Uncertain tax positions are assessed individually and are generally recognised as part of non-current tax assets or liabilities. The uncertain tax positions that materialise and become certain or virtually certain are classified as current tax assets or liabilities.Interest income and expenses related to current taxes are included in financial items. Deferred tax is measured using the balance sheet liability method, based on temporary differences between the carrying amounts of assets and liabilities and their respective tax bases. Deferred tax is not recognised for differences arising from the initial recognition of assets or liabilities in transactions that do not affect accounting profit or taxable income, unless the transaction is part of a business combination. In such cases, deferred tax is determined based on management\u2019s intended use of the assets and settlement of the liabilities.Deferred tax assets are recognised to the extent it is probable that future positive taxable income will be generated, against which the temporary differences and tax losses can be utilised. Deferred tax assets are measured at expected net realisable values. The value of future tax deductions related to share option programmes is recognised as deferred tax, until they are exercised by the employees. Any estimated excess tax deduction compared to the costs realised in the income statement is charged to equity.Deferred tax is measured according to current tax regulations and the tax rates assumed to apply in year in which the asset or liability is expected to crystallise as current tax. Changes in deferred tax due to changed tax rates are recognised in the income statement or in the equity, depending on where the underlying item is recognised.No deferred tax is recognised on undistributed earnings in subsidiaries, as Coloplast has control over the timing of the distribution and can prevent the realisation of the related tax liability.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__57-1": {
"value": "Accounting policiesCurrent income tax assets and liabilities are measured at the amounts expected to be recovered from or paid to the tax authorities, based on tax legislation that is either enacted or substantively enacted as of the reporting date.Current and deferred income tax related to profit for the year is recognised in income statement, current and deferred income tax related to other comprehensive income is recognised in statement of comprehensive income and current and deferred income tax related to items recognised directly in equity is recognised in equity.Uncertain tax positions are assessed individually and are generally recognised as part of non-current tax assets or liabilities. The uncertain tax positions that materialise and become certain or virtually certain are classified as current tax assets or liabilities.Interest income and expenses related to current taxes are included in financial items. Deferred tax is measured using the balance sheet liability method, based on temporary differences between the carrying amounts of assets and liabilities and their respective tax bases. Deferred tax is not recognised for differences arising from the initial recognition of assets or liabilities in transactions that do not affect accounting profit or taxable income, unless the transaction is part of a business combination. In such cases, deferred tax is determined based on management\u2019s intended use of the assets and settlement of the liabilities.Deferred tax assets are recognised to the extent it is probable that future positive taxable income will be generated, against which the temporary differences and tax losses can be utilised. Deferred tax assets are measured at expected net realisable values. The value of future tax deductions related to share option programmes is recognised as deferred tax, until they are exercised by the employees. Any estimated excess tax deduction compared to the costs realised in the income statement is charged to equity.Deferred tax is measured according to current tax regulations and the tax rates assumed to apply in year in which the asset or liability is expected to crystallise as current tax. Changes in deferred tax due to changed tax rates are recognised in the income statement or in the equity, depending on where the underlying item is recognised.No deferred tax is recognised on undistributed earnings in subsidiaries, as Coloplast has control over the timing of the distribution and can prevent the realisation of the related tax liability.Key accounting estimates and judgementsThe recognition of deferred tax assets and uncertain tax positions requires judgement by management. Deferred tax assets, including those arising from tax loss carry-forwards, are recognised when management assesses that it is probable the assets can be utilised within a foreseeable future through offsetting against future taxable income. This assessment is conducted annually and is based on updated forecasts and business plans, including any planned strategic initiatives. Given the Group\u2019s global operations, transfer pricing disputes may arise with tax authorities concerning intercompany pricing and related matters. Management evaluates such exposures using a probability-weighted approach to determine the appropriate recognition of obligations related to these disputes.Deferred taxDKK million 2024/25 2023/24Deferred tax at 1 October, net -1,857 -1,238Exchange adjustments -10 27Prior-year adjustments 8 26Changes in deferred tax \u2013 charged to income statement -415 -676Change in deferred tax - charged to equity -181 4,Deferred tax at 30 September, net -2,455-1,8574DKK million 2025 2024Recognised in the balance sheet as followsDeferred tax assets 587 624Deferred tax liability -3,042 -2,481Deferred tax at 30 September, net-2,455--1,857Deferred tax relates to the following itemsIntangible assets -3,620 -2,723Property, plant and equipment, and right-of-use assets -312 -311Indirect production costs -13 -14Unrealised gain from intra-group sale of goods 569 469Trade receivables -110 -74Provisions 264 140Share options \u2013 14Tax losses carried forward and tax credits 540 294Lease liabilities 222 219Effect from hedge of cash flow and interest rates -37 84Other 42 45Deferred tax at 30 September, net -2,455 -2,455 -1,857 The tax value of the Group\u2019s tax credits amounts to DKK 227 million at 30 September 2025 (DKK 203 million at 30 September 2024). This amount includes a recognised tax asset of DKK 54 million at 30 September 2025 (DKK 54 million at 30 September 2024). Tax credits of DKK 32 million expires after five years.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfDeferredTaxesExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__64": {
"value": "Note 9Earnings per share (EPS)Accounting policiesEarnings per share (EPS) reflects the ratio between profit for the year and the year\u2019s weighted average of issued, ordinary shares, excluding ordinary shares purchased by the Group and held as treasury shares. Earnings per share, diluted, is calculated as the net profit for the year divided by the average number of outstanding shares adjusted for the dilutive effect of outstanding share options in the money.2024/25 2023/24Net profit for the year, DKK million 3,636 5,052 Weighted average number of outstanding shares, millions of units 225.4 224.9 Dilutive effect of outstanding share options, millions of units 0 0 Average number of unrestricted shares including dilutive effect of outstanding share options, millions of units 225.4 224.9 Earnings per share, DKK 16.13 22.46 Earnings per share, diluted, DKK 16.13 22.46 2024/25 2023/24Outstanding shares ('000): A shares B shares A shares B sharesOutstanding shares at 1 October 18,000 207,335 18,000 206,660 Sale of treasury shares \u2013 32 \u2013 675 Outstanding shares at 30 September 18,000 207,367 18,000 207,335 Holding of treasury shares at 30 September \u2013 2,833 \u2013 2,865 Total shares issued at 30 September 18,000 210,200 18,000 210,200 Both share classes have a face value of DKK 1 per share. Class A shares carry 10 votes each, while class B shares carry 1 vote each. The class A shares are non-negotiable instruments. Any change of ownership or pledging of class A shares requires the consent of the Board of Directors. B shares are negotiable instruments, and no restrictions apply to their negotiability. No special dividend rights attach to either share class. The Group does not hold A shares.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfTreasurySharesExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__63": {
"value": "Note 9Earnings per share (EPS)Accounting policiesEarnings per share (EPS) reflects the ratio between profit for the year and the year\u2019s weighted average of issued, ordinary shares, excluding ordinary shares purchased by the Group and held as treasury shares. Earnings per share, diluted, is calculated as the net profit for the year divided by the average number of outstanding shares adjusted for the dilutive effect of outstanding share options in the money.2024/25 2023/24Net profit for the year, DKK million 3,636 5,052 Weighted average number of outstanding shares, millions of units 225.4 224.9 Dilutive effect of outstanding share options, millions of units 0 0 Average number of unrestricted shares including dilutive effect of outstanding share options, millions of units 225.4 224.9 Earnings per share, DKK 16.13 22.46 Earnings per share, diluted, DKK 16.13 22.46 2024/25 2023/24Outstanding shares ('000): A shares B shares A shares B sharesOutstanding shares at 1 October 18,000 207,335 18,000 206,660 Sale of treasury shares \u2013 32 \u2013 675 Outstanding shares at 30 September 18,000 207,367 18,000 207,335 Holding of treasury shares at 30 September \u2013 2,833 \u2013 2,865 Total shares issued at 30 September 18,000 210,200 18,000 210,200 Both share classes have a face value of DKK 1 per share. Class A shares carry 10 votes each, while class B shares carry 1 vote each. The class A shares are non-negotiable instruments. Any change of ownership or pledging of class A shares requires the consent of the Board of Directors. B shares are negotiable instruments, and no restrictions apply to their negotiability. No special dividend rights attach to either share class. The Group does not hold A shares.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfIssuedCapitalExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__62": {
"value": "Note 9Earnings per share (EPS)Accounting policiesEarnings per share (EPS) reflects the ratio between profit for the year and the year\u2019s weighted average of issued, ordinary shares, excluding ordinary shares purchased by the Group and held as treasury shares. Earnings per share, diluted, is calculated as the net profit for the year divided by the average number of outstanding shares adjusted for the dilutive effect of outstanding share options in the money.2024/25 2023/24Net profit for the year, DKK million 3,636 5,052 Weighted average number of outstanding shares, millions of units 225.4 224.9 Dilutive effect of outstanding share options, millions of units 0 0 Average number of unrestricted shares including dilutive effect of outstanding share options, millions of units 225.4 224.9 Earnings per share, DKK 16.13 22.46 Earnings per share, diluted, DKK 16.13 22.46 2024/25 2023/24Outstanding shares ('000): A shares B shares A shares B sharesOutstanding shares at 1 October 18,000 207,335 18,000 206,660 Sale of treasury shares \u2013 32 \u2013 675 Outstanding shares at 30 September 18,000 207,367 18,000 207,335 Holding of treasury shares at 30 September \u2013 2,833 \u2013 2,865 Total shares issued at 30 September 18,000 210,200 18,000 210,200 Both share classes have a face value of DKK 1 per share. Class A shares carry 10 votes each, while class B shares carry 1 vote each. The class A shares are non-negotiable instruments. Any change of ownership or pledging of class A shares requires the consent of the Board of Directors. B shares are negotiable instruments, and no restrictions apply to their negotiability. No special dividend rights attach to either share class. The Group does not hold A shares.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__65": {
"value": "Accounting policiesEarnings per share (EPS) reflects the ratio between profit for the year and the year\u2019s weighted average of issued, ordinary shares, excluding ordinary shares purchased by the Group and held as treasury shares. Earnings per share, diluted, is calculated as the net profit for the year divided by the average number of outstanding shares adjusted for the dilutive effect of outstanding share options in the money",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__66": {
"value": "Note 10Dividend per shareDKK 2024/25 2023/24Interim dividend per share5.00 5.00Proposed dividend per share18.00 17.00Total dividend per share 23.00 22.00Total dividend for the year, DKK million5,184 4,956Payout ratio 143 % 98 %The Board of Directors recommends that the shareholders attending the general meeting approve an additional dividend of DKK 18.00 per share. An interim dividend of DKK 5.00 per share was distributed in the financial year, bringing the total dividend per share for the year to DKK 23.00. The increase in dividend per share, compared to last financial year, amounts to 5%. The payout ratio after special items for the year is 143%.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfDividendsExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__67": {
"value": "5.0",
"decimals": 2,
"dimensions": {
"concept": "ifrs-full:DividendsRecognisedAsDistributionsToOwnersPerShare",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK/xbrli:shares"
}
},
"f0__s7__8__68": {
"value": "5.0",
"decimals": 2,
"dimensions": {
"concept": "ifrs-full:DividendsRecognisedAsDistributionsToOwnersPerShare",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK/xbrli:shares"
}
},
"f0__s7__7__69": {
"value": "18.0",
"decimals": 2,
"dimensions": {
"concept": "ifrs-full:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00",
"unit": "iso4217:DKK/xbrli:shares"
}
},
"f0__s7__8__69": {
"value": "17.0",
"decimals": 2,
"dimensions": {
"concept": "ifrs-full:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2023-10-01T00:00:00/2024-10-01T00:00:00",
"unit": "iso4217:DKK/xbrli:shares"
}
},
"f0__s7__7__73": {
"value": "Note 11Intangible assetsAccounting policiesIntangible assets with a finite life are measured at cost less accumulated amortisation and impairment losses. Subsequent milestone payments related to acquired patents, trademarks and know-how payable on achievement of a contingent event will be capitalised when the contingent event is achieved. Amortisation is made on a straight-line basis over the expected useful lives of the assets, which are: Software 3 \u2013 5 yearsAcquired patents, customer list, trademarks and know-how etc. 5 \u2013 20 yearsGoodwill and other intangible assets with indefinite lives are tested for impairment annually or whenever there is an indication of impairment, while the carrying amount of intangible assets with finite lives measured at cost or amortised cost are assessed if there is an indication of impairment. If a write-down is required, the carrying amount is written down to the recoverable amount. For the purpose of assessing impairment, assets are grouped in the smallest group of assets that generates identifiable cash inflows (cash-generating units). The cash-generating units are defined as the smallest identifiable group of assets that generates cash inflows and which are largely independent of cash flows from other assets or groups of assets.For other intangible assets, the amortisation period is determined on the basis of Management\u2019s best estimate of the expected economic lives of the assets. The expected economic lives are assessed at least annually, and the amortisation period is determined based on the latest assessment. For purposes of calculating amortisation, the residual value of the assets is zero, unless a third party has committed to purchasing the asset after its use or there is an active market for the asset. With the exception of goodwill and some specific trademarks, all intangible assets have a finite life.All in-house research and development costs are recognised in the income statement as incurred. Management believes that mandatory regulatory approvals of products, completing the development of new products involves a high degree of uncertainty, for which reason the technical feasibility criteria are not considered to have been met.Gains or losses on the disposal of intangible assets are stated as the difference between the selling price less costs to sell and the carrying amount at the date of disposal and are included in the income statement under other operating income or other operating expenses, respectively.Key accounting estimates and judgementsGoodwill and other intangible assets: The measurement of intangible assets, including goodwill and acquired patents, trademarks and know-how etc., could be materially affected by significant changes in estimates and assumptions underlying the calculation of recoverable amount. The carrying amount of these intangible assets was DKK 29,349 million as at 30 September 2025 (30 September 2024: DKK 29,736 million).AcquiredPrepay-patents,ments andtrademarksintangibleTotaland know-assets inintangibleDKK millionhow etc. Goodwill Softwareprogressassets2024/25Cost at 1 October 12,788 19,375 951 239 33,353 Exchange adjustment -68 -46 1 \u2013 -113 Transfers \u2013 \u2013 205 -205 \u2013 Additions during the year \u2013 \u2013 41 80 121 Disposals during the year \u2013 \u2013 -9 \u2013 -9 Cost at 30 September 12,720 19,329 1,189 114 33,352Amortisation at 1 October 2,427 \u2013 594 \u2013 3,021 Exchange adjustment -61 \u2013 -2 \u2013 -63 Amortisation for the year 334 \u2013 256 \u2013 590 Amortisation reversed on disposals during the year \u2013 \u2013 -7 \u2013 -7 Amortisation at 30 September 2,700 \u2013 841 \u2013 3,541 Carrying amount at 30 September 10,020 19,329 348 114 29,811 AcquiredPrepay-patents,ments andtrademarksintangibleTotaland know-assets inintangibleDKK millionhow etc. Goodwill Softwareprogressassets2023/24Cost at 1 October 12,911 19,974 783 225 33,893 Exchange adjustment -123 -133 2 \u2013 -254 Adjustment to acquisitions previous years \u2013 -466 \u2013 \u2013 -466 Transfers \u2013 \u2013 129 -129 \u2013 Additions during the year \u2013 \u2013 37 143 180 Cost at 30 September 12,788 19,375 951 239 33,353 Amortisation at 1 October 2,167 \u2013 471 \u2013 2,638 Exchange adjustment -70 \u2013 2 \u2013 -68 Amortisation for the year 330 \u2013 121 \u2013 451 Amortisation at 30 September 2,427 \u2013 594 \u2013 3,021 Carrying amount at 30 September 10,361 19,375 357 239 30,332 GoodwillGoodwill mainly relates to the acquisitions of Kerecis in 2023, Atos Medical in 2022, Lilial in 2018, Comfort Medical in 2016, Mpathy in 2010 and Mentor's urology and continence business in 2006. Goodwill from the acquired businesses has been allocated to the individual cash-generating units. The allocation was made to the operating segment Chronic Care (Ostomy Care and Continence Care), Interventional Urology, Voice & Respiratory Care and Biologics. Pursuant to IAS 36, a goodwill impairment test is performed when there is an indication of impairment, but at least once a year. In the impairment test, the carrying amount is compared with the recoverable amount (value in use) of each cash-generating units, calculated as the discounted expected future cash flows. No impairment related to goodwill was identified in 2024/25 or 2023/24.Future cash flows are determined using forecasts based on anticipated sales growth, earnings and strategy plans, etc. These forecasts are based on specific assumptions for each cash-generating unit during the forecast period with respect to sales, results of operations, working capital, capital investments and assumptions for cost of capital, inflation and the level of interest rates. Growth rates for Chronic Care, Biologics and Interventional Urology during the terminal period correspond to the expected long-term rate of inflation. Growth rate for Voice & Respiratory Care is slightly higher, due to the expectation of higher growth within the business area after the forecast period. For Chronic Care and Voice & Respiratory Care, the discount rate is based on the median WACC used by the external analysts\u2019 covering Coloplast. For Interventional Urology , the discount rate is based on the median WACC used by the external analysts\u2019 covering Coloplast added 3% to account for the higher assessed market risk premium related to the interventional urology area. For Biologics, the discount rate is based on the WACC used in the management approved business case.2024/25 2023/24Interventional Voice &Interventional Voice &Chronic CareUrologyRespiratory Care Biologics Chronic CareUrologyRespiratory Care BiologicsCarrying amount, DKK millionTrademarks\u00b9\u207e 50 \u2013 3,206 1,357 50 \u2013 3,138 1,425 Goodwill 1,686 337 11,981 5,324 1,706 352 11,727 5,590 Key parameters appliedRevenue growth in terminal period 2.0 % 2.0 % 2,5% 2.0 % 2.0 % 2.0 % 3.5 % 2.0 %Tax percentage 23.0 % 27.0 % 23.0 % 21,6% 23.0 % 27.0 % 23.0 % 21.2 %Discount rate, before tax 8.0 % 11.0 % 8.3 % 11,6% 8.6 % 13.3 % 8.1 % 11.6 %Discount rate, after tax 7.0 % 10.0 % 7.0 % 9.0 % 7.0 % 10.0 % 7.0 % 9.0 %\u00b9\u207e Carrying amount includes only those trademarks with indefinite useful lives.Special assumptions applied in impairment tests performed in Chronic Care (Ostomy Care and Continence Care)The Ostomy Care business involves the production and sale of ostomy pouches and accessories. The Continence Care business involves the production and sales of disposable catheters and various types of products designed for people suffering from urinary or faecal incontinence. The impairment test performed for Chronic Care was based on forecasts for the new strategy period for the financial years 2025/26 to 2029/30. Revenue growth rates of 7-9% were assumed for the budget period, which are supported by the organic growth rates in recent financial years. It was assumed that the gross margin will increase slightly until the terminal period.The Group\u2019s general tax rate was applied in the impairment test for Chronic Care because these products are sold in all of the Group\u2019s markets. Working capital invested has been projected using the same growth rate as that for revenue.Special assumptions applied in impairment tests performed in Interventional UrologyThe interventional urology business consists of the production and sale of products used in surgical procedures in urology and gynaecology, including prostate catheters, stents, vaginal slings used to restore continence, mesh products used to treat weak pelvic floor and penile implants for men experiencing severe impotence. The impairment test performed for Interventional Urology was based on forecasts for the new strategy period for the financial years 2025/26 to 2029/30. Revenue growth rates of 6-13% were assumed for the budget period, which are supported by the Interventional Urology organic growth rates in recent financial years. It was assumed that the gross margin will increase slightly until the terminal period. The tax rate applied in the impairment test for Interventional Urology was higher than the rate applied for the Group because sales and production mostly take place in the US, which imposes a corporate tax rate higher than the Group average. Working capital invested has been projected using the same growth rate as that for revenue. Special assumptions applied on Voice & Respiratory Care The voice & respiratory care business consists of production and sales of laryngectomy and tracheostomy products, used to treat removal of all or part of the larynex.The impairment test performed for Voice & Respiratory Care was based on forecasts for the new strategy period for the financial years 2025/26 to 2029/30. Revenue growth rates of 12-13% were assumed for the budget period, which are supported by the organic growth rates in recent financial years. It was assumed that the gross margin will increase slightly until the terminal period. The Group\u2019s general tax rate was applied in the impairment test for Voice & Respiratory Care because these products are sold in most of the Group\u2019s markets. Working capital invested has been projected using the same growth rate as that for revenue. Special assumptions applied on BiologicsThe biologics business consists of production and sales of fish-skin technology for wound care treatment.The impairment test performed for Biologics was based on forecasts for the new strategy period for the financial years 2025/26 to 2039/40. Revenue growth rates of 2-29% were assumed for the budget period, which are supported by the organic growth rates in recent financial years. On the other hand, it was assumed that the gross margin will decrease slightly until the terminal period. It was also assumed that the Group\u2019s focus on cost management and regular efficiency improvements will ensure that overhead costs will increase at a rate lower than revenue, which will produce an annual EBIT margin improvement.The Group\u2019s general tax rate was applied in the impairment test for Biologics. Working capital invested has been projected using the same growth rate as that for revenue.Acquired patents, trademarks and know-how etc.Acquired patents and trademarks are primarily associated with the acquisition of Kerecis in 2023, Atos Medical in 2022 and Nine Continents Medical in 2020. In connection with the acquisitions, intangible assets were identified, and the cost was allocated to net assets at fair value at the date of acquisition, calculated on the basis of factors such as expected sales and revenue trends. Each component is amortised over its estimated useful life using the straight line method. Patented and unpatented technologies are tested for impairment together with goodwill impairment test.Patented and unpatented technologiesOn acquiring Kerecis in August 2023, Coloplast acquired several patented technologies and unpatented technologies. Unpatented technologies include inventions not patentable or protectable, know-how, confidential information and copyrights on computer software and the like. Most relate to know-how regarding various technologies. Allocation of the individual components into small intangible assets is not considered material or relevant.On acquiring Atos Medical in January 2022, Coloplast acquired a number of patented and unpatented technologies. Unpatented technologies include inventions not patentable or protectable, know-how, confidential information and copyrights on computer software and the like. Most relate to know-how regarding various technologies. Allocation of the individual components into small intangible assets is not considered material or relevant.On acquiring Nine Continents Medical in November 2020, Coloplast acquired a number of patented and unpatented technologies. Unpatented technologies include inventions not patentable or protectable, know-how, confidential information and copyrights on computer software and the like. Most relate to know-how regarding various technologies. Allocation of the individual components into small intangible assets is not considered material or relevant.TrademarksIn addition to patented and unpatented technologies, Coloplast acquired the Kerecis trademark through the acquisition of Kerecis, and the Atos Medical and TRACOE trademarks through the acquisition of Atos Medical.Management has assessed that the value of trademarks with indefinite useful life, which consist primarily of Kerecis, Atos Medical and TRACOE, can be maintained for an indefinite period, as these are well-established trademarks in their markets, having existed for many years. The industry is characterised as being very stable with consistent consumer demand and a predictable competitive environment, and is expected to be profitable for the foreseeable future. Control of the trademarks is legally established and enforceable indefinitely. In management\u2019s opinion, the risk of the useful life of these brands becoming finite is minimal because of their individual market positions and because current and planned marketing initiatives are expected to sustain their useful life.Customer lists/loyaltiesColoplast also acquired a substantial number of customer relationships on acquiring Kerecis and Atos Medical. Customer relationships include lists of and access to Kerecis\u2019 and Atos Medical\u2019s existing customers, both users, hospitals, distributors and private offices.Material acquired patents, trademarks and know-how etc.RemainingamortisationDKK million Assetperiod 2025 2024Kerecis Trademarks indefinite 1,357 1,425 Technologies and 1,391 1,559 Kereciscustomer relationships8-18 years Atos Medical and TRACOE Trademarks indefinite 3,206 3,138 Technologies and 2,769 2,921 Atos Medical and TRACOEcustomer relationships 6-16 years Nine Continents Technologies n/a 1,218 1,218 Carrying value at 30 September 9,941 10,261 2024/25 2023/24Amortisations on intangible assets break down as followsProduction costs 47 38 Distribution costs 407 386 Administrative expenses 29 20 Research and development costs 8 7 Special items 99 \u2013 Total 590 451",
"dimensions": {
"concept": "ifrs-full:DisclosureOfImpairmentOfAssetsExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__72": {
"value": "Note 11Intangible assetsAccounting policiesIntangible assets with a finite life are measured at cost less accumulated amortisation and impairment losses. Subsequent milestone payments related to acquired patents, trademarks and know-how payable on achievement of a contingent event will be capitalised when the contingent event is achieved. Amortisation is made on a straight-line basis over the expected useful lives of the assets, which are: Software 3 \u2013 5 yearsAcquired patents, customer list, trademarks and know-how etc. 5 \u2013 20 yearsGoodwill and other intangible assets with indefinite lives are tested for impairment annually or whenever there is an indication of impairment, while the carrying amount of intangible assets with finite lives measured at cost or amortised cost are assessed if there is an indication of impairment. If a write-down is required, the carrying amount is written down to the recoverable amount. For the purpose of assessing impairment, assets are grouped in the smallest group of assets that generates identifiable cash inflows (cash-generating units). The cash-generating units are defined as the smallest identifiable group of assets that generates cash inflows and which are largely independent of cash flows from other assets or groups of assets.For other intangible assets, the amortisation period is determined on the basis of Management\u2019s best estimate of the expected economic lives of the assets. The expected economic lives are assessed at least annually, and the amortisation period is determined based on the latest assessment. For purposes of calculating amortisation, the residual value of the assets is zero, unless a third party has committed to purchasing the asset after its use or there is an active market for the asset. With the exception of goodwill and some specific trademarks, all intangible assets have a finite life.All in-house research and development costs are recognised in the income statement as incurred. Management believes that mandatory regulatory approvals of products, completing the development of new products involves a high degree of uncertainty, for which reason the technical feasibility criteria are not considered to have been met.Gains or losses on the disposal of intangible assets are stated as the difference between the selling price less costs to sell and the carrying amount at the date of disposal and are included in the income statement under other operating income or other operating expenses, respectively.Key accounting estimates and judgementsGoodwill and other intangible assets: The measurement of intangible assets, including goodwill and acquired patents, trademarks and know-how etc., could be materially affected by significant changes in estimates and assumptions underlying the calculation of recoverable amount. The carrying amount of these intangible assets was DKK 29,349 million as at 30 September 2025 (30 September 2024: DKK 29,736 million).AcquiredPrepay-patents,ments andtrademarksintangibleTotaland know-assets inintangibleDKK millionhow etc. Goodwill Softwareprogressassets2024/25Cost at 1 October 12,788 19,375 951 239 33,353 Exchange adjustment -68 -46 1 \u2013 -113 Transfers \u2013 \u2013 205 -205 \u2013 Additions during the year \u2013 \u2013 41 80 121 Disposals during the year \u2013 \u2013 -9 \u2013 -9 Cost at 30 September 12,720 19,329 1,189 114 33,352Amortisation at 1 October 2,427 \u2013 594 \u2013 3,021 Exchange adjustment -61 \u2013 -2 \u2013 -63 Amortisation for the year 334 \u2013 256 \u2013 590 Amortisation reversed on disposals during the year \u2013 \u2013 -7 \u2013 -7 Amortisation at 30 September 2,700 \u2013 841 \u2013 3,541 Carrying amount at 30 September 10,020 19,329 348 114 29,811 AcquiredPrepay-patents,ments andtrademarksintangibleTotaland know-assets inintangibleDKK millionhow etc. Goodwill Softwareprogressassets2023/24Cost at 1 October 12,911 19,974 783 225 33,893 Exchange adjustment -123 -133 2 \u2013 -254 Adjustment to acquisitions previous years \u2013 -466 \u2013 \u2013 -466 Transfers \u2013 \u2013 129 -129 \u2013 Additions during the year \u2013 \u2013 37 143 180 Cost at 30 September 12,788 19,375 951 239 33,353 Amortisation at 1 October 2,167 \u2013 471 \u2013 2,638 Exchange adjustment -70 \u2013 2 \u2013 -68 Amortisation for the year 330 \u2013 121 \u2013 451 Amortisation at 30 September 2,427 \u2013 594 \u2013 3,021 Carrying amount at 30 September 10,361 19,375 357 239 30,332 GoodwillGoodwill mainly relates to the acquisitions of Kerecis in 2023, Atos Medical in 2022, Lilial in 2018, Comfort Medical in 2016, Mpathy in 2010 and Mentor's urology and continence business in 2006. Goodwill from the acquired businesses has been allocated to the individual cash-generating units. The allocation was made to the operating segment Chronic Care (Ostomy Care and Continence Care), Interventional Urology, Voice & Respiratory Care and Biologics. Pursuant to IAS 36, a goodwill impairment test is performed when there is an indication of impairment, but at least once a year. In the impairment test, the carrying amount is compared with the recoverable amount (value in use) of each cash-generating units, calculated as the discounted expected future cash flows. No impairment related to goodwill was identified in 2024/25 or 2023/24.Future cash flows are determined using forecasts based on anticipated sales growth, earnings and strategy plans, etc. These forecasts are based on specific assumptions for each cash-generating unit during the forecast period with respect to sales, results of operations, working capital, capital investments and assumptions for cost of capital, inflation and the level of interest rates. Growth rates for Chronic Care, Biologics and Interventional Urology during the terminal period correspond to the expected long-term rate of inflation. Growth rate for Voice & Respiratory Care is slightly higher, due to the expectation of higher growth within the business area after the forecast period. For Chronic Care and Voice & Respiratory Care, the discount rate is based on the median WACC used by the external analysts\u2019 covering Coloplast. For Interventional Urology , the discount rate is based on the median WACC used by the external analysts\u2019 covering Coloplast added 3% to account for the higher assessed market risk premium related to the interventional urology area. For Biologics, the discount rate is based on the WACC used in the management approved business case.2024/25 2023/24Interventional Voice &Interventional Voice &Chronic CareUrologyRespiratory Care Biologics Chronic CareUrologyRespiratory Care BiologicsCarrying amount, DKK millionTrademarks\u00b9\u207e 50 \u2013 3,206 1,357 50 \u2013 3,138 1,425 Goodwill 1,686 337 11,981 5,324 1,706 352 11,727 5,590 Key parameters appliedRevenue growth in terminal period 2.0 % 2.0 % 2,5% 2.0 % 2.0 % 2.0 % 3.5 % 2.0 %Tax percentage 23.0 % 27.0 % 23.0 % 21,6% 23.0 % 27.0 % 23.0 % 21.2 %Discount rate, before tax 8.0 % 11.0 % 8.3 % 11,6% 8.6 % 13.3 % 8.1 % 11.6 %Discount rate, after tax 7.0 % 10.0 % 7.0 % 9.0 % 7.0 % 10.0 % 7.0 % 9.0 %\u00b9\u207e Carrying amount includes only those trademarks with indefinite useful lives.Special assumptions applied in impairment tests performed in Chronic Care (Ostomy Care and Continence Care)The Ostomy Care business involves the production and sale of ostomy pouches and accessories. The Continence Care business involves the production and sales of disposable catheters and various types of products designed for people suffering from urinary or faecal incontinence. The impairment test performed for Chronic Care was based on forecasts for the new strategy period for the financial years 2025/26 to 2029/30. Revenue growth rates of 7-9% were assumed for the budget period, which are supported by the organic growth rates in recent financial years. It was assumed that the gross margin will increase slightly until the terminal period.The Group\u2019s general tax rate was applied in the impairment test for Chronic Care because these products are sold in all of the Group\u2019s markets. Working capital invested has been projected using the same growth rate as that for revenue.Special assumptions applied in impairment tests performed in Interventional UrologyThe interventional urology business consists of the production and sale of products used in surgical procedures in urology and gynaecology, including prostate catheters, stents, vaginal slings used to restore continence, mesh products used to treat weak pelvic floor and penile implants for men experiencing severe impotence. The impairment test performed for Interventional Urology was based on forecasts for the new strategy period for the financial years 2025/26 to 2029/30. Revenue growth rates of 6-13% were assumed for the budget period, which are supported by the Interventional Urology organic growth rates in recent financial years. It was assumed that the gross margin will increase slightly until the terminal period. The tax rate applied in the impairment test for Interventional Urology was higher than the rate applied for the Group because sales and production mostly take place in the US, which imposes a corporate tax rate higher than the Group average. Working capital invested has been projected using the same growth rate as that for revenue. Special assumptions applied on Voice & Respiratory Care The voice & respiratory care business consists of production and sales of laryngectomy and tracheostomy products, used to treat removal of all or part of the larynex.The impairment test performed for Voice & Respiratory Care was based on forecasts for the new strategy period for the financial years 2025/26 to 2029/30. Revenue growth rates of 12-13% were assumed for the budget period, which are supported by the organic growth rates in recent financial years. It was assumed that the gross margin will increase slightly until the terminal period. The Group\u2019s general tax rate was applied in the impairment test for Voice & Respiratory Care because these products are sold in most of the Group\u2019s markets. Working capital invested has been projected using the same growth rate as that for revenue. Special assumptions applied on BiologicsThe biologics business consists of production and sales of fish-skin technology for wound care treatment.The impairment test performed for Biologics was based on forecasts for the new strategy period for the financial years 2025/26 to 2039/40. Revenue growth rates of 2-29% were assumed for the budget period, which are supported by the organic growth rates in recent financial years. On the other hand, it was assumed that the gross margin will decrease slightly until the terminal period. It was also assumed that the Group\u2019s focus on cost management and regular efficiency improvements will ensure that overhead costs will increase at a rate lower than revenue, which will produce an annual EBIT margin improvement.The Group\u2019s general tax rate was applied in the impairment test for Biologics. Working capital invested has been projected using the same growth rate as that for revenue.Acquired patents, trademarks and know-how etc.Acquired patents and trademarks are primarily associated with the acquisition of Kerecis in 2023, Atos Medical in 2022 and Nine Continents Medical in 2020. In connection with the acquisitions, intangible assets were identified, and the cost was allocated to net assets at fair value at the date of acquisition, calculated on the basis of factors such as expected sales and revenue trends. Each component is amortised over its estimated useful life using the straight line method. Patented and unpatented technologies are tested for impairment together with goodwill impairment test.Patented and unpatented technologiesOn acquiring Kerecis in August 2023, Coloplast acquired several patented technologies and unpatented technologies. Unpatented technologies include inventions not patentable or protectable, know-how, confidential information and copyrights on computer software and the like. Most relate to know-how regarding various technologies. Allocation of the individual components into small intangible assets is not considered material or relevant.On acquiring Atos Medical in January 2022, Coloplast acquired a number of patented and unpatented technologies. Unpatented technologies include inventions not patentable or protectable, know-how, confidential information and copyrights on computer software and the like. Most relate to know-how regarding various technologies. Allocation of the individual components into small intangible assets is not considered material or relevant.On acquiring Nine Continents Medical in November 2020, Coloplast acquired a number of patented and unpatented technologies. Unpatented technologies include inventions not patentable or protectable, know-how, confidential information and copyrights on computer software and the like. Most relate to know-how regarding various technologies. Allocation of the individual components into small intangible assets is not considered material or relevant.TrademarksIn addition to patented and unpatented technologies, Coloplast acquired the Kerecis trademark through the acquisition of Kerecis, and the Atos Medical and TRACOE trademarks through the acquisition of Atos Medical.Management has assessed that the value of trademarks with indefinite useful life, which consist primarily of Kerecis, Atos Medical and TRACOE, can be maintained for an indefinite period, as these are well-established trademarks in their markets, having existed for many years. The industry is characterised as being very stable with consistent consumer demand and a predictable competitive environment, and is expected to be profitable for the foreseeable future. Control of the trademarks is legally established and enforceable indefinitely. In management\u2019s opinion, the risk of the useful life of these brands becoming finite is minimal because of their individual market positions and because current and planned marketing initiatives are expected to sustain their useful life.Customer lists/loyaltiesColoplast also acquired a substantial number of customer relationships on acquiring Kerecis and Atos Medical. Customer relationships include lists of and access to Kerecis\u2019 and Atos Medical\u2019s existing customers, both users, hospitals, distributors and private offices.Material acquired patents, trademarks and know-how etc.RemainingamortisationDKK million Assetperiod 2025 2024Kerecis Trademarks indefinite 1,357 1,425 Technologies and 1,391 1,559 Kereciscustomer relationships8-18 years Atos Medical and TRACOE Trademarks indefinite 3,206 3,138 Technologies and 2,769 2,921 Atos Medical and TRACOEcustomer relationships 6-16 years Nine Continents Technologies n/a 1,218 1,218 Carrying value at 30 September 9,941 10,261 2024/25 2023/24Amortisations on intangible assets break down as followsProduction costs 47 38 Distribution costs 407 386 Administrative expenses 29 20 Research and development costs 8 7 Special items 99 \u2013 Total 590 451",
"dimensions": {
"concept": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__71": {
"value": "Note 11Intangible assetsAccounting policiesIntangible assets with a finite life are measured at cost less accumulated amortisation and impairment losses. Subsequent milestone payments related to acquired patents, trademarks and know-how payable on achievement of a contingent event will be capitalised when the contingent event is achieved. Amortisation is made on a straight-line basis over the expected useful lives of the assets, which are: Software 3 \u2013 5 yearsAcquired patents, customer list, trademarks and know-how etc. 5 \u2013 20 yearsGoodwill and other intangible assets with indefinite lives are tested for impairment annually or whenever there is an indication of impairment, while the carrying amount of intangible assets with finite lives measured at cost or amortised cost are assessed if there is an indication of impairment. If a write-down is required, the carrying amount is written down to the recoverable amount. For the purpose of assessing impairment, assets are grouped in the smallest group of assets that generates identifiable cash inflows (cash-generating units). The cash-generating units are defined as the smallest identifiable group of assets that generates cash inflows and which are largely independent of cash flows from other assets or groups of assets.For other intangible assets, the amortisation period is determined on the basis of Management\u2019s best estimate of the expected economic lives of the assets. The expected economic lives are assessed at least annually, and the amortisation period is determined based on the latest assessment. For purposes of calculating amortisation, the residual value of the assets is zero, unless a third party has committed to purchasing the asset after its use or there is an active market for the asset. With the exception of goodwill and some specific trademarks, all intangible assets have a finite life.All in-house research and development costs are recognised in the income statement as incurred. Management believes that mandatory regulatory approvals of products, completing the development of new products involves a high degree of uncertainty, for which reason the technical feasibility criteria are not considered to have been met.Gains or losses on the disposal of intangible assets are stated as the difference between the selling price less costs to sell and the carrying amount at the date of disposal and are included in the income statement under other operating income or other operating expenses, respectively.Key accounting estimates and judgementsGoodwill and other intangible assets: The measurement of intangible assets, including goodwill and acquired patents, trademarks and know-how etc., could be materially affected by significant changes in estimates and assumptions underlying the calculation of recoverable amount. The carrying amount of these intangible assets was DKK 29,349 million as at 30 September 2025 (30 September 2024: DKK 29,736 million).AcquiredPrepay-patents,ments andtrademarksintangibleTotaland know-assets inintangibleDKK millionhow etc. Goodwill Softwareprogressassets2024/25Cost at 1 October 12,788 19,375 951 239 33,353 Exchange adjustment -68 -46 1 \u2013 -113 Transfers \u2013 \u2013 205 -205 \u2013 Additions during the year \u2013 \u2013 41 80 121 Disposals during the year \u2013 \u2013 -9 \u2013 -9 Cost at 30 September 12,720 19,329 1,189 114 33,352Amortisation at 1 October 2,427 \u2013 594 \u2013 3,021 Exchange adjustment -61 \u2013 -2 \u2013 -63 Amortisation for the year 334 \u2013 256 \u2013 590 Amortisation reversed on disposals during the year \u2013 \u2013 -7 \u2013 -7 Amortisation at 30 September 2,700 \u2013 841 \u2013 3,541 Carrying amount at 30 September 10,020 19,329 348 114 29,811 AcquiredPrepay-patents,ments andtrademarksintangibleTotaland know-assets inintangibleDKK millionhow etc. Goodwill Softwareprogressassets2023/24Cost at 1 October 12,911 19,974 783 225 33,893 Exchange adjustment -123 -133 2 \u2013 -254 Adjustment to acquisitions previous years \u2013 -466 \u2013 \u2013 -466 Transfers \u2013 \u2013 129 -129 \u2013 Additions during the year \u2013 \u2013 37 143 180 Cost at 30 September 12,788 19,375 951 239 33,353 Amortisation at 1 October 2,167 \u2013 471 \u2013 2,638 Exchange adjustment -70 \u2013 2 \u2013 -68 Amortisation for the year 330 \u2013 121 \u2013 451 Amortisation at 30 September 2,427 \u2013 594 \u2013 3,021 Carrying amount at 30 September 10,361 19,375 357 239 30,332 GoodwillGoodwill mainly relates to the acquisitions of Kerecis in 2023, Atos Medical in 2022, Lilial in 2018, Comfort Medical in 2016, Mpathy in 2010 and Mentor's urology and continence business in 2006. Goodwill from the acquired businesses has been allocated to the individual cash-generating units. The allocation was made to the operating segment Chronic Care (Ostomy Care and Continence Care), Interventional Urology, Voice & Respiratory Care and Biologics. Pursuant to IAS 36, a goodwill impairment test is performed when there is an indication of impairment, but at least once a year. In the impairment test, the carrying amount is compared with the recoverable amount (value in use) of each cash-generating units, calculated as the discounted expected future cash flows. No impairment related to goodwill was identified in 2024/25 or 2023/24.Future cash flows are determined using forecasts based on anticipated sales growth, earnings and strategy plans, etc. These forecasts are based on specific assumptions for each cash-generating unit during the forecast period with respect to sales, results of operations, working capital, capital investments and assumptions for cost of capital, inflation and the level of interest rates. Growth rates for Chronic Care, Biologics and Interventional Urology during the terminal period correspond to the expected long-term rate of inflation. Growth rate for Voice & Respiratory Care is slightly higher, due to the expectation of higher growth within the business area after the forecast period. For Chronic Care and Voice & Respiratory Care, the discount rate is based on the median WACC used by the external analysts\u2019 covering Coloplast. For Interventional Urology , the discount rate is based on the median WACC used by the external analysts\u2019 covering Coloplast added 3% to account for the higher assessed market risk premium related to the interventional urology area. For Biologics, the discount rate is based on the WACC used in the management approved business case.2024/25 2023/24Interventional Voice &Interventional Voice &Chronic CareUrologyRespiratory Care Biologics Chronic CareUrologyRespiratory Care BiologicsCarrying amount, DKK millionTrademarks\u00b9\u207e 50 \u2013 3,206 1,357 50 \u2013 3,138 1,425 Goodwill 1,686 337 11,981 5,324 1,706 352 11,727 5,590 Key parameters appliedRevenue growth in terminal period 2.0 % 2.0 % 2,5% 2.0 % 2.0 % 2.0 % 3.5 % 2.0 %Tax percentage 23.0 % 27.0 % 23.0 % 21,6% 23.0 % 27.0 % 23.0 % 21.2 %Discount rate, before tax 8.0 % 11.0 % 8.3 % 11,6% 8.6 % 13.3 % 8.1 % 11.6 %Discount rate, after tax 7.0 % 10.0 % 7.0 % 9.0 % 7.0 % 10.0 % 7.0 % 9.0 %\u00b9\u207e Carrying amount includes only those trademarks with indefinite useful lives.Special assumptions applied in impairment tests performed in Chronic Care (Ostomy Care and Continence Care)The Ostomy Care business involves the production and sale of ostomy pouches and accessories. The Continence Care business involves the production and sales of disposable catheters and various types of products designed for people suffering from urinary or faecal incontinence. The impairment test performed for Chronic Care was based on forecasts for the new strategy period for the financial years 2025/26 to 2029/30. Revenue growth rates of 7-9% were assumed for the budget period, which are supported by the organic growth rates in recent financial years. It was assumed that the gross margin will increase slightly until the terminal period.The Group\u2019s general tax rate was applied in the impairment test for Chronic Care because these products are sold in all of the Group\u2019s markets. Working capital invested has been projected using the same growth rate as that for revenue.Special assumptions applied in impairment tests performed in Interventional UrologyThe interventional urology business consists of the production and sale of products used in surgical procedures in urology and gynaecology, including prostate catheters, stents, vaginal slings used to restore continence, mesh products used to treat weak pelvic floor and penile implants for men experiencing severe impotence. The impairment test performed for Interventional Urology was based on forecasts for the new strategy period for the financial years 2025/26 to 2029/30. Revenue growth rates of 6-13% were assumed for the budget period, which are supported by the Interventional Urology organic growth rates in recent financial years. It was assumed that the gross margin will increase slightly until the terminal period. The tax rate applied in the impairment test for Interventional Urology was higher than the rate applied for the Group because sales and production mostly take place in the US, which imposes a corporate tax rate higher than the Group average. Working capital invested has been projected using the same growth rate as that for revenue. Special assumptions applied on Voice & Respiratory Care The voice & respiratory care business consists of production and sales of laryngectomy and tracheostomy products, used to treat removal of all or part of the larynex.The impairment test performed for Voice & Respiratory Care was based on forecasts for the new strategy period for the financial years 2025/26 to 2029/30. Revenue growth rates of 12-13% were assumed for the budget period, which are supported by the organic growth rates in recent financial years. It was assumed that the gross margin will increase slightly until the terminal period. The Group\u2019s general tax rate was applied in the impairment test for Voice & Respiratory Care because these products are sold in most of the Group\u2019s markets. Working capital invested has been projected using the same growth rate as that for revenue. Special assumptions applied on BiologicsThe biologics business consists of production and sales of fish-skin technology for wound care treatment.The impairment test performed for Biologics was based on forecasts for the new strategy period for the financial years 2025/26 to 2039/40. Revenue growth rates of 2-29% were assumed for the budget period, which are supported by the organic growth rates in recent financial years. On the other hand, it was assumed that the gross margin will decrease slightly until the terminal period. It was also assumed that the Group\u2019s focus on cost management and regular efficiency improvements will ensure that overhead costs will increase at a rate lower than revenue, which will produce an annual EBIT margin improvement.The Group\u2019s general tax rate was applied in the impairment test for Biologics. Working capital invested has been projected using the same growth rate as that for revenue.Acquired patents, trademarks and know-how etc.Acquired patents and trademarks are primarily associated with the acquisition of Kerecis in 2023, Atos Medical in 2022 and Nine Continents Medical in 2020. In connection with the acquisitions, intangible assets were identified, and the cost was allocated to net assets at fair value at the date of acquisition, calculated on the basis of factors such as expected sales and revenue trends. Each component is amortised over its estimated useful life using the straight line method. Patented and unpatented technologies are tested for impairment together with goodwill impairment test.Patented and unpatented technologiesOn acquiring Kerecis in August 2023, Coloplast acquired several patented technologies and unpatented technologies. Unpatented technologies include inventions not patentable or protectable, know-how, confidential information and copyrights on computer software and the like. Most relate to know-how regarding various technologies. Allocation of the individual components into small intangible assets is not considered material or relevant.On acquiring Atos Medical in January 2022, Coloplast acquired a number of patented and unpatented technologies. Unpatented technologies include inventions not patentable or protectable, know-how, confidential information and copyrights on computer software and the like. Most relate to know-how regarding various technologies. Allocation of the individual components into small intangible assets is not considered material or relevant.On acquiring Nine Continents Medical in November 2020, Coloplast acquired a number of patented and unpatented technologies. Unpatented technologies include inventions not patentable or protectable, know-how, confidential information and copyrights on computer software and the like. Most relate to know-how regarding various technologies. Allocation of the individual components into small intangible assets is not considered material or relevant.TrademarksIn addition to patented and unpatented technologies, Coloplast acquired the Kerecis trademark through the acquisition of Kerecis, and the Atos Medical and TRACOE trademarks through the acquisition of Atos Medical.Management has assessed that the value of trademarks with indefinite useful life, which consist primarily of Kerecis, Atos Medical and TRACOE, can be maintained for an indefinite period, as these are well-established trademarks in their markets, having existed for many years. The industry is characterised as being very stable with consistent consumer demand and a predictable competitive environment, and is expected to be profitable for the foreseeable future. Control of the trademarks is legally established and enforceable indefinitely. In management\u2019s opinion, the risk of the useful life of these brands becoming finite is minimal because of their individual market positions and because current and planned marketing initiatives are expected to sustain their useful life.Customer lists/loyaltiesColoplast also acquired a substantial number of customer relationships on acquiring Kerecis and Atos Medical. Customer relationships include lists of and access to Kerecis\u2019 and Atos Medical\u2019s existing customers, both users, hospitals, distributors and private offices.Material acquired patents, trademarks and know-how etc.RemainingamortisationDKK million Assetperiod 2025 2024Kerecis Trademarks indefinite 1,357 1,425 Technologies and 1,391 1,559 Kereciscustomer relationships8-18 years Atos Medical and TRACOE Trademarks indefinite 3,206 3,138 Technologies and 2,769 2,921 Atos Medical and TRACOEcustomer relationships 6-16 years Nine Continents Technologies n/a 1,218 1,218 Carrying value at 30 September 9,941 10,261 2024/25 2023/24Amortisations on intangible assets break down as followsProduction costs 47 38 Distribution costs 407 386 Administrative expenses 29 20 Research and development costs 8 7 Special items 99 \u2013 Total 590 451",
"dimensions": {
"concept": "ifrs-full:DisclosureOfGoodwillExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__70": {
"value": "Note 11Intangible assetsAccounting policiesIntangible assets with a finite life are measured at cost less accumulated amortisation and impairment losses. Subsequent milestone payments related to acquired patents, trademarks and know-how payable on achievement of a contingent event will be capitalised when the contingent event is achieved. Amortisation is made on a straight-line basis over the expected useful lives of the assets, which are: Software 3 \u2013 5 yearsAcquired patents, customer list, trademarks and know-how etc. 5 \u2013 20 yearsGoodwill and other intangible assets with indefinite lives are tested for impairment annually or whenever there is an indication of impairment, while the carrying amount of intangible assets with finite lives measured at cost or amortised cost are assessed if there is an indication of impairment. If a write-down is required, the carrying amount is written down to the recoverable amount. For the purpose of assessing impairment, assets are grouped in the smallest group of assets that generates identifiable cash inflows (cash-generating units). The cash-generating units are defined as the smallest identifiable group of assets that generates cash inflows and which are largely independent of cash flows from other assets or groups of assets.For other intangible assets, the amortisation period is determined on the basis of Management\u2019s best estimate of the expected economic lives of the assets. The expected economic lives are assessed at least annually, and the amortisation period is determined based on the latest assessment. For purposes of calculating amortisation, the residual value of the assets is zero, unless a third party has committed to purchasing the asset after its use or there is an active market for the asset. With the exception of goodwill and some specific trademarks, all intangible assets have a finite life.All in-house research and development costs are recognised in the income statement as incurred. Management believes that mandatory regulatory approvals of products, completing the development of new products involves a high degree of uncertainty, for which reason the technical feasibility criteria are not considered to have been met.Gains or losses on the disposal of intangible assets are stated as the difference between the selling price less costs to sell and the carrying amount at the date of disposal and are included in the income statement under other operating income or other operating expenses, respectively.Key accounting estimates and judgementsGoodwill and other intangible assets: The measurement of intangible assets, including goodwill and acquired patents, trademarks and know-how etc., could be materially affected by significant changes in estimates and assumptions underlying the calculation of recoverable amount. The carrying amount of these intangible assets was DKK 29,349 million as at 30 September 2025 (30 September 2024: DKK 29,736 million).AcquiredPrepay-patents,ments andtrademarksintangibleTotaland know-assets inintangibleDKK millionhow etc. Goodwill Softwareprogressassets2024/25Cost at 1 October 12,788 19,375 951 239 33,353 Exchange adjustment -68 -46 1 \u2013 -113 Transfers \u2013 \u2013 205 -205 \u2013 Additions during the year \u2013 \u2013 41 80 121 Disposals during the year \u2013 \u2013 -9 \u2013 -9 Cost at 30 September 12,720 19,329 1,189 114 33,352Amortisation at 1 October 2,427 \u2013 594 \u2013 3,021 Exchange adjustment -61 \u2013 -2 \u2013 -63 Amortisation for the year 334 \u2013 256 \u2013 590 Amortisation reversed on disposals during the year \u2013 \u2013 -7 \u2013 -7 Amortisation at 30 September 2,700 \u2013 841 \u2013 3,541 Carrying amount at 30 September 10,020 19,329 348 114 29,811 AcquiredPrepay-patents,ments andtrademarksintangibleTotaland know-assets inintangibleDKK millionhow etc. Goodwill Softwareprogressassets2023/24Cost at 1 October 12,911 19,974 783 225 33,893 Exchange adjustment -123 -133 2 \u2013 -254 Adjustment to acquisitions previous years \u2013 -466 \u2013 \u2013 -466 Transfers \u2013 \u2013 129 -129 \u2013 Additions during the year \u2013 \u2013 37 143 180 Cost at 30 September 12,788 19,375 951 239 33,353 Amortisation at 1 October 2,167 \u2013 471 \u2013 2,638 Exchange adjustment -70 \u2013 2 \u2013 -68 Amortisation for the year 330 \u2013 121 \u2013 451 Amortisation at 30 September 2,427 \u2013 594 \u2013 3,021 Carrying amount at 30 September 10,361 19,375 357 239 30,332 GoodwillGoodwill mainly relates to the acquisitions of Kerecis in 2023, Atos Medical in 2022, Lilial in 2018, Comfort Medical in 2016, Mpathy in 2010 and Mentor's urology and continence business in 2006. Goodwill from the acquired businesses has been allocated to the individual cash-generating units. The allocation was made to the operating segment Chronic Care (Ostomy Care and Continence Care), Interventional Urology, Voice & Respiratory Care and Biologics. Pursuant to IAS 36, a goodwill impairment test is performed when there is an indication of impairment, but at least once a year. In the impairment test, the carrying amount is compared with the recoverable amount (value in use) of each cash-generating units, calculated as the discounted expected future cash flows. No impairment related to goodwill was identified in 2024/25 or 2023/24.Future cash flows are determined using forecasts based on anticipated sales growth, earnings and strategy plans, etc. These forecasts are based on specific assumptions for each cash-generating unit during the forecast period with respect to sales, results of operations, working capital, capital investments and assumptions for cost of capital, inflation and the level of interest rates. Growth rates for Chronic Care, Biologics and Interventional Urology during the terminal period correspond to the expected long-term rate of inflation. Growth rate for Voice & Respiratory Care is slightly higher, due to the expectation of higher growth within the business area after the forecast period. For Chronic Care and Voice & Respiratory Care, the discount rate is based on the median WACC used by the external analysts\u2019 covering Coloplast. For Interventional Urology , the discount rate is based on the median WACC used by the external analysts\u2019 covering Coloplast added 3% to account for the higher assessed market risk premium related to the interventional urology area. For Biologics, the discount rate is based on the WACC used in the management approved business case.2024/25 2023/24Interventional Voice &Interventional Voice &Chronic CareUrologyRespiratory Care Biologics Chronic CareUrologyRespiratory Care BiologicsCarrying amount, DKK millionTrademarks\u00b9\u207e 50 \u2013 3,206 1,357 50 \u2013 3,138 1,425 Goodwill 1,686 337 11,981 5,324 1,706 352 11,727 5,590 Key parameters appliedRevenue growth in terminal period 2.0 % 2.0 % 2,5% 2.0 % 2.0 % 2.0 % 3.5 % 2.0 %Tax percentage 23.0 % 27.0 % 23.0 % 21,6% 23.0 % 27.0 % 23.0 % 21.2 %Discount rate, before tax 8.0 % 11.0 % 8.3 % 11,6% 8.6 % 13.3 % 8.1 % 11.6 %Discount rate, after tax 7.0 % 10.0 % 7.0 % 9.0 % 7.0 % 10.0 % 7.0 % 9.0 %\u00b9\u207e Carrying amount includes only those trademarks with indefinite useful lives.Special assumptions applied in impairment tests performed in Chronic Care (Ostomy Care and Continence Care)The Ostomy Care business involves the production and sale of ostomy pouches and accessories. The Continence Care business involves the production and sales of disposable catheters and various types of products designed for people suffering from urinary or faecal incontinence. The impairment test performed for Chronic Care was based on forecasts for the new strategy period for the financial years 2025/26 to 2029/30. Revenue growth rates of 7-9% were assumed for the budget period, which are supported by the organic growth rates in recent financial years. It was assumed that the gross margin will increase slightly until the terminal period.The Group\u2019s general tax rate was applied in the impairment test for Chronic Care because these products are sold in all of the Group\u2019s markets. Working capital invested has been projected using the same growth rate as that for revenue.Special assumptions applied in impairment tests performed in Interventional UrologyThe interventional urology business consists of the production and sale of products used in surgical procedures in urology and gynaecology, including prostate catheters, stents, vaginal slings used to restore continence, mesh products used to treat weak pelvic floor and penile implants for men experiencing severe impotence. The impairment test performed for Interventional Urology was based on forecasts for the new strategy period for the financial years 2025/26 to 2029/30. Revenue growth rates of 6-13% were assumed for the budget period, which are supported by the Interventional Urology organic growth rates in recent financial years. It was assumed that the gross margin will increase slightly until the terminal period. The tax rate applied in the impairment test for Interventional Urology was higher than the rate applied for the Group because sales and production mostly take place in the US, which imposes a corporate tax rate higher than the Group average. Working capital invested has been projected using the same growth rate as that for revenue. Special assumptions applied on Voice & Respiratory Care The voice & respiratory care business consists of production and sales of laryngectomy and tracheostomy products, used to treat removal of all or part of the larynex.The impairment test performed for Voice & Respiratory Care was based on forecasts for the new strategy period for the financial years 2025/26 to 2029/30. Revenue growth rates of 12-13% were assumed for the budget period, which are supported by the organic growth rates in recent financial years. It was assumed that the gross margin will increase slightly until the terminal period. The Group\u2019s general tax rate was applied in the impairment test for Voice & Respiratory Care because these products are sold in most of the Group\u2019s markets. Working capital invested has been projected using the same growth rate as that for revenue. Special assumptions applied on BiologicsThe biologics business consists of production and sales of fish-skin technology for wound care treatment.The impairment test performed for Biologics was based on forecasts for the new strategy period for the financial years 2025/26 to 2039/40. Revenue growth rates of 2-29% were assumed for the budget period, which are supported by the organic growth rates in recent financial years. On the other hand, it was assumed that the gross margin will decrease slightly until the terminal period. It was also assumed that the Group\u2019s focus on cost management and regular efficiency improvements will ensure that overhead costs will increase at a rate lower than revenue, which will produce an annual EBIT margin improvement.The Group\u2019s general tax rate was applied in the impairment test for Biologics. Working capital invested has been projected using the same growth rate as that for revenue.Acquired patents, trademarks and know-how etc.Acquired patents and trademarks are primarily associated with the acquisition of Kerecis in 2023, Atos Medical in 2022 and Nine Continents Medical in 2020. In connection with the acquisitions, intangible assets were identified, and the cost was allocated to net assets at fair value at the date of acquisition, calculated on the basis of factors such as expected sales and revenue trends. Each component is amortised over its estimated useful life using the straight line method. Patented and unpatented technologies are tested for impairment together with goodwill impairment test.Patented and unpatented technologiesOn acquiring Kerecis in August 2023, Coloplast acquired several patented technologies and unpatented technologies. Unpatented technologies include inventions not patentable or protectable, know-how, confidential information and copyrights on computer software and the like. Most relate to know-how regarding various technologies. Allocation of the individual components into small intangible assets is not considered material or relevant.On acquiring Atos Medical in January 2022, Coloplast acquired a number of patented and unpatented technologies. Unpatented technologies include inventions not patentable or protectable, know-how, confidential information and copyrights on computer software and the like. Most relate to know-how regarding various technologies. Allocation of the individual components into small intangible assets is not considered material or relevant.On acquiring Nine Continents Medical in November 2020, Coloplast acquired a number of patented and unpatented technologies. Unpatented technologies include inventions not patentable or protectable, know-how, confidential information and copyrights on computer software and the like. Most relate to know-how regarding various technologies. Allocation of the individual components into small intangible assets is not considered material or relevant.TrademarksIn addition to patented and unpatented technologies, Coloplast acquired the Kerecis trademark through the acquisition of Kerecis, and the Atos Medical and TRACOE trademarks through the acquisition of Atos Medical.Management has assessed that the value of trademarks with indefinite useful life, which consist primarily of Kerecis, Atos Medical and TRACOE, can be maintained for an indefinite period, as these are well-established trademarks in their markets, having existed for many years. The industry is characterised as being very stable with consistent consumer demand and a predictable competitive environment, and is expected to be profitable for the foreseeable future. Control of the trademarks is legally established and enforceable indefinitely. In management\u2019s opinion, the risk of the useful life of these brands becoming finite is minimal because of their individual market positions and because current and planned marketing initiatives are expected to sustain their useful life.Customer lists/loyaltiesColoplast also acquired a substantial number of customer relationships on acquiring Kerecis and Atos Medical. Customer relationships include lists of and access to Kerecis\u2019 and Atos Medical\u2019s existing customers, both users, hospitals, distributors and private offices.Material acquired patents, trademarks and know-how etc.RemainingamortisationDKK million Assetperiod 2025 2024Kerecis Trademarks indefinite 1,357 1,425 Technologies and 1,391 1,559 Kereciscustomer relationships8-18 years Atos Medical and TRACOE Trademarks indefinite 3,206 3,138 Technologies and 2,769 2,921 Atos Medical and TRACOEcustomer relationships 6-16 years Nine Continents Technologies n/a 1,218 1,218 Carrying value at 30 September 9,941 10,261 2024/25 2023/24Amortisations on intangible assets break down as followsProduction costs 47 38 Distribution costs 407 386 Administrative expenses 29 20 Research and development costs 8 7 Special items 99 \u2013 Total 590 451",
"dimensions": {
"concept": "ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__79": {
"value": "Accounting policiesIntangible assets with a finite life are measured at cost less accumulated amortisation and impairment losses. Subsequent milestone payments related to acquired patents, trademarks and know-how payable on achievement of a contingent event will be capitalised when the contingent event is achieved. Amortisation is made on a straight-line basis over the expected useful lives of the assets, which are: Software 3 \u2013 5 yearsAcquired patents, customer list, trademarks and know-how etc. 5 \u2013 20 yearsGoodwill and other intangible assets with indefinite lives are tested for impairment annually or whenever there is an indication of impairment, while the carrying amount of intangible assets with finite lives measured at cost or amortised cost are assessed if there is an indication of impairment. If a write-down is required, the carrying amount is written down to the recoverable amount. For the purpose of assessing impairment, assets are grouped in the smallest group of assets that generates identifiable cash inflows (cash-generating units). The cash-generating units are defined as the smallest identifiable group of assets that generates cash inflows and which are largely independent of cash flows from other assets or groups of assets.For other intangible assets, the amortisation period is determined on the basis of Management\u2019s best estimate of the expected economic lives of the assets. The expected economic lives are assessed at least annually, and the amortisation period is determined based on the latest assessment. For purposes of calculating amortisation, the residual value of the assets is zero, unless a third party has committed to purchasing the asset after its use or there is an active market for the asset. With the exception of goodwill and some specific trademarks, all intangible assets have a finite life.All in-house research and development costs are recognised in the income statement as incurred. Management believes that mandatory regulatory approvals of products, completing the development of new products involves a high degree of uncertainty, for which reason the technical feasibility criteria are not considered to have been met.Gains or losses on the disposal of intangible assets are stated as the difference between the selling price less costs to sell and the carrying amount at the date of disposal and are included in the income statement under other operating income or other operating expenses, respectively.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__78": {
"value": "Accounting policiesIntangible assets with a finite life are measured at cost less accumulated amortisation and impairment losses. Subsequent milestone payments related to acquired patents, trademarks and know-how payable on achievement of a contingent event will be capitalised when the contingent event is achieved. Amortisation is made on a straight-line basis over the expected useful lives of the assets, which are: Software 3 \u2013 5 yearsAcquired patents, customer list, trademarks and know-how etc. 5 \u2013 20 yearsGoodwill and other intangible assets with indefinite lives are tested for impairment annually or whenever there is an indication of impairment, while the carrying amount of intangible assets with finite lives measured at cost or amortised cost are assessed if there is an indication of impairment. If a write-down is required, the carrying amount is written down to the recoverable amount. For the purpose of assessing impairment, assets are grouped in the smallest group of assets that generates identifiable cash inflows (cash-generating units). The cash-generating units are defined as the smallest identifiable group of assets that generates cash inflows and which are largely independent of cash flows from other assets or groups of assets.For other intangible assets, the amortisation period is determined on the basis of Management\u2019s best estimate of the expected economic lives of the assets. The expected economic lives are assessed at least annually, and the amortisation period is determined based on the latest assessment. For purposes of calculating amortisation, the residual value of the assets is zero, unless a third party has committed to purchasing the asset after its use or there is an active market for the asset. With the exception of goodwill and some specific trademarks, all intangible assets have a finite life.All in-house research and development costs are recognised in the income statement as incurred. Management believes that mandatory regulatory approvals of products, completing the development of new products involves a high degree of uncertainty, for which reason the technical feasibility criteria are not considered to have been met.Gains or losses on the disposal of intangible assets are stated as the difference between the selling price less costs to sell and the carrying amount at the date of disposal and are included in the income statement under other operating income or other operating expenses, respectively.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__77-1": {
"value": "Accounting policiesIntangible assets with a finite life are measured at cost less accumulated amortisation and impairment losses. Subsequent milestone payments related to acquired patents, trademarks and know-how payable on achievement of a contingent event will be capitalised when the contingent event is achieved. Amortisation is made on a straight-line basis over the expected useful lives of the assets, which are: Software 3 \u2013 5 yearsAcquired patents, customer list, trademarks and know-how etc. 5 \u2013 20 yearsGoodwill and other intangible assets with indefinite lives are tested for impairment annually or whenever there is an indication of impairment, while the carrying amount of intangible assets with finite lives measured at cost or amortised cost are assessed if there is an indication of impairment. If a write-down is required, the carrying amount is written down to the recoverable amount. For the purpose of assessing impairment, assets are grouped in the smallest group of assets that generates identifiable cash inflows (cash-generating units). The cash-generating units are defined as the smallest identifiable group of assets that generates cash inflows and which are largely independent of cash flows from other assets or groups of assets.For other intangible assets, the amortisation period is determined on the basis of Management\u2019s best estimate of the expected economic lives of the assets. The expected economic lives are assessed at least annually, and the amortisation period is determined based on the latest assessment. For purposes of calculating amortisation, the residual value of the assets is zero, unless a third party has committed to purchasing the asset after its use or there is an active market for the asset. With the exception of goodwill and some specific trademarks, all intangible assets have a finite life.All in-house research and development costs are recognised in the income statement as incurred. Management believes that mandatory regulatory approvals of products, completing the development of new products involves a high degree of uncertainty, for which reason the technical feasibility criteria are not considered to have been met.Gains or losses on the disposal of intangible assets are stated as the difference between the selling price less costs to sell and the carrying amount at the date of disposal and are included in the income statement under other operating income or other operating expenses, respectively.2024/25 2023/24Amortisations on intangible assets break down as followsProduction costs 47 38 Distribution costs 407 386 Administrative expenses 29 20 Research and development costs 8 7 Special items 99 \u2013 Total 590 451Accounting policiesProperty, plant and equipment is measured at cost less accumulated depreciation and impairment losses. Cost comprises the cost of acquisition and expenses directly attributable to an acquisition until the asset is ready for use. In case of assets manufactured by the company, cost comprises materials, components, sub-supplier services, direct labour and costs directly attributable to the manufactured asset. In addition, borrowing costs are recognised as part of cost. Depreciation is provided on a straight-line basis over the expected useful lives of the assets. The expected useful lives are:Land Not depreciatedBuildings 15 - 25 yearsBuilding installations 5 - 10 yearsPlant and machinery 5 - 15 yearsOther fixtures and fittings, tools and equipment 3 - 7 yearsDKK million 2024/25 2023/24Depreciations on property, plant and equipment break down as followsProduction costs 462 431 Distribution costs 51 45 Administrative expenses 26 38 Research and development costs 36 38 Total 575 552DKK million2024/25 2023/24Depreciations on right-of-use assets break down as followsProduction costs 36 37 Distribution costs 224 209 Administrative expenses 26 39 Research and development costs 2 2 Total 288 287 Other lease expenses recorded in the Statement of comprehensive incomeLease payments related to short-term leases 18 22 Lease payments related to low-value assets 24 28 Variable lease payments 31 13 Total 73 63 Total cash outflow for leasesPayments related to right-of-use assets 324 289 Payments related to other lease contracts 64 61 Total 388 350 DKK million 2025 2024Maturity analysis of lease liabilities (undiscounted)In less than one year 287 266 Current lease liability (undiscounted) 287 266 Within 1 to 5 years 547 579 After more than 5 years 243 252 Non-current lease liability (undiscounted) 790 831 Total lease liability (undiscounted) 1,077 1,097",
"dimensions": {
"concept": "ifrs-full:DisclosureOfDepreciationAndAmortisationExpenseExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__76": {
"value": "Accounting policiesIntangible assets with a finite life are measured at cost less accumulated amortisation and impairment losses. Subsequent milestone payments related to acquired patents, trademarks and know-how payable on achievement of a contingent event will be capitalised when the contingent event is achieved. Amortisation is made on a straight-line basis over the expected useful lives of the assets, which are: Software 3 \u2013 5 yearsAcquired patents, customer list, trademarks and know-how etc. 5 \u2013 20 yearsGoodwill and other intangible assets with indefinite lives are tested for impairment annually or whenever there is an indication of impairment, while the carrying amount of intangible assets with finite lives measured at cost or amortised cost are assessed if there is an indication of impairment. If a write-down is required, the carrying amount is written down to the recoverable amount. For the purpose of assessing impairment, assets are grouped in the smallest group of assets that generates identifiable cash inflows (cash-generating units). The cash-generating units are defined as the smallest identifiable group of assets that generates cash inflows and which are largely independent of cash flows from other assets or groups of assets.For other intangible assets, the amortisation period is determined on the basis of Management\u2019s best estimate of the expected economic lives of the assets. The expected economic lives are assessed at least annually, and the amortisation period is determined based on the latest assessment. For purposes of calculating amortisation, the residual value of the assets is zero, unless a third party has committed to purchasing the asset after its use or there is an active market for the asset. With the exception of goodwill and some specific trademarks, all intangible assets have a finite life.All in-house research and development costs are recognised in the income statement as incurred. Management believes that mandatory regulatory approvals of products, completing the development of new products involves a high degree of uncertainty, for which reason the technical feasibility criteria are not considered to have been met.Gains or losses on the disposal of intangible assets are stated as the difference between the selling price less costs to sell and the carrying amount at the date of disposal and are included in the income statement under other operating income or other operating expenses, respectively.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__75": {
"value": "Accounting policiesIntangible assets with a finite life are measured at cost less accumulated amortisation and impairment losses. Subsequent milestone payments related to acquired patents, trademarks and know-how payable on achievement of a contingent event will be capitalised when the contingent event is achieved. Amortisation is made on a straight-line basis over the expected useful lives of the assets, which are: Software 3 \u2013 5 yearsAcquired patents, customer list, trademarks and know-how etc. 5 \u2013 20 yearsGoodwill and other intangible assets with indefinite lives are tested for impairment annually or whenever there is an indication of impairment, while the carrying amount of intangible assets with finite lives measured at cost or amortised cost are assessed if there is an indication of impairment. If a write-down is required, the carrying amount is written down to the recoverable amount. For the purpose of assessing impairment, assets are grouped in the smallest group of assets that generates identifiable cash inflows (cash-generating units). The cash-generating units are defined as the smallest identifiable group of assets that generates cash inflows and which are largely independent of cash flows from other assets or groups of assets.For other intangible assets, the amortisation period is determined on the basis of Management\u2019s best estimate of the expected economic lives of the assets. The expected economic lives are assessed at least annually, and the amortisation period is determined based on the latest assessment. For purposes of calculating amortisation, the residual value of the assets is zero, unless a third party has committed to purchasing the asset after its use or there is an active market for the asset. With the exception of goodwill and some specific trademarks, all intangible assets have a finite life.All in-house research and development costs are recognised in the income statement as incurred. Management believes that mandatory regulatory approvals of products, completing the development of new products involves a high degree of uncertainty, for which reason the technical feasibility criteria are not considered to have been met.Gains or losses on the disposal of intangible assets are stated as the difference between the selling price less costs to sell and the carrying amount at the date of disposal and are included in the income statement under other operating income or other operating expenses, respectively.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForGoodwillExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__74": {
"value": "Accounting policiesIntangible assets with a finite life are measured at cost less accumulated amortisation and impairment losses. Subsequent milestone payments related to acquired patents, trademarks and know-how payable on achievement of a contingent event will be capitalised when the contingent event is achieved. Amortisation is made on a straight-line basis over the expected useful lives of the assets, which are: Software 3 \u2013 5 yearsAcquired patents, customer list, trademarks and know-how etc. 5 \u2013 20 yearsGoodwill and other intangible assets with indefinite lives are tested for impairment annually or whenever there is an indication of impairment, while the carrying amount of intangible assets with finite lives measured at cost or amortised cost are assessed if there is an indication of impairment. If a write-down is required, the carrying amount is written down to the recoverable amount. For the purpose of assessing impairment, assets are grouped in the smallest group of assets that generates identifiable cash inflows (cash-generating units). The cash-generating units are defined as the smallest identifiable group of assets that generates cash inflows and which are largely independent of cash flows from other assets or groups of assets.For other intangible assets, the amortisation period is determined on the basis of Management\u2019s best estimate of the expected economic lives of the assets. The expected economic lives are assessed at least annually, and the amortisation period is determined based on the latest assessment. For purposes of calculating amortisation, the residual value of the assets is zero, unless a third party has committed to purchasing the asset after its use or there is an active market for the asset. With the exception of goodwill and some specific trademarks, all intangible assets have a finite life.All in-house research and development costs are recognised in the income statement as incurred. Management believes that mandatory regulatory approvals of products, completing the development of new products involves a high degree of uncertainty, for which reason the technical feasibility criteria are not considered to have been met.Gains or losses on the disposal of intangible assets are stated as the difference between the selling price less costs to sell and the carrying amount at the date of disposal and are included in the income statement under other operating income or other operating expenses, respectively.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__86": {
"value": "Note 12Property, plant and equipmentAccounting policiesProperty, plant and equipment is measured at cost less accumulated depreciation and impairment losses. Cost comprises the cost of acquisition and expenses directly attributable to an acquisition until the asset is ready for use. In case of assets manufactured by the company, cost comprises materials, components, sub-supplier services, direct labour and costs directly attributable to the manufactured asset. In addition, borrowing costs are recognised as part of cost. Depreciation is provided on a straight-line basis over the expected useful lives of the assets. The expected useful lives are:Land Not depreciatedBuildings 15 - 25 yearsBuilding installations 5 - 10 yearsPlant and machinery 5 - 15 yearsOther fixtures and fittings, tools and equipment 3 - 7 yearsDKK million 2024/25 2023/24Depreciations on property, plant and equipment break down as followsProduction costs 462 431 Distribution costs 51 45 Administrative expenses 26 38 Research and development costs 36 38 Total 575 552Other fixtures and Prepayments Total fittings, and assets property, Land and Plant and tools and under plant and DKK millionbuildingsmachineryequipmentconstructionequipment2024/25Cost at 1 October 3,630 5,843 1,579 1,297 12,349 Exchange and other adjustments -35 -21 -27 -11 -94 Transfers 211 453 186 -850 \u2013 Additions during the year 20 18 53 1,215 1,306 Disposals during the year -81 -123 -92 \u2013 -296 Cost at 30 September 3,745 6,170 1,699 1,651 13,265 Depreciation at 1 October 1,818 3,770 1,112 \u2013 6,700 Exchange and other adjustments -12 -1 -1 \u2013 -14 Depreciations for the year 150 255 170 \u2013 575 Depreciations reversed on disposals during the year -53 -66 -78 \u2013 -197 Depreciation at 30 September 1,903 3,958 1,203 \u2013 7,064 Carrying amount at 30 September 1,842 2,212 496 1,651 6,201 Coloplast has incurred cost of DKK 450 million in connection with the construction of the new factory in Portugal. The amount includes capitalised borrow costs related to the construction of the factory of DKK 8 million, and the applied interest was the blended rate of 2.62%. Other fixtures and Prepayments Total fittings, and assets property, Land and Plant and tools and under plant and DKK millionbuildingsmachineryequipmentconstructionequipment2023/24Cost at 1 October 3,477 5,418 1,357 1,241 11,493 Exchange and other adjustments -55 -45 1 -9 -108 Transfers 246 585 176 -1,007 \u2013 Additions during the year 7 20 67 1,072 1,166 Disposals during the year -45 -135 -22 \u2013 -202 Cost at 30 September 3,630 5,843 1,579 1,297 12,349 Depreciation at 1 October 1,727 3,649 986 \u2013 6,362 Exchange and other adjustments -22 -22 -7 \u2013 -51 Depreciations for the year 148 254 150 \u2013 552 Depreciations reversed on disposals during the year -35 -111 -17 \u2013 -163 Depreciation at 30 September 1,818 3,770 1,112 \u2013 6,700 Carrying amount at 30 September 1,812 2,073 467 1,297 5,649 The Group has signed agreements with contractors for the supply of buildings, technical plant and machinery for DKK 561 million at 30 September 2025 (DKK 576 million at 30 September 2024). The Group has no security upon properties at 30 September 2025 (DKK 0 million at 30 September 2024).",
"dimensions": {
"concept": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__90": {
"value": "Accounting policiesProperty, plant and equipment is measured at cost less accumulated depreciation and impairment losses. Cost comprises the cost of acquisition and expenses directly attributable to an acquisition until the asset is ready for use. In case of assets manufactured by the company, cost comprises materials, components, sub-supplier services, direct labour and costs directly attributable to the manufactured asset. In addition, borrowing costs are recognised as part of cost. Depreciation is provided on a straight-line basis over the expected useful lives of the assets. The expected useful lives are:Land Not depreciatedBuildings 15 - 25 yearsBuilding installations 5 - 10 yearsPlant and machinery 5 - 15 yearsOther fixtures and fittings, tools and equipment 3 - 7 years",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__89": {
"value": "Accounting policiesProperty, plant and equipment is measured at cost less accumulated depreciation and impairment losses. Cost comprises the cost of acquisition and expenses directly attributable to an acquisition until the asset is ready for use. In case of assets manufactured by the company, cost comprises materials, components, sub-supplier services, direct labour and costs directly attributable to the manufactured asset. In addition, borrowing costs are recognised as part of cost. Depreciation is provided on a straight-line basis over the expected useful lives of the assets. The expected useful lives are:Land Not depreciatedBuildings 15 - 25 yearsBuilding installations 5 - 10 yearsPlant and machinery 5 - 15 yearsOther fixtures and fittings, tools and equipment 3 - 7 years",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForBorrowingCostsExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__88": {
"value": "Accounting policiesProperty, plant and equipment is measured at cost less accumulated depreciation and impairment losses. Cost comprises the cost of acquisition and expenses directly attributable to an acquisition until the asset is ready for use. In case of assets manufactured by the company, cost comprises materials, components, sub-supplier services, direct labour and costs directly attributable to the manufactured asset. In addition, borrowing costs are recognised as part of cost. Depreciation is provided on a straight-line basis over the expected useful lives of the assets. The expected useful lives are:Land Not depreciatedBuildings 15 - 25 yearsBuilding installations 5 - 10 yearsPlant and machinery 5 - 15 yearsOther fixtures and fittings, tools and equipment 3 - 7 years",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForDepreciationExpenseExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__96": {
"value": "Note 13Right-of-use assetsAccounting policiesAt the commencement date, when a leased asset is made available for use, a right-of-use asset and a corresponding lease liability is recognised on the balance sheet.Right-of-use assets are initially measured at cost, which comprises the initial amount of the lease liability, any lease payments made prior to the commencement date and any initial direct costs. Subsequently, the right-of-use asset is measured at cost less depreciation and impairment losses and adjusted for the remeasurement of the lease liability. The right-of-use assets are depreciated on a straight-line basis over the shorter of the lease term or the useful life of the right-of-use asset.Options to extend the initial leasing period are only included in the initial measurement if it is reasonably certain that the option will be utilised.Lease liabilities are initially measured at the present value of future lease payments. The lease payments are discounted using the implicit rate of the lease contract or, if not readily determinable, the incremental borrowing rate of Coloplast for loans with similar term and security. As a practical expedient, the discount rates are determined on basis of a portfolio of leases with similar characteristics, e.g. a portfolio of leased cars in a specific country. The lease liabilities are subsequently reduced by the portion of lease payments which is regarded as repayment of those lease liabilities. Lease liabilities are remeasured in the event of a lease modification or a reassessment of the lease term which in turn may also impact the carrying value of the right-of-use assets. The lease term is reassessed when a significant event or change, which is within the control of Coloplast, affects the prior assessment.Short-term leases and leases of low-value assets are exempted from the above accounting model. Consequently, lease payments associated with such lease contracts are recognised as an operating expense on either a straight-line basis over the lease term or another systematic basis which is more representative of the pattern of the benefit of the leased assets.The extent of residual value guarantees for right-of-use assets is limited and expected payments are included in the initial amount of the lease liability.The majority of the Group's right-of-use assets comprise office space, warehouses, cars and IT equipment. Leasing arrangements are preferred for certain types of assets as it stabilises cash flows and reduces capital invested in non-current assets. In certain situations, the leasing contracts include a right for Coloplast to extend the leasing period but this is only reflected in the cost of the right-of-use assets, and the corresponding lease liability, if it is reasonably certain that the option will be utilised.Variable lease payments, which are not included in the measurement of the lease liability, are expensed directly in profit or loss. These payments are mainly related to consumption-based charges, e.g. extra mileage in leased cars. The Group enters into new lease contracts continually, e.g. to replace an old right-of-use asset which is returned to lessor. The new contracts are usually entered prior to commencing the leasing period when a right-of-use assets is available for use. Consequently, the Group may have committed to lease contracts, which are insignificant from an individual perspective, at the balance sheet date which are not yet recognised on the balance sheet date.Right-of-use assetsOther fixtures and Land andfittings, tools and Total DKK millionbuildingsequipmentright-of-use assets2024/25Carrying amount at 1 October 696 226 922 Exchange and other adjustments -16 -6 -22 Additions during the year 150 165 315 Disposals during the year -112 -142 -254 Depreciations for the year -155 -133 -288 Depreciations reversed on disposals during the year 90 121 211 Carrying amount at 30 September 653 231 884 Other fixtures and Land andfittings, tools and Total DKK millionbuildingsequipmentright-of-use assets2023/24Carrying amount at 1 October 666 182 848 Exchange and other adjustments -1 -1 -2 Additions during the year 228 190 418 Disposals during the year -106 -134 -240 Depreciations for the year -161 -126 -287 Depreciations reversed on disposals during the year 70 115 185 Carrying amount at 30 September 696 226 922 DKK million2024/25 2023/24Depreciations on right-of-use assets break down as followsProduction costs 36 37 Distribution costs 224 209 Administrative expenses 26 39 Research and development costs 2 2 Total 288 287 Other lease expenses recorded in the Statement of comprehensive incomeLease payments related to short-term leases 18 22 Lease payments related to low-value assets 24 28 Variable lease payments 31 13 Total 73 63 Total cash outflow for leasesPayments related to right-of-use assets 324 289 Payments related to other lease contracts 64 61 Total 388 350 DKK million 2025 2024Maturity analysis of lease liabilities (undiscounted)In less than one year 287 266 Current lease liability (undiscounted) 287 266 Within 1 to 5 years 547 579 After more than 5 years 243 252 Non-current lease liability (undiscounted) 790 831 Total lease liability (undiscounted) 1,077 1,097",
"dimensions": {
"concept": "ifrs-full:DisclosureOfLeasesExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__97": {
"value": "Accounting policiesAt the commencement date, when a leased asset is made available for use, a right-of-use asset and a corresponding lease liability is recognised on the balance sheet.Right-of-use assets are initially measured at cost, which comprises the initial amount of the lease liability, any lease payments made prior to the commencement date and any initial direct costs. Subsequently, the right-of-use asset is measured at cost less depreciation and impairment losses and adjusted for the remeasurement of the lease liability. The right-of-use assets are depreciated on a straight-line basis over the shorter of the lease term or the useful life of the right-of-use asset.Options to extend the initial leasing period are only included in the initial measurement if it is reasonably certain that the option will be utilised.Lease liabilities are initially measured at the present value of future lease payments. The lease payments are discounted using the implicit rate of the lease contract or, if not readily determinable, the incremental borrowing rate of Coloplast for loans with similar term and security. As a practical expedient, the discount rates are determined on basis of a portfolio of leases with similar characteristics, e.g. a portfolio of leased cars in a specific country. The lease liabilities are subsequently reduced by the portion of lease payments which is regarded as repayment of those lease liabilities. Lease liabilities are remeasured in the event of a lease modification or a reassessment of the lease term which in turn may also impact the carrying value of the right-of-use assets. The lease term is reassessed when a significant event or change, which is within the control of Coloplast, affects the prior assessment.Short-term leases and leases of low-value assets are exempted from the above accounting model. Consequently, lease payments associated with such lease contracts are recognised as an operating expense on either a straight-line basis over the lease term or another systematic basis which is more representative of the pattern of the benefit of the leased assets.The extent of residual value guarantees for right-of-use assets is limited and expected payments are included in the initial amount of the lease liability.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__98-1": {
"value": "DKK million2024/25 2023/24Depreciations on right-of-use assets break down as followsProduction costs 36 37 Distribution costs 224 209 Administrative expenses 26 39 Research and development costs 2 2 Total 288 287 Other lease expenses recorded in the Statement of comprehensive incomeLease payments related to short-term leases 18 22 Lease payments related to low-value assets 24 28 Variable lease payments 31 13 Total 73 63 Total cash outflow for leasesPayments related to right-of-use assets 324 289 Payments related to other lease contracts 64 61 Total 388 350 DKK million 2025 2024Maturity analysis of lease liabilities (undiscounted)In less than one year 287 266 Current lease liability (undiscounted) 287 266 Within 1 to 5 years 547 579 After more than 5 years 243 252 Non-current lease liability (undiscounted) 790 831 Total lease liability (undiscounted) 1,077 1,097Note 19Credit institutionsAccounting policiesBorrowings from credit institutions are recognised at fair value less expenses incurred and subsequently at amortised cost.Certain borrowings are subject to specific leverage covenants which are complied with.DKK million 2025 2024 MaturityTerm loan 7,783 5,000 Matures in 2027Other borrowings from credit institutions 2,328 5,085 Less than one yearBorrowings from credit institutions at 30 September 10,111 10,085 Bonds 11,570 11,557 Matures in 2027 and 2030See note 13 'Right-of-use Lease liability 958 987 assets'Bank balances -947 -788 Available for withdrawalNet interest-bearing debt at 30 September 21,692 21,841 Other borrowings from credit institutionsOther borrowings from credit institutions mainly comprise drawdowns on revolving credit facilities which are committed for three years on the balance sheet date in addition to minor bank overdrafts on authorised short-term facilities. BondsColoplast raised in 2021/22 EUR 2.2 billion in debt financing through the issuance of senior unsecured notes in an aggregate principal amount of EUR 2.2 billion under the Coloplast Euro Medium Term Note programme. The notes are unconditionally and irrevocably guaranteed by Coloplast. COLOCB1 EUR 650 million expired in 2023/24. COLOCB2 EUR 850 million carries a fixed coupon until maturity in 2027, and COLOCB3 EUR 700 million a fixed coupon until maturity in 2030. COLOCB2 and COLOCB3 can be redeemed at a market price fixed on the redemption date in relation to named EUR bonds with similar maturity. A pre-hedge was made with Interest swaps on the two fixed rate bonds COLOCB2 and COLOCB3. The swaps were closed down upon issue of the bonds. The objective was to lock in interest rates to the level prevailing when entering into the swaps. The gain of DKK 521 million has been recognised in the cash flow hedge reserve and transferred to financial items as an offset to the fixed interest coupons during the lifetime of the bonds.Nom. amount, Less than one Within 1 to 5 More than 5 Short name Currencymillionyear, millionyears, millionyears, million Coupon, %COLOCB2 EUR 850 19 869 \u2013 2.25COLOCB3 EUR 700 19 777 \u2013 2.75",
"dimensions": {
"concept": "ifrs-full:DisclosureOfBorrowingsExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__105": {
"value": "Note 14InventoriesAccounting policiesInventories are measured at the lower of cost and net realisable value. Cost is determined using the FIFO principle. The cost of finished goods and work in progress comprises raw materials, direct labour, other direct costs and indirect production overheads. Production overheads comprise indirect material and labour costs, maintenance and depreciation of the machinery and production buildings used in the manufacturing process as well as costs of production administration and management. Net realisable value is the expected selling price less cost of completion and costs to sell.Key accounting estimates and judgementsCapitalised production overheads have been calculated using a standard cost method, which is reviewed regularly to ensure the relevant assumptions concerning capacity utilisation, lead times and other relevant factors in the calculation of actual costs of sales. Changes to the calculation method for production overheads, including levels of capacity utilisation, lead times, etc. could affect the gross margin and the overall valuation of inventories.DKK million 2025 2024Raw materials and consumables 833 808 Work in progress 886 797 Manufactured goods 2,200 2,067 Inventories at 30 September 3,919 3,672 DKK million 2024/25 2023/24Write-downs at 1 October 54 55 Write-downs realised during the year -22 -20 Write-downs reversed during the year -16 -18 Additional write-downs made during the year 41 37 Write-downs at 30 September 57 54 Production overheads was included in the carrying amount of inventories with DKK 1,116 million at 30 September 2025 (DKK 911 million at 30 September 2024).Production costs include directly attributable production costs of DKK 5,576 million related to goods sold (2023/24: DKK 5,634 million).",
"dimensions": {
"concept": "ifrs-full:DisclosureOfInventoriesExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__106": {
"value": "Accounting policiesInventories are measured at the lower of cost and net realisable value. Cost is determined using the FIFO principle. The cost of finished goods and work in progress comprises raw materials, direct labour, other direct costs and indirect production overheads. Production overheads comprise indirect material and labour costs, maintenance and depreciation of the machinery and production buildings used in the manufacturing process as well as costs of production administration and management. Net realisable value is the expected selling price less cost of completion and costs to sell.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__109-1": {
"value": "Note 15Trade receivables and other receivablesAccounting policiesReceivables consist mainly of trade receivables. On initial recognition, receivables are measured at fair value and subsequently at amortised cost. Receivables are written down on the basis of an individual assessment and the simplified approach in accordance with IFRS 9 where loss allowances are based on lifetime expected credit losses.DKK million 2025 2024Ageing of trade receivablesNot due 3,371 3,552 Due up to 30 days 435 474 Due between 30 and 90 days 437 246 Due more than 90 days 602 566 Trade receivables at 30 September, gross 4,845 4,838 Loss allowance at 30 September -187 -163 Trade receivables at 30 September, net 4,658 4,675 Loss allowance at 1 October -163 -110 Exchange adjustment 6 5 Adjustment to acquisitions previous years \u2013 -31 Allowances used during the year (realised losses) 17 22 Additional allowances recognised during the year -47 -49 Loss allowance at 30 September -187 -163 Given the profile of our customers, including large wholesalers and government-backed agencies, the risk of loss allowance is assessed to be limited, consequently the loss allowance in percent of due amounts is low.Other receivables, non-currentThe portion of other receivables, which are falling due after more than one year after the balance sheet date, is recognised in the balance sheet as non-current assets and amounts to DKK 25 million (DKK 28 million at 30 September 2024).Note 21Financial risksRisk management policyFinancial risks are managed centrally and, accordingly, all derivative instruments are managed and controlled by the parent company. The framework is determined by the financial policy approved annually by the Board of Directors. The financial policy comprises policies for foreign exchange, funding, liquidity and financial counterparts. The core principle is for financial risk to be managed with a view to reducing significant risk.Foreign exchange riskA number of the Group\u2019s financial instruments is exposed foreign exchange risks as a natural consequence of its global activities. The Board of Directors determines the level of risk as a percentage of EBITDA. Foreign exchange risk is calculated by applying the principles of a cash-flow-at-risk model. The foreign exchange risk related to financial instruments is concentrated in receivables, payables and cash positions denominated in foreign currencies. In addition to this, the fair value of the Group\u2019s hedging instruments is significantly exposed to changes in foreign exchange rates. On the other hand, there is only a low foreign exchange risk attached to the Group\u2019s issue of bond as these are denominated in EUR.While EUR is a key currency for the Group, the foreign exchange risk is regarded as low due to fixed exchange rate policy of the central bank of Denmark.As at 30 September 2025, an average of 57% of the following twelve months of expected net cash flows in foreign currency were hedged (30 September 2024: 61% of the following twelve months of cash flows).The table below shows how a theoretical change of +/- 2% in all currencies against Danish kroner will impact the financial instruments recognised at the balance sheet date. The impact on profit or loss comes mainly from receivables denominated in foreign currencies. The impact on other comprehensive income relates to the fair value of hedging instruments. The hedged exposure is included in the sensitivity analysis and, therefore, the effect is reduced. 2024/25 2023/24DKK million USD GBP HUF EUR Other USD GBP HUF EUR OtherImpact from a 2% increase in currenciesProfit or loss 35 3 9 -209 21 18 -6 11 -243 35 Other comprehensive income -35 -31 15 -15 -21 -32 -32 8 -9 -22 Total comprehensive income \u2013 -28 24 -224 \u2013 -14 -38 19 -252 13 Impact from a 2% decrease in currenciesProfit or loss -35 -3 -9 209 -21 -18 6 -11 243 -35 Other comprehensive income 35 31 -15 15 21 32 32 -8 9 22 Total comprehensive income \u2013 28 -24 224 \u2013 14 38 -19 252 -13 The increase and decrease resulting from a 2% change are the same as all hedging instruments are forward contracts.Interest rate risk55% of the Group's net interest-bearing debt is carrying fixed interest rate for 2-5 years, and 45% is at floating interest rate. The duration as per balance sheet date was 1.6 years. An interest rate increase of 1% on the floating part of the outstanding debt as per 30 September 2025 would impact the Interest charges with an increase of DKK 101 million.Liquidity riskThe exposure to liquidity risks is considered to be low. In addition to cash available for withdrawal and marketable securities, the Group\u2019s cash reserves comprise a mix of committed and uncommitted credit facilities to ensure an adequate level of funding for the Group\u2019s activities, even in periods of operational uncertainty.DKK million 2025 2024Cash and cash equivalents 947 788 Liquid assets recorded on the balance sheet at 30 September 947 788 Committed credit facilities, unutilised (more than 1 year) 3,190 1,301 Uncommitted credit facilities, unutilised (short-term) 2,856 3,337 Financial reserves at 30 September 6,993 5,426 The Board of Directors generally intends to distribute excess cash to the shareholders by way of dividends and share buybacks. It is expected that dividends will be paid twice a year: after the Annual General Meeting and after the release of the half-year interim report. However, share buybacks and distribution of dividend will always be made with due consideration for the Group\u2019s liquidity requirements and plans.The capital management objective of the Group is to raise new debt only for acquisition purposes or for other special purposes. The Group assesses the capital on the basis of the solvency ratio, which is calculated in accordance with the guidelines issued by the Danish Society of Financial Analysts.Credit riskThe Group\u2019s credit risk relates to the possibility that the counterparties of its financial assets are not able to meet their obligations as they fall due. The carrying amount of the financial assets represents the maximum credit risk exposure. The Group\u2019s policy for managing credit risks involves an ongoing credit assessment of major customers and other key business partners.The credit risk exposure relates to (i) receivables, (ii) bank deposits as well as (iii) derivative financial instruments (forward exchange contracts) with a positive fair value at the balance sheet date. The credit risk related to trade receivables and other receivables is diversified over a large number of customers and other counterparties. For this reason, the credit risk is regarded as insignificant. See Note 15 to the financial statement.The credit risk related to bank deposits is, pursuant to the Group\u2019s counterparty policy, managed and mitigated by making money market deposits only with selected financial institutions holding a satisfactory credit rating. In addition, the maximum deposit limits have been defined for each financial counterparty. The credit risk related to marketable securities is considered to be limited as investment is only made in selected liquid bonds with a high credit rating.The credit risk related to derivative financial instruments is aligned with the credit risk for bank deposits as derivative contracts are only entered with selected financial institutions with a satisfactory credit rating.Pursuant to the Group\u2019s foreign exchange policy, forward exchange contracts are used for the purpose of neutralising and delaying the effect of exchange rate fluctuations in profit or loss and thereby enhance the predictability of the financial results. The foreign exchange risk is calculated by applying the principles of a cash-flow-at-risk model, with the Board of Directors determining the level of risk as a percentage of operating profit (EBITDA). The risk is managed and mitigated through cash flow hedges and, in some cases, through fair value hedges. Sources of hedging ineffectiveness comprise mainly those that arise from assumptions on expected 12-month rolling cash flows not being realised.The Group hedges key currencies e.g. USD, GBP, JPY and HUF, and selectively hedges emerging markets currencies taking the cost of hedging into consideration.The Group does not hedge forecasted cash flows denominated in EUR as the foreign exchange risk is regarded as low due to the fixed exchange rate policy of the central bank of Denmark.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__108": {
"value": "Note 15Trade receivables and other receivablesAccounting policiesReceivables consist mainly of trade receivables. On initial recognition, receivables are measured at fair value and subsequently at amortised cost. Receivables are written down on the basis of an individual assessment and the simplified approach in accordance with IFRS 9 where loss allowances are based on lifetime expected credit losses.DKK million 2025 2024Ageing of trade receivablesNot due 3,371 3,552 Due up to 30 days 435 474 Due between 30 and 90 days 437 246 Due more than 90 days 602 566 Trade receivables at 30 September, gross 4,845 4,838 Loss allowance at 30 September -187 -163 Trade receivables at 30 September, net 4,658 4,675 Loss allowance at 1 October -163 -110 Exchange adjustment 6 5 Adjustment to acquisitions previous years \u2013 -31 Allowances used during the year (realised losses) 17 22 Additional allowances recognised during the year -47 -49 Loss allowance at 30 September -187 -163 Given the profile of our customers, including large wholesalers and government-backed agencies, the risk of loss allowance is assessed to be limited, consequently the loss allowance in percent of due amounts is low.Other receivables, non-currentThe portion of other receivables, which are falling due after more than one year after the balance sheet date, is recognised in the balance sheet as non-current assets and amounts to DKK 25 million (DKK 28 million at 30 September 2024).",
"dimensions": {
"concept": "ifrs-full:DisclosureOfAllowanceForCreditLossesExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__107": {
"value": "Note 15Trade receivables and other receivablesAccounting policiesReceivables consist mainly of trade receivables. On initial recognition, receivables are measured at fair value and subsequently at amortised cost. Receivables are written down on the basis of an individual assessment and the simplified approach in accordance with IFRS 9 where loss allowances are based on lifetime expected credit losses.DKK million 2025 2024Ageing of trade receivablesNot due 3,371 3,552 Due up to 30 days 435 474 Due between 30 and 90 days 437 246 Due more than 90 days 602 566 Trade receivables at 30 September, gross 4,845 4,838 Loss allowance at 30 September -187 -163 Trade receivables at 30 September, net 4,658 4,675 Loss allowance at 1 October -163 -110 Exchange adjustment 6 5 Adjustment to acquisitions previous years \u2013 -31 Allowances used during the year (realised losses) 17 22 Additional allowances recognised during the year -47 -49 Loss allowance at 30 September -187 -163 Given the profile of our customers, including large wholesalers and government-backed agencies, the risk of loss allowance is assessed to be limited, consequently the loss allowance in percent of due amounts is low.Other receivables, non-currentThe portion of other receivables, which are falling due after more than one year after the balance sheet date, is recognised in the balance sheet as non-current assets and amounts to DKK 25 million (DKK 28 million at 30 September 2024).",
"dimensions": {
"concept": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__110": {
"value": "Accounting policiesReceivables consist mainly of trade receivables. On initial recognition, receivables are measured at fair value and subsequently at amortised cost. Receivables are written down on the basis of an individual assessment and the simplified approach in accordance with IFRS 9 where loss allowances are based on lifetime expected credit losses.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__113-1": {
"value": "Note 16Share optionsAccounting policiesShare options are granted to the executive management and senior management. For equity-settled schemes, the fair value of options is determined at the grant date. The option value is subsequently recognised over the vesting period as staff costs. For cash-settled schemes, the fair value of options granted during the period is recognised as staff costs, whereas the fair value adjustment of granted options from previous periods is recognised under financial items. The purchase and selling prices of treasury shares on exercise of share options are deducted from or added to equity, as the case may be.Share options are granted to members of the executive management and other senior management for the purpose of motivating and retaining a qualified management group and in order to align the interests of management with those of the shareholders. Options are awarded as unconditional allocations at the date of grant, but vest over a three-year period. The value of options at the date of grant equalled an average of three months' salary for each recipient, with the exception of the executive management.The carrying amount of the cash settled share option programmes was DKK 0 million at 30 September 2025 (DKK 2 million at 30 September 2024), while the fair value of all option programmes at grant date amounted to DKK 417 million at 30 September 2025 (DKK 291 million at 30 September 2024).DKK million2024/25 2023/24Share options have affected the profit or loss for the year as followsStaff costs, accounting value of cash and equity-settled programmes 79 70 Financial costs, fair value adjustment of cash-settled programmes -2 \u2013 Cost of share options recognised in profit or loss 77 70 The fair value of the options was calculated using the Black-Scholes formula at the date of the grant, in which the interest rate applied was the yield on Danish government securities. Volatility in the share is calculated as monthly movements (period-end to period-end) over five years. Options are assumed to be exercised on average one year into the exercise period.2024 2023The following assumptions were applied in determining the fair value of share options granted during the financial yearBlack-Scholes value, DKK125.12 121.41Share price, DKK787.60 773.22Exercise price, DKK826.98 811.88Expected dividend per share, DKK 1.50 % 1.50 %Expected duration, years4.00 4.00Volatility 23.35 % 22.12 %Risk-free interest 1.72 % 2.21 %Fair value at grant date, million DKK90.30 76.452024/25 2023/24Average Average Average Average No. of exercise share No. of exercise share optionspriceprice\u00b9\u207eoptionspriceprice\u00b9\u207eOutstanding share options at 1 October 2,041,988 888 2,129,562 871 Options awarded 721,701 827 629,716 812 Options expired -97,445 859 -2 608 Options forfeited -164,297 860 -36,990 862 Options exercised -31,341 849 917 -680,298 740 891 Outstanding share options at 30 September 2,470,606 867 2,041,988 8881) At the date of exerciseNot exercised No. ofShareat 30 options optionsOptionsSeptember ExerciseYear of issueissuedlapsedexercised2025\u00b9\u207eprice\u00b2\u207e\u00b3\u207e Exercise periodSpecification of outstanding share options2020 535,152 -335,224 \u2013 199,928 949 31/12/23 - 31/12/252020, repriced 241,296 -11,291 -32,836 197,169 897 31/12/23 - 31/12/252020 US 109,900 -97,446 \u2013 12,454 981 31/12/23 - 31/12/252020 US, repriced 65,197 -13,163 -3,816 48,218 920 31/12/23 - 31/12/252021 441,494 -287,303 \u2013 154,191 1,183 31/12/24 - 31/12/262021, repriced 103,554 -7,700 \u2013 95,854 897 31/12/24 - 31/12/262021 US 95,846 -83,387 \u2013 12,459 1,213 31/12/24 - 31/12/262021 US, repriced 29,592 -7,416 \u2013 22,176 920 31/12/24 - 31/12/262022 424,561 -26,609 \u2013 397,952 832 31/12/25 - 31/12/272022 US 108,646 -26,428 \u2013 82,218 855 31/12/25 - 31/12/272023 514,397 -25,688 \u2013 488,709 798 31/12/26 - 31/12/282023 US 115,319 -31,214 \u2013 84,105 812 31/12/26 - 31/12/282024 706,431 -43,592 \u2013 662,839 822 31/12/27 - 31/12/292024 US 15,270 -2,936 \u2013 12,334 827 31/12/27 - 31/12/29Total 3,506,655 -999,397 -36,652 2,470,606\u00b9\u207e Exercisable options as per 30 September 2025 was 742,449.\u00b2\u207e Average exercise price for options exercisable at the balance sheet date was DKK 979.33.\u00b3\u207e The exercise prices are adjusted for payment of dividend. In 2024/25, the adjustment of the exercise price was DKK -8.67.In 2024/25 111,201 options (2023/24: 141,526) were granted to key management. As per 30 September 2025 key managements holds 139,106 options (2023/24: 304,279) at an average exercise price of 907.84 (2023/24: 949.36).Coloplast's holding of treasury shares fully covers the option programmes, so the options exercised under the programme will not influence the Group's cash position by forcing it to buy up shares in the market. See Note 9 to the financial statements for an overview of treasury shares held by Coloplast at the balance sheet date.Note 27Remuneration of the Board of Directors and Executive ManagementThe current policy for the remuneration of the Board of Directors and Executive Management was adopted in 2023 and sets out the general guidelines for the remuneration of the Group\u2019s management. The guidelines for the remuneration of the Board of Directors and Executive Management are available on the Group website. Executive Management is defined as members registered with the Danish Business Authority. The board of directors decided 5 November 2024, that the CEO and CFO were to remain as the sole registered executives. In addition to the disclosures provided in this note, more details on the remuneration of Executive Management and Directors are provided in the separate Remuneration report for the Coloplast Group, which is not a part of the audited consolidated financial statements. The report is also available on the Group website.Fees to Board members in respect of the current financial yearBoard member fees has remained unchanged for the past nine years. At the Annual General Meeting held on 5 December 2024, it was decided to increase the remuneration for the Board of Directors, the Audit Committee, and the Remuneration and Nomination Committee. The total remuneration for the fiscal year 2024/25 amounts to DKK 7.6 million (2023/24: DKK 6.9 million), which is included in total staff costs (see Note 5 to the financial statements) and are specified as follows:DKK million 2024/25 2023/24Ordinary board member fee 5.7 5.3 Audit Committee 1.1 0.9 Nomination and Remuneration Committee 0.8 0.7 Fee to members of the Board of Directors 7.6 6.9 Remuneration of members of the Executive Management in respect of the current financial year Remuneration to members of the Executive Management make up DKK 83.2 million (2023/24: DKK 63.5 million) of the total staff costs (see Note 5 to the financial statements) and are specified as follows:DKK million 2024/25 2023/24Base salaries 20.2 35.6Pension 3.2 5.1Other benefits 0.5 1.4Cash bonus 0.8 4.9Severance payment to Executive Management 50.5 \u2013Remuneration of Executive Management, excluding value of share options and contingent salary items 75.2 47.0Share options 8.0 16.5Remuneration of Executive Management 83.2 63.5The value of share options, which is calculated as the fair value of share options at the grant date using the Black-Scholes Formula in line with IFRS 2, comprise the annual accounting cost of share options awarded in the current and in prior years in accordance with the accounting policies applied. Consequently, it does not represent the fair value of share options awarded or exercised in the current financial year.If a member of Executive Management is given notice of termination by the company and such termination is not due to breach on the part of the member of Executive Management, such member is entitled to compensation corresponding to a maximum of two years\u2019 salary and pension contribution.Share options are granted to members of Executive Management and senior management. See Note 16 to the financial statements for further information regarding share-based payments as well as the separate Remuneration Report for the Coloplast Group, which is not part of the audited financial statements. The report is available on the Group website.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__112-1": {
"value": "Note 16Share optionsAccounting policiesShare options are granted to the executive management and senior management. For equity-settled schemes, the fair value of options is determined at the grant date. The option value is subsequently recognised over the vesting period as staff costs. For cash-settled schemes, the fair value of options granted during the period is recognised as staff costs, whereas the fair value adjustment of granted options from previous periods is recognised under financial items. The purchase and selling prices of treasury shares on exercise of share options are deducted from or added to equity, as the case may be.Share options are granted to members of the executive management and other senior management for the purpose of motivating and retaining a qualified management group and in order to align the interests of management with those of the shareholders. Options are awarded as unconditional allocations at the date of grant, but vest over a three-year period. The value of options at the date of grant equalled an average of three months' salary for each recipient, with the exception of the executive management.The carrying amount of the cash settled share option programmes was DKK 0 million at 30 September 2025 (DKK 2 million at 30 September 2024), while the fair value of all option programmes at grant date amounted to DKK 417 million at 30 September 2025 (DKK 291 million at 30 September 2024).DKK million2024/25 2023/24Share options have affected the profit or loss for the year as followsStaff costs, accounting value of cash and equity-settled programmes 79 70 Financial costs, fair value adjustment of cash-settled programmes -2 \u2013 Cost of share options recognised in profit or loss 77 70 The fair value of the options was calculated using the Black-Scholes formula at the date of the grant, in which the interest rate applied was the yield on Danish government securities. Volatility in the share is calculated as monthly movements (period-end to period-end) over five years. Options are assumed to be exercised on average one year into the exercise period.2024 2023The following assumptions were applied in determining the fair value of share options granted during the financial yearBlack-Scholes value, DKK125.12 121.41Share price, DKK787.60 773.22Exercise price, DKK826.98 811.88Expected dividend per share, DKK 1.50 % 1.50 %Expected duration, years4.00 4.00Volatility 23.35 % 22.12 %Risk-free interest 1.72 % 2.21 %Fair value at grant date, million DKK90.30 76.452024/25 2023/24Average Average Average Average No. of exercise share No. of exercise share optionspriceprice\u00b9\u207eoptionspriceprice\u00b9\u207eOutstanding share options at 1 October 2,041,988 888 2,129,562 871 Options awarded 721,701 827 629,716 812 Options expired -97,445 859 -2 608 Options forfeited -164,297 860 -36,990 862 Options exercised -31,341 849 917 -680,298 740 891 Outstanding share options at 30 September 2,470,606 867 2,041,988 8881) At the date of exerciseNot exercised No. ofShareat 30 options optionsOptionsSeptember ExerciseYear of issueissuedlapsedexercised2025\u00b9\u207eprice\u00b2\u207e\u00b3\u207e Exercise periodSpecification of outstanding share options2020 535,152 -335,224 \u2013 199,928 949 31/12/23 - 31/12/252020, repriced 241,296 -11,291 -32,836 197,169 897 31/12/23 - 31/12/252020 US 109,900 -97,446 \u2013 12,454 981 31/12/23 - 31/12/252020 US, repriced 65,197 -13,163 -3,816 48,218 920 31/12/23 - 31/12/252021 441,494 -287,303 \u2013 154,191 1,183 31/12/24 - 31/12/262021, repriced 103,554 -7,700 \u2013 95,854 897 31/12/24 - 31/12/262021 US 95,846 -83,387 \u2013 12,459 1,213 31/12/24 - 31/12/262021 US, repriced 29,592 -7,416 \u2013 22,176 920 31/12/24 - 31/12/262022 424,561 -26,609 \u2013 397,952 832 31/12/25 - 31/12/272022 US 108,646 -26,428 \u2013 82,218 855 31/12/25 - 31/12/272023 514,397 -25,688 \u2013 488,709 798 31/12/26 - 31/12/282023 US 115,319 -31,214 \u2013 84,105 812 31/12/26 - 31/12/282024 706,431 -43,592 \u2013 662,839 822 31/12/27 - 31/12/292024 US 15,270 -2,936 \u2013 12,334 827 31/12/27 - 31/12/29Total 3,506,655 -999,397 -36,652 2,470,606\u00b9\u207e Exercisable options as per 30 September 2025 was 742,449.\u00b2\u207e Average exercise price for options exercisable at the balance sheet date was DKK 979.33.\u00b3\u207e The exercise prices are adjusted for payment of dividend. In 2024/25, the adjustment of the exercise price was DKK -8.67.In 2024/25 111,201 options (2023/24: 141,526) were granted to key management. As per 30 September 2025 key managements holds 139,106 options (2023/24: 304,279) at an average exercise price of 907.84 (2023/24: 949.36).Coloplast's holding of treasury shares fully covers the option programmes, so the options exercised under the programme will not influence the Group's cash position by forcing it to buy up shares in the market. See Note 9 to the financial statements for an overview of treasury shares held by Coloplast at the balance sheet date.Note 27Remuneration of the Board of Directors and Executive ManagementThe current policy for the remuneration of the Board of Directors and Executive Management was adopted in 2023 and sets out the general guidelines for the remuneration of the Group\u2019s management. The guidelines for the remuneration of the Board of Directors and Executive Management are available on the Group website. Executive Management is defined as members registered with the Danish Business Authority. The board of directors decided 5 November 2024, that the CEO and CFO were to remain as the sole registered executives. In addition to the disclosures provided in this note, more details on the remuneration of Executive Management and Directors are provided in the separate Remuneration report for the Coloplast Group, which is not a part of the audited consolidated financial statements. The report is also available on the Group website.Fees to Board members in respect of the current financial yearBoard member fees has remained unchanged for the past nine years. At the Annual General Meeting held on 5 December 2024, it was decided to increase the remuneration for the Board of Directors, the Audit Committee, and the Remuneration and Nomination Committee. The total remuneration for the fiscal year 2024/25 amounts to DKK 7.6 million (2023/24: DKK 6.9 million), which is included in total staff costs (see Note 5 to the financial statements) and are specified as follows:DKK million 2024/25 2023/24Ordinary board member fee 5.7 5.3 Audit Committee 1.1 0.9 Nomination and Remuneration Committee 0.8 0.7 Fee to members of the Board of Directors 7.6 6.9 Remuneration of members of the Executive Management in respect of the current financial year Remuneration to members of the Executive Management make up DKK 83.2 million (2023/24: DKK 63.5 million) of the total staff costs (see Note 5 to the financial statements) and are specified as follows:DKK million 2024/25 2023/24Base salaries 20.2 35.6Pension 3.2 5.1Other benefits 0.5 1.4Cash bonus 0.8 4.9Severance payment to Executive Management 50.5 \u2013Remuneration of Executive Management, excluding value of share options and contingent salary items 75.2 47.0Share options 8.0 16.5Remuneration of Executive Management 83.2 63.5The value of share options, which is calculated as the fair value of share options at the grant date using the Black-Scholes Formula in line with IFRS 2, comprise the annual accounting cost of share options awarded in the current and in prior years in accordance with the accounting policies applied. Consequently, it does not represent the fair value of share options awarded or exercised in the current financial year.If a member of Executive Management is given notice of termination by the company and such termination is not due to breach on the part of the member of Executive Management, such member is entitled to compensation corresponding to a maximum of two years\u2019 salary and pension contribution.Share options are granted to members of Executive Management and senior management. See Note 16 to the financial statements for further information regarding share-based payments as well as the separate Remuneration Report for the Coloplast Group, which is not part of the audited financial statements. The report is available on the Group website.Note 28Related party transactionsRelated parties to the Coloplast Group include members of the Board of Directors and the Executive Management and main shareholders of Coloplast A/S. There were no major transactions with related parties except from dividend payments. Information about the remuneration of the Management is set out in Note 27 to the consolidated financial statements.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__111": {
"value": "Note 16Share optionsAccounting policiesShare options are granted to the executive management and senior management. For equity-settled schemes, the fair value of options is determined at the grant date. The option value is subsequently recognised over the vesting period as staff costs. For cash-settled schemes, the fair value of options granted during the period is recognised as staff costs, whereas the fair value adjustment of granted options from previous periods is recognised under financial items. The purchase and selling prices of treasury shares on exercise of share options are deducted from or added to equity, as the case may be.Share options are granted to members of the executive management and other senior management for the purpose of motivating and retaining a qualified management group and in order to align the interests of management with those of the shareholders. Options are awarded as unconditional allocations at the date of grant, but vest over a three-year period. The value of options at the date of grant equalled an average of three months' salary for each recipient, with the exception of the executive management.The carrying amount of the cash settled share option programmes was DKK 0 million at 30 September 2025 (DKK 2 million at 30 September 2024), while the fair value of all option programmes at grant date amounted to DKK 417 million at 30 September 2025 (DKK 291 million at 30 September 2024).DKK million2024/25 2023/24Share options have affected the profit or loss for the year as followsStaff costs, accounting value of cash and equity-settled programmes 79 70 Financial costs, fair value adjustment of cash-settled programmes -2 \u2013 Cost of share options recognised in profit or loss 77 70 The fair value of the options was calculated using the Black-Scholes formula at the date of the grant, in which the interest rate applied was the yield on Danish government securities. Volatility in the share is calculated as monthly movements (period-end to period-end) over five years. Options are assumed to be exercised on average one year into the exercise period.2024 2023The following assumptions were applied in determining the fair value of share options granted during the financial yearBlack-Scholes value, DKK125.12 121.41Share price, DKK787.60 773.22Exercise price, DKK826.98 811.88Expected dividend per share, DKK 1.50 % 1.50 %Expected duration, years4.00 4.00Volatility 23.35 % 22.12 %Risk-free interest 1.72 % 2.21 %Fair value at grant date, million DKK90.30 76.452024/25 2023/24Average Average Average Average No. of exercise share No. of exercise share optionspriceprice\u00b9\u207eoptionspriceprice\u00b9\u207eOutstanding share options at 1 October 2,041,988 888 2,129,562 871 Options awarded 721,701 827 629,716 812 Options expired -97,445 859 -2 608 Options forfeited -164,297 860 -36,990 862 Options exercised -31,341 849 917 -680,298 740 891 Outstanding share options at 30 September 2,470,606 867 2,041,988 8881) At the date of exerciseNot exercised No. ofShareat 30 options optionsOptionsSeptember ExerciseYear of issueissuedlapsedexercised2025\u00b9\u207eprice\u00b2\u207e\u00b3\u207e Exercise periodSpecification of outstanding share options2020 535,152 -335,224 \u2013 199,928 949 31/12/23 - 31/12/252020, repriced 241,296 -11,291 -32,836 197,169 897 31/12/23 - 31/12/252020 US 109,900 -97,446 \u2013 12,454 981 31/12/23 - 31/12/252020 US, repriced 65,197 -13,163 -3,816 48,218 920 31/12/23 - 31/12/252021 441,494 -287,303 \u2013 154,191 1,183 31/12/24 - 31/12/262021, repriced 103,554 -7,700 \u2013 95,854 897 31/12/24 - 31/12/262021 US 95,846 -83,387 \u2013 12,459 1,213 31/12/24 - 31/12/262021 US, repriced 29,592 -7,416 \u2013 22,176 920 31/12/24 - 31/12/262022 424,561 -26,609 \u2013 397,952 832 31/12/25 - 31/12/272022 US 108,646 -26,428 \u2013 82,218 855 31/12/25 - 31/12/272023 514,397 -25,688 \u2013 488,709 798 31/12/26 - 31/12/282023 US 115,319 -31,214 \u2013 84,105 812 31/12/26 - 31/12/282024 706,431 -43,592 \u2013 662,839 822 31/12/27 - 31/12/292024 US 15,270 -2,936 \u2013 12,334 827 31/12/27 - 31/12/29Total 3,506,655 -999,397 -36,652 2,470,606\u00b9\u207e Exercisable options as per 30 September 2025 was 742,449.\u00b2\u207e Average exercise price for options exercisable at the balance sheet date was DKK 979.33.\u00b3\u207e The exercise prices are adjusted for payment of dividend. In 2024/25, the adjustment of the exercise price was DKK -8.67.In 2024/25 111,201 options (2023/24: 141,526) were granted to key management. As per 30 September 2025 key managements holds 139,106 options (2023/24: 304,279) at an average exercise price of 907.84 (2023/24: 949.36).Coloplast's holding of treasury shares fully covers the option programmes, so the options exercised under the programme will not influence the Group's cash position by forcing it to buy up shares in the market. See Note 9 to the financial statements for an overview of treasury shares held by Coloplast at the balance sheet date.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__116": {
"value": "Accounting policiesShare options are granted to the executive management and senior management. For equity-settled schemes, the fair value of options is determined at the grant date. The option value is subsequently recognised over the vesting period as staff costs. For cash-settled schemes, the fair value of options granted during the period is recognised as staff costs, whereas the fair value adjustment of granted options from previous periods is recognised under financial items. The purchase and selling prices of treasury shares on exercise of share options are deducted from or added to equity, as the case may be.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__117-1": {
"value": "Note 17Provisions for pensions and similar obligationsAccounting policiesIn defined contribution plans, the Group makes regular payments of fixed contributions to independent pension funds and insurance companies. The Group is under no obligation to pay additional contributions. Costs for defined contribution plans are recognised in the income statement as Coloplast assumes an obligation to make the payment.In defined benefit plans, the Group is under an obligation to pay a defined benefit on retirement. The actuarially calculated present value less the fair value of any plan assets is recognised in the balance sheet under provision for pension and similar obligations or in plan assets in the balance sheet. The total service costs of the year plus calculated interest based on actuarial estimates and financial assumptions at the beginning of the year are recognised in the income statement. The difference between the forecast development in plan assets and liabilities and the realised values at the end of the year is called actuarial gains or losses and is recognised in other comprehensive income. In connection with a change in benefits regarding the employees\u2019 employment with the Group to date, there will be a change in the actuarial calculation of the net present value, which is taken directly to the profit or loss.Defined contribution plansThe Group offers pension plans to certain groups of employees in Denmark and abroad. Most of the pension plans are defined contribution plans. The Group funds the plans through regular payments of premiums to independent insurance companies responsible for the pension obligations towards the beneficiaries. Once the pension contributions for defined contribution plans have been made, the Group has no further obligation towards current or former employees. Contributions to defined contribution plans are recognised in the income statement when paid. In 2024/25, DKK 458 million (2023/24: DKK 472 million) was recognised.Defined benefit plansFor certain groups of employees in foreign subsidiaries, the Group has signed agreements to pay defined benefits, including pension payments.Share of gross defined benefit obligations by country 2025 2024France 26 % 22 %Germany 12 % 11 %UK 61 % 66 %Italy 1 % 1 %Total 100 % 100 %These pension liabilities are not or are only partly covered by insurance (in the UK). Defined benefit liabilities are recognised in the balance sheet and in the statement of comprehensive income as indicated below. Coloplast funds the plans in the UK.The pension plans are based on the individual employee's salary and years of service with the company, and benefits are paid as a lifelong pension. The active plans are not exclusive to any particular employee group.Special funding requirements apply in the UK, while this is not the case for the other countries. In the UK, employee interests are handled by a Trustee Board. Accounts are prepared every three years and funding of any deficit is determined. Coloplast have an unconditional right to any surplus in the scheme at the end of the life of the scheme when all the liabilities have been run off. Any deficit in the Scheme is recovered by additional contributions from the employer over a fixed period of time. The plans have no requirements for risk diversification on equities or for matching strategies The plans have a duration of an average of 11 years, and all plans generally mature after more than 10 years.The Group expects to pay DKK 8 million to the defined benefit plans in 2024/25 (2023/24: DKK 7 million).DKK million2024/25 2023/24Defined contribution plans 458 472 Defined benefit plans 14 13 Cost of pension plans recognised in profit or loss 472 485 Pension costs concerning current financial year 10 8 Net interest expenses 4 5 Cost of defined benefit plans recognised in profit or loss 14 13 Actuarial gains/losses on pension obligations 46 -10 Actuarial gains/losses on plan assets -25 16 Actuarial gains/losses on defined benefit plans recognisedin other comprehensive income 21 7 Plan assets at 1 October 254 225 Exchange adjustments -12 8 Actual rate of interest 13 12 Actuarial gains/losses on plan assets -25 16 Paid by the Coloplast Group 7 7 Benefit paid out -15 -14 Plan assets at 30 September 222 254 DKK million2025 2024Specification of plan assetsShares, listed 35 31 Bonds, listed 89 112 Investments funds, listed 97 109 Cash and similar assets 1 2 Plan assets at 30 September 222 254 DKK million2024/25 2023/24Specification of present value of defined benefit obligationPresent value of defined benefit liability at 1 October 387 356 Exchange adjustments -12 10 Current service costs 10 8 Calculated interest on liability 17 17 Actuarial gains/losses, financial assumptions -26 10 Actuarial gains/losses, demographic assumptions -5 5 Actuarial gains/losses, experience -15 -5 Benefit paid out -15 -14 Present value of defined benefit liability at 30 September 341 387 Fair value of plan assets at 30 September -222 -254 Net liability of defined benefit plans at 30 September 119 133 Net liability of defined benefit plans at 1 October 133 131 Expenditure for the year 14 13 Actuarial gains/losses on pension obligation -46 10 Exchange adjustment \u2013 1 Actuarial gains/losses on plan assets 25 -16 Payments received -7 -7 Net liability of defined benefit plans at 30 September 119 133 Actuarial assumptions applied at the balance sheet date (expressed as an average)Discount rate 3.6 % 3.6 %Future rate of salary increases 2.3 % 2.0 %Inflation 1.3 % 2.2 %The below sensibility analysis shows the change in one of the actuarial assumptions, while other assumptions are kept constant. In practice, a change in one of the assumptions will in many instances be matched by a change in the other assumptions.2024/25 2023/24+1%-point -1%-point +1%-point -1%-pointPercentage increase/decrease in the gross liability resulting from a change in a single actuarial assumptionDiscount rate -12 % 13 % -13 % 15 %Future rate of salary increases 3 % -3 % 3 % -2 %Inflation 7 % -6 % 8 % -8 %Note 18Other provisionsAccounting policiesProvisions are recognised when the Group has a legal or constructive obligation arising from a past event, and it is probable that an outflow of the Group\u2019s financial resources will be required to settle the obligation. Provisions are measured as Management's best estimate of the amount with which the liability is expected to be settled. The Group recognises a provision for the replacement of products covered by warranties at the balance sheet date.Key accounting estimates and judgementsProvisions for legal obligations consist of provisions for pending litigation. Management makes assessments of provisions and contingent liabilities, including the probable outcome of pending and possible future litigation, which is inherently subject to uncertain future events. Based on information available, Management believes that adequate provisions have been made for pending litigation, but there can be no assurance that the scope of these matters will not be extended, nor that material lawsuits, claims, legal proceedings or investigations will not arise in the future2024/25 2023/24Legal Legal DKK millionclaims Other Totalclaims Other TotalProvisions at 1 October 16 53 69 116 141 257 Exchange adjustment \u2013 \u2013 \u2013 \u2013 1 1 Provisions used during the year -1 \u2013 -1 -97 \u2013 -97 Unused provisions reversed during the year -1 1 \u2013 -6 -92 -98 Additional provisions 8 \u2013 8 3 3 6 Provisions at 30 September 22 54 76 16 53 69 Expected maturitiesNon-current liabilities 16 9 25 12 9 21 Current liabilities 6 45 51 4 44 48 Provisions at 30 September 22 54 76 16 53 69 Provisions charged to profit or loss during the year 7 -16 -9 -3 -89 -92 Legal claimsThe amounts are gross amounts relating to certain legal claims.Coloplast is occasionally part in various legal proceedings with third parties. None of these proceedings are expected to have a material effect on the financial position or future earnings.OtherOther liabilities relate to provisions for expenses associated with restructuring, guarantees and other non-legal claims.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfProvisionsExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__121-1": {
"value": "Accounting policiesIn defined contribution plans, the Group makes regular payments of fixed contributions to independent pension funds and insurance companies. The Group is under no obligation to pay additional contributions. Costs for defined contribution plans are recognised in the income statement as Coloplast assumes an obligation to make the payment.In defined benefit plans, the Group is under an obligation to pay a defined benefit on retirement. The actuarially calculated present value less the fair value of any plan assets is recognised in the balance sheet under provision for pension and similar obligations or in plan assets in the balance sheet. The total service costs of the year plus calculated interest based on actuarial estimates and financial assumptions at the beginning of the year are recognised in the income statement. The difference between the forecast development in plan assets and liabilities and the realised values at the end of the year is called actuarial gains or losses and is recognised in other comprehensive income. In connection with a change in benefits regarding the employees\u2019 employment with the Group to date, there will be a change in the actuarial calculation of the net present value, which is taken directly to the profit or loss.Accounting policiesProvisions are recognised when the Group has a legal or constructive obligation arising from a past event, and it is probable that an outflow of the Group\u2019s financial resources will be required to settle the obligation. Provisions are measured as Management's best estimate of the amount with which the liability is expected to be settled. The Group recognises a provision for the replacement of products covered by warranties at the balance sheet date.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__120": {
"value": "Accounting policiesIn defined contribution plans, the Group makes regular payments of fixed contributions to independent pension funds and insurance companies. The Group is under no obligation to pay additional contributions. Costs for defined contribution plans are recognised in the income statement as Coloplast assumes an obligation to make the payment.In defined benefit plans, the Group is under an obligation to pay a defined benefit on retirement. The actuarially calculated present value less the fair value of any plan assets is recognised in the balance sheet under provision for pension and similar obligations or in plan assets in the balance sheet. The total service costs of the year plus calculated interest based on actuarial estimates and financial assumptions at the beginning of the year are recognised in the income statement. The difference between the forecast development in plan assets and liabilities and the realised values at the end of the year is called actuarial gains or losses and is recognised in other comprehensive income. In connection with a change in benefits regarding the employees\u2019 employment with the Group to date, there will be a change in the actuarial calculation of the net present value, which is taken directly to the profit or loss.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__125": {
"value": "Accounting policiesBorrowings from credit institutions are recognised at fair value less expenses incurred and subsequently at amortised cost.Certain borrowings are subject to specific leverage covenants which are complied with.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForBorrowingsExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__128": {
"value": "Note 20Financial instruments by categoryAccounting policiesFinancial instruments are measured at either amortised cost or fair value. Those financial instruments, which are measured at fair value, can be categorised according to the fair value measurement hierarchy below:Level 1: Observable prices in active markets for identical instruments.Level 2: Valuation models primarily based on observable prices or traded prices of comparable instruments.Level 3: Valuation models primarily based on non-observable prices.The fair value of forward exchange contracts and other derivative financial instruments are considered a level 2 fair value measurement as the fair value is determined directly based on the published exchange rates and quoted forward exchange rates at balance sheet dates. The fair value of derivative financial instruments is calculated on the basis of current market data.Contingent Financial consideration Fair value instruments at fair value through at fair value through profit Amortised profit or lossthrough OCI or loss DKK millioncost(level 1)(level 2)(level 3) Total2025Trade receivables 4,658 \u2013 \u2013 \u2013 4,658 Other receivables 299 \u2013 180 \u2013 479 Cash and cash equivalents 947 \u2013 \u2013 \u2013 947 Financial assets 5,904 \u2013 180 \u2013 6,084 Other credit institutions 10,111 \u2013 \u2013 \u2013 10,111 Bonds\u00b9) 11,570 \u2013 \u2013 \u2013 11,570 Trade payables 1,324 \u2013 \u2013 \u2013 1,324 Other payables 2,390 \u2013 11 \u2013 2,401 Lease liabilities 958 \u2013 \u2013 \u2013 958 Financial liabilities 26,353 \u2013 11 \u2013 26,364 2024Trade receivables 4,675 \u2013 \u2013 \u2013 4,675 Other receivables 355 \u2013 39 \u2013 394 Cash and cash equivalents 788 \u2013 \u2013 \u2013 788 Financial assets 5,818 \u2013 39 \u2013 5,857 Other credit institutions 10,085 \u2013 \u2013 \u2013 10,085 Bonds\u00b9) 11,557 \u2013 \u2013 \u2013 11,557 Trade payables 1,519 \u2013 \u2013 \u2013 1,519 Other payables 2,353 \u2013 73 \u2013 2,426 Lease liabilities 987 \u2013 \u2013 \u2013 987 Financial liabilities 26,501 \u2013 73 \u2013 26,574 \u00b9\u207e The fair value of the bonds amounts to DKK 11,493 million (DKK 11,392 million 30 September 2024) calculated based on market prices (level 1).",
"dimensions": {
"concept": "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__127": {
"value": "Note 20Financial instruments by categoryAccounting policiesFinancial instruments are measured at either amortised cost or fair value. Those financial instruments, which are measured at fair value, can be categorised according to the fair value measurement hierarchy below:Level 1: Observable prices in active markets for identical instruments.Level 2: Valuation models primarily based on observable prices or traded prices of comparable instruments.Level 3: Valuation models primarily based on non-observable prices.The fair value of forward exchange contracts and other derivative financial instruments are considered a level 2 fair value measurement as the fair value is determined directly based on the published exchange rates and quoted forward exchange rates at balance sheet dates. The fair value of derivative financial instruments is calculated on the basis of current market data.Contingent Financial consideration Fair value instruments at fair value through at fair value through profit Amortised profit or lossthrough OCI or loss DKK millioncost(level 1)(level 2)(level 3) Total2025Trade receivables 4,658 \u2013 \u2013 \u2013 4,658 Other receivables 299 \u2013 180 \u2013 479 Cash and cash equivalents 947 \u2013 \u2013 \u2013 947 Financial assets 5,904 \u2013 180 \u2013 6,084 Other credit institutions 10,111 \u2013 \u2013 \u2013 10,111 Bonds\u00b9) 11,570 \u2013 \u2013 \u2013 11,570 Trade payables 1,324 \u2013 \u2013 \u2013 1,324 Other payables 2,390 \u2013 11 \u2013 2,401 Lease liabilities 958 \u2013 \u2013 \u2013 958 Financial liabilities 26,353 \u2013 11 \u2013 26,364 2024Trade receivables 4,675 \u2013 \u2013 \u2013 4,675 Other receivables 355 \u2013 39 \u2013 394 Cash and cash equivalents 788 \u2013 \u2013 \u2013 788 Financial assets 5,818 \u2013 39 \u2013 5,857 Other credit institutions 10,085 \u2013 \u2013 \u2013 10,085 Bonds\u00b9) 11,557 \u2013 \u2013 \u2013 11,557 Trade payables 1,519 \u2013 \u2013 \u2013 1,519 Other payables 2,353 \u2013 73 \u2013 2,426 Lease liabilities 987 \u2013 \u2013 \u2013 987 Financial liabilities 26,501 \u2013 73 \u2013 26,574 \u00b9\u207e The fair value of the bonds amounts to DKK 11,493 million (DKK 11,392 million 30 September 2024) calculated based on market prices (level 1).",
"dimensions": {
"concept": "ifrs-full:DisclosureOfFairValueMeasurementExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__126": {
"value": "Note 20Financial instruments by categoryAccounting policiesFinancial instruments are measured at either amortised cost or fair value. Those financial instruments, which are measured at fair value, can be categorised according to the fair value measurement hierarchy below:Level 1: Observable prices in active markets for identical instruments.Level 2: Valuation models primarily based on observable prices or traded prices of comparable instruments.Level 3: Valuation models primarily based on non-observable prices.The fair value of forward exchange contracts and other derivative financial instruments are considered a level 2 fair value measurement as the fair value is determined directly based on the published exchange rates and quoted forward exchange rates at balance sheet dates. The fair value of derivative financial instruments is calculated on the basis of current market data.Contingent Financial consideration Fair value instruments at fair value through at fair value through profit Amortised profit or lossthrough OCI or loss DKK millioncost(level 1)(level 2)(level 3) Total2025Trade receivables 4,658 \u2013 \u2013 \u2013 4,658 Other receivables 299 \u2013 180 \u2013 479 Cash and cash equivalents 947 \u2013 \u2013 \u2013 947 Financial assets 5,904 \u2013 180 \u2013 6,084 Other credit institutions 10,111 \u2013 \u2013 \u2013 10,111 Bonds\u00b9) 11,570 \u2013 \u2013 \u2013 11,570 Trade payables 1,324 \u2013 \u2013 \u2013 1,324 Other payables 2,390 \u2013 11 \u2013 2,401 Lease liabilities 958 \u2013 \u2013 \u2013 958 Financial liabilities 26,353 \u2013 11 \u2013 26,364 2024Trade receivables 4,675 \u2013 \u2013 \u2013 4,675 Other receivables 355 \u2013 39 \u2013 394 Cash and cash equivalents 788 \u2013 \u2013 \u2013 788 Financial assets 5,818 \u2013 39 \u2013 5,857 Other credit institutions 10,085 \u2013 \u2013 \u2013 10,085 Bonds\u00b9) 11,557 \u2013 \u2013 \u2013 11,557 Trade payables 1,519 \u2013 \u2013 \u2013 1,519 Other payables 2,353 \u2013 73 \u2013 2,426 Lease liabilities 987 \u2013 \u2013 \u2013 987 Financial liabilities 26,501 \u2013 73 \u2013 26,574 \u00b9\u207e The fair value of the bonds amounts to DKK 11,493 million (DKK 11,392 million 30 September 2024) calculated based on market prices (level 1).",
"dimensions": {
"concept": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__131": {
"value": "Accounting policiesFinancial instruments are measured at either amortised cost or fair value. Those financial instruments, which are measured at fair value, can be categorised according to the fair value measurement hierarchy below:Level 1: Observable prices in active markets for identical instruments.Level 2: Valuation models primarily based on observable prices or traded prices of comparable instruments.Level 3: Valuation models primarily based on non-observable prices.The fair value of forward exchange contracts and other derivative financial instruments are considered a level 2 fair value measurement as the fair value is determined directly based on the published exchange rates and quoted forward exchange rates at balance sheet dates. The fair value of derivative financial instruments is calculated on the basis of current market data.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__130": {
"value": "Accounting policiesFinancial instruments are measured at either amortised cost or fair value. Those financial instruments, which are measured at fair value, can be categorised according to the fair value measurement hierarchy below:Level 1: Observable prices in active markets for identical instruments.Level 2: Valuation models primarily based on observable prices or traded prices of comparable instruments.Level 3: Valuation models primarily based on non-observable prices.The fair value of forward exchange contracts and other derivative financial instruments are considered a level 2 fair value measurement as the fair value is determined directly based on the published exchange rates and quoted forward exchange rates at balance sheet dates. The fair value of derivative financial instruments is calculated on the basis of current market data.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__135": {
"value": "Foreign exchange riskA number of the Group\u2019s financial instruments is exposed foreign exchange risks as a natural consequence of its global activities. The Board of Directors determines the level of risk as a percentage of EBITDA. Foreign exchange risk is calculated by applying the principles of a cash-flow-at-risk model. The foreign exchange risk related to financial instruments is concentrated in receivables, payables and cash positions denominated in foreign currencies. In addition to this, the fair value of the Group\u2019s hedging instruments is significantly exposed to changes in foreign exchange rates. On the other hand, there is only a low foreign exchange risk attached to the Group\u2019s issue of bond as these are denominated in EUR.While EUR is a key currency for the Group, the foreign exchange risk is regarded as low due to fixed exchange rate policy of the central bank of Denmark.As at 30 September 2025, an average of 57% of the following twelve months of expected net cash flows in foreign currency were hedged (30 September 2024: 61% of the following twelve months of cash flows).The table below shows how a theoretical change of +/- 2% in all currencies against Danish kroner will impact the financial instruments recognised at the balance sheet date. The impact on profit or loss comes mainly from receivables denominated in foreign currencies. The impact on other comprehensive income relates to the fair value of hedging instruments. The hedged exposure is included in the sensitivity analysis and, therefore, the effect is reduced. 2024/25 2023/24DKK million USD GBP HUF EUR Other USD GBP HUF EUR OtherImpact from a 2% increase in currenciesProfit or loss 35 3 9 -209 21 18 -6 11 -243 35 Other comprehensive income -35 -31 15 -15 -21 -32 -32 8 -9 -22 Total comprehensive income \u2013 -28 24 -224 \u2013 -14 -38 19 -252 13 Impact from a 2% decrease in currenciesProfit or loss -35 -3 -9 209 -21 -18 6 -11 243 -35 Other comprehensive income 35 31 -15 15 21 32 32 -8 9 22 Total comprehensive income \u2013 28 -24 224 \u2013 14 38 -19 252 -13 The increase and decrease resulting from a 2% change are the same as all hedging instruments are forward contracts.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__134": {
"value": "Foreign exchange riskA number of the Group\u2019s financial instruments is exposed foreign exchange risks as a natural consequence of its global activities. The Board of Directors determines the level of risk as a percentage of EBITDA. Foreign exchange risk is calculated by applying the principles of a cash-flow-at-risk model. The foreign exchange risk related to financial instruments is concentrated in receivables, payables and cash positions denominated in foreign currencies. In addition to this, the fair value of the Group\u2019s hedging instruments is significantly exposed to changes in foreign exchange rates. On the other hand, there is only a low foreign exchange risk attached to the Group\u2019s issue of bond as these are denominated in EUR.While EUR is a key currency for the Group, the foreign exchange risk is regarded as low due to fixed exchange rate policy of the central bank of Denmark.As at 30 September 2025, an average of 57% of the following twelve months of expected net cash flows in foreign currency were hedged (30 September 2024: 61% of the following twelve months of cash flows).The table below shows how a theoretical change of +/- 2% in all currencies against Danish kroner will impact the financial instruments recognised at the balance sheet date. The impact on profit or loss comes mainly from receivables denominated in foreign currencies. The impact on other comprehensive income relates to the fair value of hedging instruments. The hedged exposure is included in the sensitivity analysis and, therefore, the effect is reduced. 2024/25 2023/24DKK million USD GBP HUF EUR Other USD GBP HUF EUR OtherImpact from a 2% increase in currenciesProfit or loss 35 3 9 -209 21 18 -6 11 -243 35 Other comprehensive income -35 -31 15 -15 -21 -32 -32 8 -9 -22 Total comprehensive income \u2013 -28 24 -224 \u2013 -14 -38 19 -252 13 Impact from a 2% decrease in currenciesProfit or loss -35 -3 -9 209 -21 -18 6 -11 243 -35 Other comprehensive income 35 31 -15 15 21 32 32 -8 9 22 Total comprehensive income \u2013 28 -24 224 \u2013 14 38 -19 252 -13 The increase and decrease resulting from a 2% change are the same as all hedging instruments are forward contracts.Interest rate risk55% of the Group's net interest-bearing debt is carrying fixed interest rate for 2-5 years, and 45% is at floating interest rate. The duration as per balance sheet date was 1.6 years. An interest rate increase of 1% on the floating part of the outstanding debt as per 30 September 2025 would impact the Interest charges with an increase of DKK 101 million.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfMarketRiskExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__136": {
"value": "Liquidity riskThe exposure to liquidity risks is considered to be low. In addition to cash available for withdrawal and marketable securities, the Group\u2019s cash reserves comprise a mix of committed and uncommitted credit facilities to ensure an adequate level of funding for the Group\u2019s activities, even in periods of operational uncertainty.DKK million 2025 2024Cash and cash equivalents 947 788 Liquid assets recorded on the balance sheet at 30 September 947 788 Committed credit facilities, unutilised (more than 1 year) 3,190 1,301 Uncommitted credit facilities, unutilised (short-term) 2,856 3,337 Financial reserves at 30 September 6,993 5,426 The Board of Directors generally intends to distribute excess cash to the shareholders by way of dividends and share buybacks. It is expected that dividends will be paid twice a year: after the Annual General Meeting and after the release of the half-year interim report. However, share buybacks and distribution of dividend will always be made with due consideration for the Group\u2019s liquidity requirements and plans.The capital management objective of the Group is to raise new debt only for acquisition purposes or for other special purposes. The Group assesses the capital on the basis of the solvency ratio, which is calculated in accordance with the guidelines issued by the Danish Society of Financial Analysts.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfLiquidityRiskExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__137": {
"value": "The Board of Directors generally intends to distribute excess cash to the shareholders by way of dividends and share buybacks. It is expected that dividends will be paid twice a year: after the Annual General Meeting and after the release of the half-year interim report. However, share buybacks and distribution of dividend will always be made with due consideration for the Group\u2019s liquidity requirements and plans.The capital management objective of the Group is to raise new debt only for acquisition purposes or for other special purposes. The Group assesses the capital on the basis of the solvency ratio, which is calculated in accordance with the guidelines issued by the Danish Society of Financial Analysts.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__138": {
"value": "Credit riskThe Group\u2019s credit risk relates to the possibility that the counterparties of its financial assets are not able to meet their obligations as they fall due. The carrying amount of the financial assets represents the maximum credit risk exposure. The Group\u2019s policy for managing credit risks involves an ongoing credit assessment of major customers and other key business partners.The credit risk exposure relates to (i) receivables, (ii) bank deposits as well as (iii) derivative financial instruments (forward exchange contracts) with a positive fair value at the balance sheet date. The credit risk related to trade receivables and other receivables is diversified over a large number of customers and other counterparties. For this reason, the credit risk is regarded as insignificant. See Note 15 to the financial statement.The credit risk related to bank deposits is, pursuant to the Group\u2019s counterparty policy, managed and mitigated by making money market deposits only with selected financial institutions holding a satisfactory credit rating. In addition, the maximum deposit limits have been defined for each financial counterparty. The credit risk related to marketable securities is considered to be limited as investment is only made in selected liquid bonds with a high credit rating.The credit risk related to derivative financial instruments is aligned with the credit risk for bank deposits as derivative contracts are only entered with selected financial institutions with a satisfactory credit rating.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfCreditRiskExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__139": {
"value": "Note 22Derivative financial instrumentsAccounting policiesAt the initiation of derivative contracts, it is assessed whether they qualify for hedge accounting and the derivatives are classified as either cash flow hedges or fair value hedges. Cash flow hedges relates to highly probable forecasted transactions at a future point in time. Fair value hedges relate to changes in the fair value of assets or liabilities recognised on the balance sheet.Upon initial recognition, the fair values of derivative financial instruments are recognised as an asset or a liability on the balance sheet date. These are presented together with other receivables or other payables, respectively. The fair values of derivative financial instruments are subsequently remeasured at fair value at each reporting date.The subsequent value adjustments of cash flow hedges are recognised through other comprehensive income as a cash flow hedge reserve when the hedging relationship continues to meet the effectiveness requirement. The reserve is recognised in the income statement upon realisation of the hedged transactions. Interest hedge of bonds with fixed rate is recognised in the other comprehensive income as reserve for hedging, until the hedged interests will be recognised in the income statement. If a derivative financial instrument used to hedge expected future transactions expires, is sold or no longer qualifies for hedge accounting, any accumulated reserve remains in equity until the hedged transaction is concluded. If a transaction is no longer expected to be concluded, any reserve accumulated under equity is transferred to the income statement.The subsequent value adjustments of fair value hedges are recognised through profit or loss along with any adjustments of the value of the hedged asset that concern the hedged risk.Pursuant to the Group\u2019s foreign exchange policy, forward exchange contracts are used for the purpose of neutralising and delaying the effect of exchange rate fluctuations in profit or loss and thereby enhance the predictability of the financial results. The foreign exchange risk is calculated by applying the principles of a cash-flow-at-risk model, with the Board of Directors determining the level of risk as a percentage of operating profit (EBITDA). The risk is managed and mitigated through cash flow hedges and, in some cases, through fair value hedges. Sources of hedging ineffectiveness comprise mainly those that arise from assumptions on expected 12-month rolling cash flows not being realised.The Group hedges key currencies e.g. USD, GBP, JPY and HUF, and selectively hedges emerging markets currencies taking the cost of hedging into consideration.The Group does not hedge forecasted cash flows denominated in EUR as the foreign exchange risk is regarded as low due to the fixed exchange rate policy of the central bank of Denmark.Specification of derivative financial instruments held at the balance sheet date.Average exchange Contract Fair value of rate per the amount at contract at hedging Expiry period of DKK millionyear-end\u00b9\u207e\u00b2\u207eyear-end\u00b3\u207econtractsthe contracts2025USD 1,924 83 656.65 Oct 25 - Sep 26GBP 1,792 35 861.34 Oct 25 - Sep 26JPY 251 14 4.56 Oct 25 - Sep 26HUF -735 30 1.79 Oct 25 - Sep 26Other currencies 918 12 n/a Oct 25 - Aug 26Forward exchange contracts at 30 September, cash flow hedges 4,150 174 Power purchase agreement 50 -6 Sep 33Power purchase agreement at 30 September, cash flow hedges 50 -6 HUF 281 -4 1.87 Oct 25 - Dec 25Forward exchange contracts at 30 September, fair value hedges 281 -4 Deferred gain on settled interest swaps:EUR 2,985 42 May 27EUR 5,598 227 May 30Interest swaps at 30 September, to hedge future interest payments 8,583 269 Average exchange Contract Fair value of rate per the amount at contract at hedging Expiry period of DKK millionyear-end\u00b9\u207e\u00b2\u207eyear-end\u00b3\u207econtractsthe contracts2024USD 1,768 29 672.07 Oct 24 - Sep 25GBP 1,752 -53 858.66 Oct 24 - Sep 25JPY 232 -6 4.64 Oct 24 - Sep 25HUF -445 \u2013 1.85 Oct 24 - Sep 25Other currencies 974 -4 n/a Oct 24 - Sep 25Forward exchange contracts at 30 September, cash flow hedges 4,281 -34 Power purchase agreement 57 -6 Sep 33Power purchase agreement at 30 September, cash flow hedges 57 -6 HUF 279 1 1.86 Nov 24 - Aug 25Forward exchange contracts at 30 September, fair value hedges 279 1 Deferred gain on settled interest swaps:EUR 2,982 68 May 27EUR 5,592 276 May 30Interest swaps at 30 September, to hedge future interest payments 8,574 344 \u00b9\u207e Amount is translated to DKK millions using the exchange rates per the hedging contracts. Positive amounts indicate a forecasted sale of the currency in question; negative amounts indicate a forecasted purchase of currency in question.\u00b2\u207e The fair value of contracts are offset per currency. The amounts is not necessarily the net positions as legal offsetting can be applied.\u00b3\u207e Positive amounts indicate that the net fair value of the hedging contracts is an asset. Negative amounts indicate that the net fair value of the hedging contracts is a liability.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__142": {
"value": "Accounting policiesAt the initiation of derivative contracts, it is assessed whether they qualify for hedge accounting and the derivatives are classified as either cash flow hedges or fair value hedges. Cash flow hedges relates to highly probable forecasted transactions at a future point in time. Fair value hedges relate to changes in the fair value of assets or liabilities recognised on the balance sheet.Upon initial recognition, the fair values of derivative financial instruments are recognised as an asset or a liability on the balance sheet date. These are presented together with other receivables or other payables, respectively. The fair values of derivative financial instruments are subsequently remeasured at fair value at each reporting date.The subsequent value adjustments of cash flow hedges are recognised through other comprehensive income as a cash flow hedge reserve when the hedging relationship continues to meet the effectiveness requirement. The reserve is recognised in the income statement upon realisation of the hedged transactions. Interest hedge of bonds with fixed rate is recognised in the other comprehensive income as reserve for hedging, until the hedged interests will be recognised in the income statement. If a derivative financial instrument used to hedge expected future transactions expires, is sold or no longer qualifies for hedge accounting, any accumulated reserve remains in equity until the hedged transaction is concluded. If a transaction is no longer expected to be concluded, any reserve accumulated under equity is transferred to the income statement.The subsequent value adjustments of fair value hedges are recognised through profit or loss along with any adjustments of the value of the hedged asset that concern the hedged risk.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForHedgingExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__141": {
"value": "Accounting policiesAt the initiation of derivative contracts, it is assessed whether they qualify for hedge accounting and the derivatives are classified as either cash flow hedges or fair value hedges. Cash flow hedges relates to highly probable forecasted transactions at a future point in time. Fair value hedges relate to changes in the fair value of assets or liabilities recognised on the balance sheet.Upon initial recognition, the fair values of derivative financial instruments are recognised as an asset or a liability on the balance sheet date. These are presented together with other receivables or other payables, respectively. The fair values of derivative financial instruments are subsequently remeasured at fair value at each reporting date.The subsequent value adjustments of cash flow hedges are recognised through other comprehensive income as a cash flow hedge reserve when the hedging relationship continues to meet the effectiveness requirement. The reserve is recognised in the income statement upon realisation of the hedged transactions. Interest hedge of bonds with fixed rate is recognised in the other comprehensive income as reserve for hedging, until the hedged interests will be recognised in the income statement. If a derivative financial instrument used to hedge expected future transactions expires, is sold or no longer qualifies for hedge accounting, any accumulated reserve remains in equity until the hedged transaction is concluded. If a transaction is no longer expected to be concluded, any reserve accumulated under equity is transferred to the income statement.The subsequent value adjustments of fair value hedges are recognised through profit or loss along with any adjustments of the value of the hedged asset that concern the hedged risk.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsAndHedgingExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__140": {
"value": "Accounting policiesAt the initiation of derivative contracts, it is assessed whether they qualify for hedge accounting and the derivatives are classified as either cash flow hedges or fair value hedges. Cash flow hedges relates to highly probable forecasted transactions at a future point in time. Fair value hedges relate to changes in the fair value of assets or liabilities recognised on the balance sheet.Upon initial recognition, the fair values of derivative financial instruments are recognised as an asset or a liability on the balance sheet date. These are presented together with other receivables or other payables, respectively. The fair values of derivative financial instruments are subsequently remeasured at fair value at each reporting date.The subsequent value adjustments of cash flow hedges are recognised through other comprehensive income as a cash flow hedge reserve when the hedging relationship continues to meet the effectiveness requirement. The reserve is recognised in the income statement upon realisation of the hedged transactions. Interest hedge of bonds with fixed rate is recognised in the other comprehensive income as reserve for hedging, until the hedged interests will be recognised in the income statement. If a derivative financial instrument used to hedge expected future transactions expires, is sold or no longer qualifies for hedge accounting, any accumulated reserve remains in equity until the hedged transaction is concluded. If a transaction is no longer expected to be concluded, any reserve accumulated under equity is transferred to the income statement.The subsequent value adjustments of fair value hedges are recognised through profit or loss along with any adjustments of the value of the hedged asset that concern the hedged risk.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__145": {
"value": "Note 24Cash and cash equivalentsDKK million2025 2024Bank deposits, short term 947 788 Cash and cash equivalents at 30 September 947 788",
"dimensions": {
"concept": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__146": {
"value": "Note 25Public grantsThe Group has received DKK 2 million in public grants for research and development purposes (2023/24: DKK 5 million), but has in 2024/25 not received public grants for investment (2023/24: DKK 2 million). No income from investment grants has in 2024/25 been recognised under production costs in the income statement (2023/24: DKK 2 million).",
"dimensions": {
"concept": "ifrs-full:DisclosureOfGovernmentGrantsExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__150": {
"value": "Note 26Contingent liabilities and guaranteesAs part of the normal course of business, Coloplast is involved in pending litigations, claims and investigations. Provisions for probable losses have been made for those matters Management has assessed as needed, but there are uncertainties associated with these estimates. Coloplast does not expect any pending litigations, claims and investigations to materially influence the Group\u2019s future earnings, cash flows or financial position, neither individually nor in aggregate, in addition to the amounts recognised as provisions.Coloplast A/S, Danish subsidiaries and Coloplast Finance BV are part of a Danish joint taxation scheme with NPLH Holding ApS, according to which the Company partly has a joint and several liability and partly a secondary liability with respect to corporate income taxes, corporate withholding taxes, etc.The company has certain contingent future regulatory milestone payment related to historical business acquisitions that may become due in the future. Such are contingent in nature and these become due and payable only upon the achievement of certain regulatory milestones. The events triggering such payments or obligations have not yet occurred.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfCollateralExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__149": {
"value": "Note 26Contingent liabilities and guaranteesAs part of the normal course of business, Coloplast is involved in pending litigations, claims and investigations. Provisions for probable losses have been made for those matters Management has assessed as needed, but there are uncertainties associated with these estimates. Coloplast does not expect any pending litigations, claims and investigations to materially influence the Group\u2019s future earnings, cash flows or financial position, neither individually nor in aggregate, in addition to the amounts recognised as provisions.Coloplast A/S, Danish subsidiaries and Coloplast Finance BV are part of a Danish joint taxation scheme with NPLH Holding ApS, according to which the Company partly has a joint and several liability and partly a secondary liability with respect to corporate income taxes, corporate withholding taxes, etc.The company has certain contingent future regulatory milestone payment related to historical business acquisitions that may become due in the future. Such are contingent in nature and these become due and payable only upon the achievement of certain regulatory milestones. The events triggering such payments or obligations have not yet occurred.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__148": {
"value": "Note 26Contingent liabilities and guaranteesAs part of the normal course of business, Coloplast is involved in pending litigations, claims and investigations. Provisions for probable losses have been made for those matters Management has assessed as needed, but there are uncertainties associated with these estimates. Coloplast does not expect any pending litigations, claims and investigations to materially influence the Group\u2019s future earnings, cash flows or financial position, neither individually nor in aggregate, in addition to the amounts recognised as provisions.Coloplast A/S, Danish subsidiaries and Coloplast Finance BV are part of a Danish joint taxation scheme with NPLH Holding ApS, according to which the Company partly has a joint and several liability and partly a secondary liability with respect to corporate income taxes, corporate withholding taxes, etc.The company has certain contingent future regulatory milestone payment related to historical business acquisitions that may become due in the future. Such are contingent in nature and these become due and payable only upon the achievement of certain regulatory milestones. The events triggering such payments or obligations have not yet occurred.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__147": {
"value": "Note 26Contingent liabilities and guaranteesAs part of the normal course of business, Coloplast is involved in pending litigations, claims and investigations. Provisions for probable losses have been made for those matters Management has assessed as needed, but there are uncertainties associated with these estimates. Coloplast does not expect any pending litigations, claims and investigations to materially influence the Group\u2019s future earnings, cash flows or financial position, neither individually nor in aggregate, in addition to the amounts recognised as provisions.Coloplast A/S, Danish subsidiaries and Coloplast Finance BV are part of a Danish joint taxation scheme with NPLH Holding ApS, according to which the Company partly has a joint and several liability and partly a secondary liability with respect to corporate income taxes, corporate withholding taxes, etc.The company has certain contingent future regulatory milestone payment related to historical business acquisitions that may become due in the future. Such are contingent in nature and these become due and payable only upon the achievement of certain regulatory milestones. The events triggering such payments or obligations have not yet occurred.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfContingentLiabilitiesExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__156": {
"value": "Note 29Fees to auditors appointed by the Annual General MeetingDKK million 2024/25 2023/24Statutory audit 13 13 Assurance engagements other than audit 2 1 Tax advisory \u2013 1 Other services 1 1 Total fees 16 16 Fee for non-audit services provided to the Group by EY Godkendt Revisionspartnerselskab, Denmark, amounted to DKK 3 million (2023/24: DKK 3 million), relating to compliance services and other assurance assessments and opinions.Certain of the Group's subsidiaries are not subject to an audit by EY.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfAuditorsRemunerationExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__157": {
"value": "Note 30Events occurring after the balance sheet dateNo events have occurred after the balance sheet date which are deemed to have a material impact on the financial results or equity at 30 September 2025 or require additional disclosers.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__159": {
"value": "Note 31Company overviewCompany Country OwnershipParent companyColoplast A/S DenmarkSales subsidiariesColoplast de Argentina SA Argentina 100 %Coloplast Pty Ltd Australia 100 %Coloplast Ges.m.b.H. Austria 100 %Coloplast Belgium NV/SA Belgium 100 %Coloplast do Brasil Ltda Brazil 100 %Coloplast Canada Corporation Canada 100 %Coloplast (China) Medical Devices Ltd. China 100 %Coloplast (Hong Kong) Ltd. China 100 %Coloplast S.A.S Columbia 100 %Coloplast Czech s.r.o. Czech Republic 100 %Coloplast Danmark A/S Denmark 100 %Coloplast Oy Finland 100 %Laboratoires Coloplast S.A.S. France 100 %Lilial S.A.S. France 100 %Coloplast GmbH Germany 100 %Coloplast (India) Private Limited India 100 %Coloplast Israel Ltd. Israel 100 %Coloplast S.p.A. Italy 100 %Coloplast K.K. Japan 100 %Coloplast Korea Limited Korea 100 %Coloplast B.V. Netherlands 100 %Company Country OwnershipSales subsidiariesColoplast Limited New Zealand 100 %Coloplast Norge AS Norway 100 %Coloplast Sp. zo.o Poland 100 %Coloplast II Portugal, Unipessoal Lda Portugal 100 %Coloplast LLC Russia 100 %Coloplast Slovakia s.r.o Slovakia 100 %Coloplast Productos M\u00e9dicos S.A Spain 100 %Coloplast AB Sweden 100 %Coloplast AG Switzerland 100 %Coloplast Taiwan Co., Ltd. Taiwan 100 %Coloplast Turkey Medikal Gere\u00e7ler San. ve Tic. A.\u015e. Turkey 100 %Charter Healthcare Limited UK 100 %Coloplast Limited UK 100 %Porges UK Limited UK 100 %Affordable Medical LLC USA 100 %Coloplast Corp. USA 100 %Comfort Medical, LLC USA 100 %Rocky Mountain Medical, LLC USA 100 %Zi-Med Supply Co., Inc. USA 100 %Sales subsidiaries - Kerecis groupKerecis GmbH Germany 100 %Kerecis ehf Iceland 100 %Kerecis AG Switzerland 100 %Kerecis LLC USA 100 %Company Country OwnershipSales subsidiaries - Atos GroupAtos Medical ApS Denmark 100 %Atos Medical SAS France 100 %Atos Medical Srl Italy 100 %Atos Medical AS Norway 100 %Atos Medical UK Ltd. UK 100 %Atos Medical Inc. USA 100 %Manufacturing subsidiariesColoplast (China) Ltd. China 100 %Coloplast Volume Manufacturing Costa Rica S.A. Costa Rica 100 %Coloplast Manufacturing France S.A.S. France 100 %Coloplast Distribution GmbH Germany 100 %TRACOE Medical GmbH Germany 100 %Coloplast Hungary Kft. Hungary 100 %Viruxal ehf Iceland 100 %Coloplast Manufacturing Portugal, Unipessoal LDA Portugal 100 %Atos Medical AB Sweden 100 %Coloplast Medical Limited UK 100 %Coloplast Manufacturing US, LLC USA 100 %Company Country OwnershipOtherColoplast Business Centre Costa Rica S.A. Costa Rica 100 %Coloplast Ejendomme A/S Denmark 100 %Kerecis Services ehf Iceland 100 %Coloplast Finance B.V. Netherlands 100 %Coloplast Business Centre Sp. zo.o. Poland 100 %Atos Medical Holding Sweden 100 %XTR Holding Ltd. UK 100 %Francis Medical USA 12 %Starling Medical, Inc USA 2 %Coloplast representative offices and branchesDubaiHungarySaudi ArabiaSingaporeSouth AfricaUkraine",
"dimensions": {
"concept": "ifrs-full:DisclosureOfInterestsInOtherEntitiesExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__158": {
"value": "Note 31Company overviewCompany Country OwnershipParent companyColoplast A/S DenmarkSales subsidiariesColoplast de Argentina SA Argentina 100 %Coloplast Pty Ltd Australia 100 %Coloplast Ges.m.b.H. Austria 100 %Coloplast Belgium NV/SA Belgium 100 %Coloplast do Brasil Ltda Brazil 100 %Coloplast Canada Corporation Canada 100 %Coloplast (China) Medical Devices Ltd. China 100 %Coloplast (Hong Kong) Ltd. China 100 %Coloplast S.A.S Columbia 100 %Coloplast Czech s.r.o. Czech Republic 100 %Coloplast Danmark A/S Denmark 100 %Coloplast Oy Finland 100 %Laboratoires Coloplast S.A.S. France 100 %Lilial S.A.S. France 100 %Coloplast GmbH Germany 100 %Coloplast (India) Private Limited India 100 %Coloplast Israel Ltd. Israel 100 %Coloplast S.p.A. Italy 100 %Coloplast K.K. Japan 100 %Coloplast Korea Limited Korea 100 %Coloplast B.V. Netherlands 100 %Company Country OwnershipSales subsidiariesColoplast Limited New Zealand 100 %Coloplast Norge AS Norway 100 %Coloplast Sp. zo.o Poland 100 %Coloplast II Portugal, Unipessoal Lda Portugal 100 %Coloplast LLC Russia 100 %Coloplast Slovakia s.r.o Slovakia 100 %Coloplast Productos M\u00e9dicos S.A Spain 100 %Coloplast AB Sweden 100 %Coloplast AG Switzerland 100 %Coloplast Taiwan Co., Ltd. Taiwan 100 %Coloplast Turkey Medikal Gere\u00e7ler San. ve Tic. A.\u015e. Turkey 100 %Charter Healthcare Limited UK 100 %Coloplast Limited UK 100 %Porges UK Limited UK 100 %Affordable Medical LLC USA 100 %Coloplast Corp. USA 100 %Comfort Medical, LLC USA 100 %Rocky Mountain Medical, LLC USA 100 %Zi-Med Supply Co., Inc. USA 100 %Sales subsidiaries - Kerecis groupKerecis GmbH Germany 100 %Kerecis ehf Iceland 100 %Kerecis AG Switzerland 100 %Kerecis LLC USA 100 %Company Country OwnershipSales subsidiaries - Atos GroupAtos Medical ApS Denmark 100 %Atos Medical SAS France 100 %Atos Medical Srl Italy 100 %Atos Medical AS Norway 100 %Atos Medical UK Ltd. UK 100 %Atos Medical Inc. USA 100 %Manufacturing subsidiariesColoplast (China) Ltd. China 100 %Coloplast Volume Manufacturing Costa Rica S.A. Costa Rica 100 %Coloplast Manufacturing France S.A.S. France 100 %Coloplast Distribution GmbH Germany 100 %TRACOE Medical GmbH Germany 100 %Coloplast Hungary Kft. Hungary 100 %Viruxal ehf Iceland 100 %Coloplast Manufacturing Portugal, Unipessoal LDA Portugal 100 %Atos Medical AB Sweden 100 %Coloplast Medical Limited UK 100 %Coloplast Manufacturing US, LLC USA 100 %Company Country OwnershipOtherColoplast Business Centre Costa Rica S.A. Costa Rica 100 %Coloplast Ejendomme A/S Denmark 100 %Kerecis Services ehf Iceland 100 %Coloplast Finance B.V. Netherlands 100 %Coloplast Business Centre Sp. zo.o. Poland 100 %Atos Medical Holding Sweden 100 %XTR Holding Ltd. UK 100 %Francis Medical USA 12 %Starling Medical, Inc USA 2 %Coloplast representative offices and branchesDubaiHungarySaudi ArabiaSingaporeSouth AfricaUkraine",
"dimensions": {
"concept": "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__160": {
"value": "Note 32Definitions of key ratiosEBITEarnings before interest and taxEBITDAEarnings before interest, tax, depreciation and amortisationCapital investedAssets less cash, less marketable securities plus accumulated goodwill amortised before 1 October 2002 less non-interest bearing debt including provisionsGearing ratioNet interest bearing debt (NIBD) relative to EBITDA before special itemsEBIT margin, %EBIT as a percentage of revenuesReturn on average invested capital (ROIC), %EBIT as a percentage of invested capital (average)Return on equity, %Profit for the year attributable to Coloplast as a percentage of equity before minority interests (average)Equity ratio, %Equity at year-end as a percentage of total assets at year-endNet asset value per share, DKKEquity excluding minority interests per outstanding shareMarket price/net asset value per shareMarket price per share relative to net asset value per sharePE, price/earnings ratioMarket price per share relative to earnings per share (EPS)Payout ratio, %Dividend declared as a percentage of profit for the year attributable to ColoplastEarnings per share (EPS)Profit for the year attributable to Coloplast per outstanding share (average of four quarters)Free cash flow per shareFree cash flow per outstanding share (average of four quarters)",
"dimensions": {
"concept": "ifrs-full:DisclosureOfAdditionalInformationExplanatory",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__225": {
"value": "Globally",
"dimensions": {
"concept": "ifrs-full:PrincipalPlaceOfBusiness",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__226": {
"value": "our business areas include Ostomy Care, Continence Care, Voice & Respiratory Care, Wound & Tissue Repair, and Interventional Urology.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__227": {
"value": "Coloplast A/S",
"dimensions": {
"concept": "ifrs-full:NameOfReportingEntityOrOtherMeansOfIdentification",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__228": {
"value": "A/S",
"dimensions": {
"concept": "ifrs-full:LegalFormOfEntity",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__229": {
"value": "Holtedam 1 3050 Humleb\u00e6k Denmark",
"dimensions": {
"concept": "ifrs-full:AddressOfRegisteredOfficeOfEntity",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
},
"f0__s7__7__230": {
"value": "Humleb\u00e6k",
"dimensions": {
"concept": "ifrs-full:DomicileOfEntity",
"language": "en",
"entity": "scheme:529900NN7SOJ5QG82X67",
"period": "2024-10-01T00:00:00/2025-10-01T00:00:00"
}
}
}
}